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DNA interstrand crosslink (ICL) repair is vital for cellular proliferation and 
survival. Defects in the repair of DNA crosslinks have been associated with 
congenital abnormalities, bone marrow and kidney failure, liver dysfunction, and 
cancer. DNA nucleases play a significant role during the repair of ICLs and they 
function at multiple repair steps. Here, we assessed the contributions of 
FANCD2/FANCI-Associated Nuclease 1 (FAN1) to the repair of ICL lesions and 
studied the consequences of its deficiency, which results in rare chronic kidney 
disease - Karyomegalic Interstitial Nephritis (KIN). FAN1 is a highly conserved 
nuclease from yeast to humans. It was first identified in an RNAi screen for 
proteins necessary for ICL repair and also as a direct interacting partner of 
FANCI/FANCD2 (ID2) complex of the Fanconi anemia pathway. Using cells 
isolated from human KIN patients and Fan1-deficient mice, we showed that ICL 
repair function of FAN1 is non-overlapping with Fanconi anemia proteins, yet 
redundant with SNM1A, an exonuclease that was previously implicated in ICL 
repair. Furthermore, the Fan1 knockout mouse model recapitulates many of the 
phenotypes observed in human KIN patients, including renal karyomegaly and 
liver dysfunction. Fan1-deficient mice displayed hypersensitivity to ICL-inducing 
chemotherapeutic drugs and developed bone marrow failure following the 
treatment. We also demonstrated that formaldehyde and acetaldehyde are likely 
not the endogenous damaging agents that lead to KIN in the absence of FAN1. 
In parallel studies, we explored the possibility of rescuing ICL sensitivity of 
Fanconi anemia patient cells through an inhibition of non-homologous end joining 
repair (NHEJ) factors.  Using both genetic and chemical approaches, we showed 
that NHEJ suppression could not compensate for the lack of FA pathway in the 
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Chapter 1: Introduction 
 2 
1.1 Types and sources of DNA damage  
 The maintenance of genomic stability is necessary to allow the faithful 
transmission of the genetic information across generations. To preserve genomic 
integrity, DNA must be protected from damage generated spontaneously during 
DNA transactions or inflicted by environmental agents (Ciccia and Elledge, 2010). 
The spontaneous lesions can arise as a result of the nucleotide misincorporation 
during DNA replication, DNA base interconversions by DNA deamination or the 
loss of DNA bases by DNA depurination (Lindahl, 1993; Lindahl and Barnes, 
2000). The environment is another important source of DNA damage. One of the 
most deleterious type of DNA damaging agents is ionizing radiation (IR) from x-
ray or g-ray that can induce DNA single strand breaks (SSBs) and DNA double 
strand breaks (DSBs). More frequently in everyday life, exposure to ultraviolet 
(UV) light leads to the formation of DNA-pyrimidine dimers and 6-4 photo-
adducts which can account for 105 DNA lesions per day (Hoeijmakers, 2009). 
Additionally, inside the cell, DNA is frequently struck by reactive oxygen species 
(ROS), which can damage DNA bases and result in DNA breaks (Hoeijmakers, 
2009). 
 
 The type of DNA damage that this thesis is concerned with is DNA 
interstrand crosslink (ICL) damage. DNA ICLs are lesions that form when the 
bases from opposite strands of DNA are linked together through a covalent bond.  
ICLs are detrimental to cells due to their ability to prevent separation of DNA 
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double helices, therefore interfering with processes such as DNA replication and 
transcription.  ICLs can be induced by many of the front-line chemotherapeutic 
drugs including nitrogen mustard derivatives such as melphalan and 
cyclophosphamide, platinum-based compounds such as cisplatin and carboplatin, 
mitomycin C (MMC), and psoralen (Deans and West, 2011; Dunnick et al., 1987; 
Eastman, 1983; Gargiulo et al., 1995; Goodman et al., 1946). Additionally, ICLs 
can also be induced by molecules made within cells (Clauson et al., 2013).  
Recent studies have implicated aldehydes as well as the oxidized DNA bases 
and nitric oxide as their potential sources (Clauson et al., 2013; Garaycoechea et 
al., 2012; Langevin et al., 2011; Pontel et al., 2015). Reactive aldehydes such as 
formaldehyde, acetaldehyde, malondialdehyde and acrolein have been shown in 
vitro and in vivo to be potent DNA crosslinkers (Kirchner et al., 1992; McGhee 
and von Hippel, 1977; Stein et al., 2006; Stone et al., 2008). Deficiency in the 
repair of ICLs has been associated with  human genetic diseases Fanconi 
anemia and Karyomegalic Interstitial Nephritis (KIN) (reviewed in (Kottemann 
and Smogorzewska, 2013; Moldovan and D’Andrea, 2009).  
 
1.2 Fanconi anemia  
Fanconi anemia (FA) is a rare genetic disease that occurs in about 1 in 
every 100,000 births. It is characterized by congenital abnormalities, bone 
marrow failure and predisposition to blood and solid cancers (Alter, 2003; 
Butturini et al., 1994; Fanconi, 1967; Schmid and Fanconi, 1978). FA patients 
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display cellular hypersensitivity to ICL inducing agents such as mitomycin C 
(MMC) and diepoxybutane (DEB), which results in increased cell death and 
characteristic chromosomal abnormalities including radial chromosomes 
(Auerbach et al., 1989; Scharer, 2005). Fanconi anemia disorder is genetically 
heterogeneous. At present, 21 genes have been found to be mutated in Fanconi 
anemia or Fanconi anemia-like patients. All of the identified mutated genes have 
been assigned a name as “FANC” genes, including FANCA, B, C, D1, D2, E, F, 
G, I, J, L, M, N, O, P, Q, R, S, T, U, and V. To date, there remain some patients 
whose complementation groups have not been assigned (Bluteau et al., 2016; 
Ceccaldi et al., 2016; Park et al., 2016).  
 
FA patients are born with a range of birth defects including short stature, 
microcephaly, the absence of radius and thumbs, pigmentation defects, 
abnormalities of the cardiovascular, gastro-intestinal, and urinary systems 
(Auerbach, 2009; Shimamura and Alter, 2010). The developmental 
malformations can vary between patients and complementation groups. FA 
patients with complementation group D1, J and N display more severe congenital 
abnormalities than others (Levran et al., 2005; Reid et al., 2007; Wagner et al., 
2004). In addition, infertility is almost universal, with almost none of the male 
patients being reported to have offspring and the affected females developing 
menopause at much earlier age (Auerbach, 2009). However, the most common 
phenotype shared among FA patients is pancytopenia caused by progressive 
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bone marrow failure (Auerbach, 2009; Kutler et al., 2003b). FA patients are also 
presented with a high risk of developing blood malignancies such as 
myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) due to bone 
marrow abnormalities (Alter et al., 2010; Rosenberg et al., 2003). 
 
Bone marrow failure is driven by dysfunctional hematopoietic stem cells 
(HSCs) and progenitor cells due to recurrent DNA damage-activated apoptosis. 
Disruption of FA pathway leads to elevated DNA damage in the HSCs, which in 
turn promotes activation of p53- and p21-mediated programmed cell death or cell 
cycle arrest (Ceccaldi et al., 2012; Tulpule et al., 2010). FA patients are born with 
lower levels of HSCs, which display lower proliferative potential and reduced 
repopulating and differentiating abilities (Ceccaldi et al., 2012; Kelly et al., 2007). 
Furthermore, exposure of hematopoietic progenitor cells to crosslinking agents 
intensifies their proliferation deficiency (Vinciguerra et al., 2010). These findings 
suggest that the FA pathway is required for the protection of hematopoietic stem 
cells from accumulating ICLs. 
 
Defective DNA repair in FA cells can lead to mutations and genomic 
instability, which promotes tumorigenesis. In addition to blood malignancy 
mentioned before, FA patients are at a high risk of developing solid tumors, 
including several hundred-fold increase in risk of head and neck squamous cell 
carcinoma over that present in the general population (Kutler et al., 2003a; 
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Rosenberg et al., 2003). A number of FA genes, which encode proteins 
participating in homology-directed repair including FANCD1 (BRCA2), FANCJ 
(BRIP1) and FANCN (PALB2) are breast and ovarian cancer susceptibility genes. 
This association demonstrates a close link between the Fanconi anemia pathway 
and tumor suppression (Deans and West, 2011; Rafnar et al., 2011; Rahman et 
al., 2007; Seal et al., 2006; Shah et al., 2013; Tischkowitz et al., 2007; Walsh et 
al., 2011).  
 
1.3 Fanconi anemia proteins and ICL repair  
The products of FANC genes – “Fanconi anemia (FA) proteins” are 
necessary for the repair of ICLs. They participate in identification of the lesion 
and activation of repair, nucleolytic processing of the crosslink, translesion 
synthesis (TLS) against an unhooked lesion, and homologous recombination 
(HR) (Figure 1.1A-D) (reviewed in (Ceccaldi et al., 2016; Kottemann and 
Smogorzewska, 2013). The role of FA proteins in ICL repair has been 
extensively studied using mammalian cells, Xenopus egg extracts, and the in 
vitro biochemical analysis. In the current model derived from these studies, the 
FA core complex proteins (A, B, C, E, F, G, L and M) and the associated proteins 
are involved in detection of the damage. Upon the recognition of the crosslink, 
FANCL, an E3 ubiquitin ligase of the FA core complex, aided by E2 ubiquitin-
conjugating enzyme, FANCT/UBE2T, monoubiquitinate FANCD2 and FANCI 
(Figure 1.1A) (reviewed in (Ceccaldi et al., 2016; Walden and Deans, 2014). 
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FANCD2 and FANCI are paralogs that can heterodimerize to form the ID2 
complex. The dynamic association and localization of FANCI/FANCD2 are 
influenced by their ubiquitination status. Human FANCD2 and FANCI are 
monoubiquitinated at residue K561 and K523 respectively (Garcia-Higuera et al., 
2001; Montes de Oca et al., 2005; Smogorzewska et al., 2007). The 
monoubiquitination of FANCD2 and FANCI are essential for the ICL repair 
function of the FA pathway (Smogorzewska et al., 2007). Additionally, 
phosphorylation of FANCI by ATR provides a crucial regulatory mechanism of 
the repair pathway (Ishiai et al., 2008; Wang, 2008).  The function of the 
ubiquitinated ID2 complex is not fully understood.  However, it has been shown 
to be required for the unhooking of the crosslink and for translesion synthesis-
mediated bypass of the lesion in the Xenopus egg extract system (Figure 1.1B, 
C) (Douwel et al., 2014; Knipscheer et al., 2009; Raschle et al., 2008).  
 
The DNA incisions around the ICL require SLX4 (FANCP), a Fanconi 
anemia protein that is associated with three structure specific nucleases, 
including XPF–ERCC1, MUS81–EME1 and SLX1 (Douwel et al., 2014; Fekairi et 
al., 2009; Munoz et al., 2009; Svendsen et al., 2009). SLX4/FANCP is a scaffold 
protein that can localize and modulate the activity of its associated nucleases at 
the site of damage (Fekairi et al., 2009; Hodskinson et al., 2014; Munoz et al., 
2009; Svendsen et al., 2009; Wyatt et al., 2017). In human cells, the interaction 
of SLX4 with MUS81–EME1 and SLX1 are important for the Holliday junctions 
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(HJs) resolution during homologous recombination (Garner et al., 2013; Kim et 
al., 2013; Svendsen et al., 2009; Wyatt et al., 2013). In contrast, the association 
between SLX4 and XPF/FANCQ -ERCC1 have been shown to be essential for 
ICL resistance and crosslink unhooking (Crossan et al., 2011; Douwel et al., 
2014; Kim et al., 2011; Kim et al., 2013; Yamamoto et al., 2011). When in 
complex with SLX4 in vitro, XPF is found to be able to completely unhook the 
crosslink substrates (Hodskinson et al., 2014). 
 
A useful working model of the ICL repair has been proposed based on the 
study in the Xenopus egg extracts. According to the model, SLX4 and XPF can 
be recruited to the crosslink substrates upon the monoubiquitination of FANCD2 
(Figure 1.1B) (Douwel et al., 2014). In this model, repair begins when two of the 
replication forks converge at the ICL. Once one of the leading strands arrives 
within 1 nucleotide of the ICL, the opposite parental strand can be incised on 
either side of the crosslink, resulting in the unhooking of the ICL (Raschle et al., 
2008; reviewed in (Zhang and Walter, 2014). To date, XPF-ERCC1 is the only 
nuclease known to be indispensable for the incision event in the Xenopus egg 
extracts system (Douwel et al., 2014).  
 
The dual fork convergence model was recently challenged by an in vivo 
study from the Seidman lab using DNA-fiber based approach with fluorescently-
tagged ICLs (Huang et al., 2013). Seidman and colleagues showed that the 
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majority of replications forks can traverse (bypass) the crosslinks without prior 
ICL unhooking. Replication traverse of ICLs requires the DNA translocase activity 
of FANCM, but not other Fanconi anemia proteins. When replication transverse 
is blocked under FANCM deficient setting, the frequency of stalled single fork 
collisions with ICLs go up, suggesting that single fork collision precedes 
replication traverse. These results indicate that, in mammalian cells, ICLs are 
mostly approached by single forks rather than converging dual forks as opposed 
to the models proposed by the Xenopus studies. The questions of how FANCM 
facilitates replication traverse and the identity of DNA translocase distal to the 
ICL remain a subject of further investigation. Nevertheless, Walter and 
colleagues argue that, regardless of either models, both dual fork convergence 
and replication traverse lead to the formation of X-shape structures at ICLs, 
which can be recognized and processed by ICL repair nucleases such as XPF-
ERCC1 (Zhang and Walter, 2014). 
Following the incision, the last steps of ICL repair involve translesion 
synthesis and homology directed repair. The unhooked base is bypassed by 
translesion DNA polymerase whose identity remains unknown before being 
extended further by DNA polymerase z (REV3/REV7) (Figure 1.1C) (Raschle et 
al., 2008). Concurrently, the double strand break generated by ICL unhooking is 
repaired by homology-directed repair, a step which is facilitated by a number of 
FA proteins including FANCD1 (BRCA2), FANCJ (BRIP1) and FANCN (PALB2), 
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FANCO (RAD51C), FANCP (SLX4), FANCR (RAD51) and FANCS (BRCA1) 
(Figure 1.1D) (reviewed in (Ceccaldi et al., 2016; Long et al., 2011; Walden and 
Deans, 2014).  
 
 Although the FA pathway plays an important role in ICL repair and human 
and mouse cells lacking the FA proteins are very sensitive to ICL-inducing 
agents, alternative ICL repair mechanisms do exist. ICL repair studies in non-
replicating Xenopus egg extracts revealed the ICL repair pathway that depends 
on translesion synthesis polymerase Pol k but not the Fanconi anemia proteins 
(Williams et al., 2012). This pathway of ICL repair is thought to be important for 
the repair of ICL damage in quiescent or slowly cycling cells that are mainly in 
G0/G1 phases of the cell cycle. More recently, a replication-dependent repair 
pathway that involves a DNA glycosylase - NEIL3 has been shown to be able to 
bypass the need for FA proteins (Semlow et al., 2016). Unlike nuclease-mediated 
ICL unhooking, NEIL3 directly cleaves the N-glycosyl bond without damaging the 
sugar phosphate backbone and functions independently of FANCI-FANCD2. 
NEIL3-mediated unhooking has been shown to be a major pathway for the repair 
of psoralen and abasic (AP) site ICLs. Following the cleavage of N-glycosyl bond, 
gaps are filled in by TLS polymerases. The significance of NEIL3-ICL repair 
pathway in vivo remains unclear as unhooking can still proceed via FANCI-
FANCD2-dependent incisions when N-glycosyl bond cleavage is prevented, 
(Semlow et al., 2016).   
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Figure 1.1 Model of the Fanconi anemia DNA repair pathway.  
(A) Upon the detection of ICL damage, ATR phosphorylates multiple repair 
proteins. This together with the monoubiquitination of FANCI and FANCD2 
of the ID2 complex by the Fanconi anemia (FA) core complex lead to the 
activation of the FA pathway. (B) ID2 complex is thought to coordinate DNA 
nucleases during ICL incision. (C-D) The unhooked intermediates are 
repaired by translesion synthesis (C) and homologous recombination (HR) 
(D). HR proteins are also required for the protection of the replication forks 
earlier during repair.  
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1.4 The identification of FANCD2/FANCI interacting protein: FAN1 
The mechanism of how monoubiquitinated ID2 complex provides a 
platform for DNA nucleases or translesion synthesis polymerases for ICL 
processing remains unclear. Multiple studies arrived at one possible effector of 
the ID2 complex function, KIAA1018/FAN1 (FANCD2/FANCI-associated 
nuclease 1) (Kratz et al., 2010; Liu et al., 2010; MacKay et al., 2010; 
Smogorzewska et al., 2010). These studies show that FAN1 interacts with 
FANCD2 and that the depletion of FAN1 leads to ICL sensitivity. FAN1 is a 
structure-specific nuclease, containing four characterized domains: ubiquitin-
binding domain UBZ, DNA binding domain SAP (SAF-A/B, Acinus and PIAS), 
protein-protein interaction domain TPR (tetratricopeptide repeat), and nuclease 
domain VRR_nuc (virus-type replication-repair nuclease) (Figure 1.2) (Iyer et al., 
2006; Kinch et al., 2005). The UBZ domain of FAN1, which belongs to RAD18 
family of zinc fingers proteins that are commonly found in DNA damage response 
proteins, facilitates its binding to the monoubiquitinated ID2 complex (Hofmann, 
2009; Kratz et al., 2010; Liu et al., 2010; MacKay et al., 2010; Smogorzewska et 
al., 2010). The UBZ domain of FAN1 is not found in unicellular eukaryotes, but is 
highly conserved in many multicellular organisms. Interestingly, the presence of 
the UBZ domain is concurrent with the evolution of the majority of FA genes 
including FANCD2 (MacKay et al., 2010; Patel and Joenje, 2007; Smogorzewska 
et al., 2010). The VRR_nuc domain of FAN1 is well conserved from bacteria to 
humans and contains a PD-D/E(X)K motif that is often found in the active site of 
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many restriction endonucleases as well as MUS81 and XPF endonucleases 
(Kinch et al., 2005; Kosinski et al., 2005). 
FAN1 is necessary for the resistance to ICL-inducing agents such as 
MMC, cisplatin and HN2 (nitrogen mustard derivative) in multiple model systems 
from S. pombe to mammals (Airik et al., 2016; Fontebasso et al., 2013; Kratz et 
al., 2010; Lachaud et al., 2016a; Liu et al., 2010; MacKay et al., 2010; 
Smogorzewska et al., 2010; Thongthip et al., 2016; Yoshikiyo et al., 2010; Zhou 
et al., 2012). Treatment of FAN1-deficient human cells with ICL-inducing agents 
leads to proliferation defect and chromosomal aberration that are accompanied 
by high level of DNA damage (Kratz et al., 2010; MacKay et al., 2010). To date, 
FAN1 has not been convincingly shown to be required for the repair of other 
types of DNA damage. 
In addition to the ID2 complex, FAN1 also interacts with DNA mismatch 
repair proteins. The analysis of MLH1 and PMS2 interactome revealed several 
peptides of FAN1, while reciprocally, the top-scoring candidates from the 
proteomic study of FAN1’s interacting partners included MLH1, MLH3, PMS1, 
and PMS2 (Cannavo et al., 2007; Kratz et al., 2010; MacKay et al., 2010; 
Smogorzewska et al., 2010). In a size exclusion study, FAN1 was found to form 
two subcomplexes one with FANCD2 and FANCI and the other with MLH1 
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(MacKay et al., 2010). It remains to be shown if FAN1 functions within the DNA 
mismatch repair pathway. 
 
1.5 FAN1 and ICL repair 
Although there are several lines of evidence that indicate the importance 
of FAN1 in the protection of cells and organisms from ICL-induced damage, its 
role during ICL repair remains elusive. Given the direct association between 
FAN1 and the monoubiquitinated ID2 complex, it has been proposed that FAN1 
nuclease activity might function downstream of ID2 monoubiquitination. As such, 
it could contribute to ICL incision, processing of the excised crosslink, or could 
even function later during homology directed repair of DNA double-strand break 
(DSB) intermediates or in the resolution of Holliday junctions (Smogorzewska et 
al., 2010). 
 
1.5.1 The structure and nuclease activity of FAN1 
To date, several high-resolution structures of FAN1 have been analyzed 
either alone or in complex with different DNA substrates (Gwon et al., 2014; 
Wang et al., 2014; Zhao et al., 2014). These studies gave some insight to the 
mechanism of DNA binding and catalysis by FAN1. The structure solved by the 
Pavletich lab shows FAN1 as a monomeric protein with a bilobal structure 
consisting of 223-residue N-terminal domain (NTD) and a 415-residue C-terminal 
domain (CTD) containing a nuclease motif. The protein was crystalized with DNA 
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substrate with a pre-nicked 1-nucleotide 5’ flap carrying 5’ phosphate group and 
a post-nicked 4-nucleotide 3’ flap. The NTD binds to the pre-nicked duplex and 3’ 
flap, whereas the CTD binds to the 5’ flap and post-nicked duplex, distorting the 
DNA substrate into a V-shape molecule. The authors proposed that this structure 
would permit sequential 3-nucleotide stepwise incisions across the crosslink 
(Wang et al., 2014). The structures solved by the Sung lab demonstrates the 
dimerization of FAN1 monomers. The binding to 5’ flap DNA substrates promotes 
a dimerization of FAN1 in a ‘head to tail’ conformation. The TPR and NUC 
domains of one FAN1 molecule interact with the SAP domain of the other FAN1 
molecule. Within the asymmetric FAN1 dimer, one of the monomers appears to 
have a primary role in catalysis by engaging DNA in its active site whereas the 
other monomer plays an ancillary role, facilitating substrate orientation and DNA 
flap unwinding (Zhao et al., 2014). The authors propose that the dimerization of 
FAN1 promotes the unwinding of the DNA duplex and guides the ssDNA towards 
the active site for incision (Zhao et al., 2014). Unwinding of the DNA duplex 
would be critical for facilitating the endonuclease activity of FAN1 on its ICL 
substrate, as the 5’ flap incision is strongly inhibited when the crosslink is located 
close to the flap branch point (Zhao et al., 2014). 
FAN1 possesses both endonuclease and exonuclease activity on 
crosslinked and non-crosslinked DNA substrates. FAN1 endonuclease activity 
exhibits preference for nicked and 5’ flap DNA structures (Gwon et al., 2014; 
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MacKay et al., 2010; Smogorzewska et al., 2010; Wang et al., 2014). Structural 
analyses by different groups suggests that binding of FAN1 to the DNA substrate 
is facilitated by the positively charged surface of the SAP domain, residues 
flanking the SAP domain and the sugar-phosphate backbone of the DNA duplex 
downstream of 5’ flap structure (Gwon et al., 2014; Wang et al., 2014; Zhao et al., 
2014). It is proposed that the direct interaction of the SAP domain with 
crosslinked DNA provides proper structural remodeling of the DNA substrate, 
which is required for incision by the nuclease domain of FAN1 (Gwon et al., 
2014; Wang et al., 2014; Zhao et al., 2014). Cleavage of 5’ flap DNA of the ICL-
stalled replication fork-like structures is followed by exonucleolytic processing of 
nicks to digest across the crosslink in 3-nucleotides stepwise incisions. This 
sequence of events is proposed to allow de facto ICL unhooking (Figure 1.2) 
(Pizzolato et al., 2015; Zhao et al., 2014).  
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Figure 1.2 FAN1 domain structure and model of FAN1 nuclease 
activity.  
(A) FAN1 contains 4 characterized domains including the UBZ, SAP, TPR, 
and NUC (nuclease) domains. (B) FAN1 is thought to participate in the ICL 
incision step. Potential substrates include the dual and single fork structures 
as well as linear DNA with an ICL. In vitro, FAN1 exhibits preference for the 
5’ flap structure via its endonuclease activity and the 5’-3’ exonuclease 
activity allowing it to digest DNA across the ICL. 
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1.5.2 Redundant functions of FAN1 and other structure-specific nucleases 
in ICL repair 
FAN1 is clearly necessary for resistance to ICL-inducing agents.  However, 
immunodepletion of FAN1 had no effect on the incision of a cisplatin ICL in the  X. 
laevis egg extract system (Douwel et al., 2014).  Normal repair in this setting 
might be attributed to the fact that FAN1 may act on structures other than dual 
convergent forks that are required for repair of the damaged plasmids in this 
system. Alternatively, FAN1 may be functionally redundant with other ICL repair 
nucleases such as MUS81, SLX1 or SNM1A (reviewed in (Zhang and Walter, 
2014). SLX1 and MUS81-EME1 are associated with SLX4 and are genetically 
epistatic in ICL repair (Castor et al., 2013; Kim et al., 2013). SLX1 is a 
promiscuous nuclease, which like FAN1 prefers 5’ flap DNA substrates in vitro. 
Therefore, it is possible that SLX1 could potentially provide 5’ flap endonuclease 
activity required for crosslink incision in the absence of FAN1 (Fricke and Brill, 
2003). 
Aside from FAN1, the SNM1 family of proteins are the only crosslink repair 
nucleases that possess a 5’-3’ exonuclease activity (Hejna et al., 2007; Wang et 
al., 2011). In yeast, Pso2 is the single SNM1 protein member, and is important 
for ICL resistance (Zhang and Walter, 2014). In higher eukaryotes, three SNM1 
homologs - SNM1A, SNM1B (Apollo) and SNM1C (Artemis) exist, with SNM1A 
and SNM1B being implicated in ICL resistance. (Cattell et al., 2010; Ishiai et al., 
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2004). SNM1A is the ortholog which has the most similarity to Pso2, and is the 
only one that can complement the ICL sensitivity of pso2Δ yeast (Hazrati et al., 
2008). SNM1A deficiency, nonetheless, confers mild crosslink sensitivity in 
mouse and human cells (Ahkter et al., 2005; Dronkert et al., 2000; Wang et al., 
2011). This suggests that SNM1A plays a minor role in mammalian ICL repair or 
that another ICL-repair nuclease, such as FAN1, compensates for the loss of 
SNM1A. Consistent with possible redundant roles of SNM1A and FAN1, the S. 
pombe Fan1 was recently shown to be non-epistatic with Pso2, as pso2Δfan1Δ 
displays greater cisplatin sensitivity than a single pso2Δ or fan1Δ mutant alone 
(Fontebasso et al., 2013). 
1.5.3 The significance of the UBZ domain and the genetic interaction 
between FAN1 and the FA pathway 
The UBZ domain located at the N-terminus of FAN1 facilitates binding 
between FAN1 and the monoubiquitinated lysine residues of FANCI/FANCD2 
(Figure 1.2A). However, the significance and function of this interaction has 
remained unclear. The UBZ-mediated interaction with the ID2 complex was first 
shown to be necessary for localization of FAN1 to ICL-induced DNA damage foci 
and psoralen-induced damage, arguing that the ICL repair activity of FAN1 may 
depend on the UBZ domain (Kratz et al., 2010; Liu et al., 2010; MacKay et al., 
2010; Smogorzewska et al., 2010). In one of the studies, the UBZ domain was 
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also shown to be necessary for resistance to DNA ICLs (Liu et al., 2010). 
More recent data from our and Seidman lab show that FAN1 lacking the 
UBZ domain can still be recruited to the site of damage (Thongthip et al., 2016). 
In experiments testing the recruitment of FAN1 to psoralen-induced ICLs, the 
Seidman lab has shown that the SAP domain was critical for rapid recruitment of 
FAN1 to ICLs. The UBZ-dependent phase of ICL-recruitment occurred more 
slowly and coincided with the localization of FANCD2 at ICLs.  These 
observations may reflect the dependency of the UBZ-dependent recruitment or 
retention of FAN1 at sites of damage on the monoubiquitination of 
FANCI/FANCD2 (Thongthip et al., 2016; Yan et al., 2012). In our hands, this 
increased recruitment/retention of FAN1 was not necessary for resistance to ICL 
damage since expression of FAN1 with mutations in the UBZ domain fully 
rescued ICL sensitivity of FAN1-deficient human cells (Zhou et al., 2012). We 
concluded that SAP domain plays a more important role in the recruitment of 
FAN1 to ICLs and that FAN1 can participate in ICL repair independently of the 
UBZ domain. 
Collectively, findings from multiple studies indicate that interaction 
between FAN1 and the ID2 complex is not required for ICL repair activity of 
FAN1 and that the crosslink repair function of FAN1 could occur independently of 
the FA pathway. Evidence from studies in the chicken DT40 cell line also support 
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this view as FAN1-/-FANCC-/- cells are more sensitive to cisplatin than wild-type, 
FAN1-/-, or FANCC-/- single knockout cells (Yoshikiyo et al., 2010). Whether the 
crosslink repair function of FAN1 is epistatic with the FA pathway in mammalian 
cells, is therefore a question of significant importance and will be experimentally 
addressed below. 
1.6 Endogenous sources of DNA damage that underlie the pathogenesis of 
ICL repair disorders 
The ICL repair pathway most likely evolved to cope with the challenges 
posed by endogenously produced ICL-inducing agents. Several sources of 
endogenous ICLs that require FA pathway’s repair activity have been proposed. 
These include the signaling molecule nitric oxide as well as the abundant abasic 
sites (also known as AP or apurinic/apyrimidinic site), which can react with the 
opposite strand of DNA to form ICLs (Dutta et al., 2007). However, reactive 
aldehydes are the most well characterized sources of DNA damage that have 
been shown to affect bone marrow and other organ system functions in vivo in an 
FA pathway deficient setting (Garaycoechea et al., 2012; Langevin et al., 2011; 
Oberbeck et al., 2014; Pontel et al., 2015). 
Aldehydes are reactive small molecules that can be found both in the 
environment and within cells as the by-products of metabolism. Examples include 
the products of lipid peroxidation, trans-4-hydroxy-2-nonenal, malondialdehyde, 
crotonaldehyde and acrolein, (Huang et al., 2010; Scharer, 2005; Stone et al., 
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2008), but also formaldehyde and acetaldehyde which can be formed from the 
protein and nucleic acid demethylation and the metabolism of amino acids and 
nucleotides (Jensen et al., 2015; Loenarz and Schofield, 2008; Matsuda et al., 
1999; Ogawa et al., 2000; Walport et al., 2012). Cells possess powerful 
detoxification systems that limit the concentration of reactive aldehydes in 
different organs. The majority of aldehyde detoxifying enzymes belong to the 
aldehyde dehydrogenase gene (ALDH) superfamily which consists of 19 gene 
members in humans (Jackson et al., 2011; Marchitti et al., 2008; Yoshida et al., 
1998). ALDH2 is one of the most characterized ALDH family members, as it is 
involved in the conversion of acetaldehyde, an intermediate of ethanol 
metabolism, to acetate (Goedde and Agarwal, 1990; Klyosov et al., 1996). 
Besides ALDHs, the glutathione-dependent alcohol dehydrogenase 5 
(ADH5/GSNOR), a class III alcohol dehydrogenase (ADH) plays a key role in the 
clearance of formaldehyde, a simpler but more toxic type of aldehyde (Sanghani 
et al., 2000; Staab et al., 2009). 
Recent work has implicated both acetaldehyde and formaldehyde as the 
endogenous ICL-inducing agents that create a problem when Fanconi anemia 
proteins are not functional. It has been shown that an increase in endogenous 
acetaldehyde or formaldehyde level due to ALDH2 or ADH5 deficiency leads to 
chromosomal instability and results in severe proliferation defects in FA-deficient 
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cell lines (Langevin et al., 2011; Marietta et al., 2009; Mechilli et al., 2008; 
Rosado et al., 2011; Wang et al., 2000). 
 
1.6.1 Acetaldehyde-induced ICL damage 
Acetaldehyde is a toxic agent found in tobacco smoke, vehicle exhaust 
and some dietary products. Acetaldehyde is a common endogenous by-product 
of threonine, tyrosine, b-alanine and deoxyribose phosphate metabolisms 
(Jacobsen, 1950; Matsuda et al., 1999; Ogawa et al., 2000). Acetaldehyde can 
also be produced by oxidation of ethanol by the NAD-dependent alcohol 
dehydrogenases in the liver (Zakhari, 2006).  
 
Acetaldehyde treatment induces H2AX phosphorylation, stimulates 
mutagenesis, and increases sister chromatid exchanges in cultured mammalian 
cells (Bird et al., 1982; Dellarco, 1988; Ristow and Obe, 1978; Wang et al., 2001).  
Mouse and human cells deficient for the FA pathway display aberrant 
chromosomes and hypersensitivity upon treatment with acetaldehyde (Langevin 
et al., 2011; Marietta et al., 2009; Mechilli et al., 2008; Ridpath et al., 2007).  
 
To study the effect of acetaldehyde detoxification on cells lacking the FA 
pathway, the Patel lab has generated mice that lack both the FA pathway and 
ALDH2.  Fancd2-/-Aldh2-/- and Fanca-/- Aldh2-/- mice show aberrant embryonic 
development as well as birth defects (Garaycoechea et al., 2012; Langevin et al., 
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2011; Oberbeck et al., 2014).  The double Fancd2-/-Aldh2-/- mutant animals 
have a reduced survival rate, with some embryos dying between embryonic day 
9.5 and 13.5. In order to produce viable pups, the pregnant females need to 
maintain at least one wild-type Aldh2 allele (Langevin et al., 2011). The presence 
of the maternal Aldh2 is even more significant for the development of Fanca-/-
Aldh2-/- embryos, as they can only be born if the embryos are surgically 
transferred to a mother that is homozygous for wild-type Aldh2. Despite this 
rescue strategy, Fanca-/-Aldh2-/- mice are born with developmental defects such 
as eye and craniofacial abnormalities (Oberbeck et al., 2014). Additionally, 
treatment with ethanol during pregnancy can promote the developmental 
abnormalities in Fancd2-/-Aldh2-/- and Fanca-/-Aldh2-/- double-mutant pups 
(Langevin et al., 2011).  
Fancd2-/-Aldh2-/- mice that were derived from Aldh2+/- mothers, allowing 
them to develop normally, succumb to acute lymphoblastic leukemia (ALL) by 6 
months of age.  Majority of the remaining survivors develop spontaneous bone 
marrow failure due to hematopoietic stem cell attrition (Garaycoechea et al., 
2012; Langevin et al., 2011). The frequency and function of the hematopoietic 
stem and progenitor cells in Fancd2-/-Aldh2-/- mice are drastically reduced 
compared to wild-type or single mutant animals. Further analysis revealed that 
Fancd2-/-Aldh2-/- HSCs are inherently damaged and demonstrate induction of g-
H2AX that is exacerbated following ethanol feeding (Garaycoechea et al., 2012). 
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These studies indicate a requirement for acetaldehyde detoxification by ALDH2 
for the normal development, hematopoietic stem cell function, and tumor 
suppression, particularly in the absence of the FA pathway. 
The relevance of acetaldehydes in the pathogenesis of Fanconi anemia 
has also been validated in human studies. Concomitant ALDH2 deficiency 
greatly exacerbates developmental abnormalities, bone marrow failure, and 
leukemia development in Japanese FA patients (Hira et al., 2013). Strikingly, FA 
patients with a single allele of the dominant negative ALDH2 variant (rs671) 
display accelerated progression to bone marrow failure. Furthermore, some FA 
patients with biallelic ALDH2 rs671 variant exhibit an onset of myelodysplastic 
syndrome and bone marrow failure at an age as young as 4 months. 
1.6.2 Formaldehyde-induced ICL damage 
Like acetaldehyde, formaldehyde is found in the environment as a 
breakdown product of compounds such as tobacco smoke, and the sweetener 
aspartame. It is also formed endogenously as a byproduct of metabolic reactions 
(Jensen et al., 2015; Trocho et al., 1998). Endogenous formaldehyde can be 
derived from oxidative demethylation reactions, for instance through 
demethylation of histones, RNA, and DNA by KDM1/JMJC or ABH family of 
enzymes within the nucleus (Loenarz and Schofield, 2008; Pontel et al., 2015; 
Walport et al., 2012). Formaldehyde is highly mutagenic and genotoxic due to its 
27 
ability to introduce DNA monoadducts (McGhee and von Hippel, 1977). DNA-
protein crosslinks (DPCs) (Casanova-Schmitz and Heck, 1983; Magana-
Schwencke and Ekert, 1978; Solomon and Varshavsky, 1985), and DNA 
interstrand crosslinks (Auerbach, 1949; Herskowitz, 1950; Lu et al., 2010). 
The FA pathway has been shown to be important for the repair of 
formaldehyde-induced damage. FA pathway deficient DT40 chicken cells, 
primary mammalian cells as well as cancer cell lines are hypersensitive to 
formaldehyde (Pontel et al., 2015; Ridpath et al., 2007; Rosado et al., 2011). The 
combined inactivation of Fancd2 and the formaldehyde detoxifying enzyme Adh5 
in the chicken DT40 cells results in synthetic lethality (Rosado et al., 2011). 
The Fancd2-/-Adh5-/- double mutant animals display HSC dysfunction, 
which leads to bone marrow failure and leukemia (Pontel et al., 2015).  
Additionally, Fancd2-/-Adh5-/- animals develop liver and kidney karyomegaly 
which may be associated with their accelerated degeneration. The kidney failure 
observed in Fancd2-/-Adh5-/- is primarily caused by glomerular damage, which 
manifests as a significant change in the glomerular anatomical structure, 
accompanied by severe proteinuria. Animals display an increase in the level of 
karyomegaly (enlarged nuclei) in the renal tubular cells and liver hepatocytes. 
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At this point it is unclear if other reactive aldehydes will have influence on 
the phenotypes of Fanconi anemia pathway deficient human or mice.  It is 
unknown if other repair pathways are involved in clearance of acetaldehyde- or 
formaldehyde-induced DNA damage.  This question will be explored in this thesis 
for FAN1. 
1.7 FAN1 is mutated in patients with Karyomegalic Interstitial Nephritis 
(KIN) 
FAN1 was considered a candidate FA gene based on the observation that 
there is a direct association between FAN1 and the ID2 complex and the finding 
that its nuclease activity is required for ICL resistance. Unexpectedly, biallelic 
loss of function mutations in FAN1 were identified in patients with Karyomegalic 
Interstitial Nephritis (KIN) (Zhou et al., 2012). KIN is a chronic kidney disease, 
characterized by the presence of enlarged, polyploid (karyomegalic) and 
hyperchromatic nuclei in the proximal and distal tubules of the kidney (Godin et 
al., 1996; Mihatsch et al., 1979; Spoendlin et al., 1995). It is a rare disease with 
less than 50 cases being reported so far (Isnard et al., 2016). Patients with KIN 
develop progressive kidney disease, which eventually leads to early onset of 
end-stage kidney failure in 20-30 year olds (Mihatsch et al., 1979; Spoendlin et 
al., 1995; Zhou et al., 2012). 
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The urine of KIN patients typically show glucosuria and mild proteinuria, 
whereas hematuria is rare (Bhandari et al., 2002; Isnard et al., 2016; Mihatsch et 
al., 1979). Histologically, the kidney of KIN individuals display tubular basement 
membrane degeneration, tubular atrophy with significantly thicker tubular 
basement membrane, microcysts, interstitial infiltrations and pronounced fibrosis 
(Zhou et al., 2012). In addition to the renal tissue, systemic karyomegaly in other 
tissues such as liver, lung, brain, skin, and digestive tissues has also been 
observed in many patients (Burry, 1974; Mihatsch et al., 1979; Sclare, 1976). 
Furthermore, a number of cases exhibit elevated serum markers of hepatocyte 
damage, mild anemia and recurrent upper respiratory infections of unknown 
etiology (Bhandari et al., 2002; Godin et al., 1996; Mihatsch et al., 1979; 
Spoendlin et al., 1995). 
Genetically, KIN is caused by autosomal recessive mutations in FAN1, 
with mostly nonsense mutations that lead to open reading frame truncations 
(Zhou et al., 2012). A number of missense mutations found in 3 of the studied 
families, are in the conserved functional nuclease domain, suggesting that the 
nuclease activity of FAN1 is important in protection against KIN development 
(Zhou et al., 2012). It is unclear whether KIN is driven by endogenous or 
exogenous sources of lesions. Viral infections and exposure to 
immunosuppressants or environmental genotoxins such as ochratoxin A, heavy 
metals or herbal medicines are typically excluded in cases described in the 
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literature (Bhandari et al., 2002; Godin et al., 1996; Mihatsch et al., 1979; Radha 
et al., 2014; Uz et al., 2011).  Based on our current knowledge that FAN1 is 
necessary for ICL repair, the likely damage that accumulates in KIN patients are 
ICLs but their source is unknown. 
In this thesis, I will present our studies on the ICL repair function of FAN1 
and the pathogenesis of Karyomegalic Interstitial Nephritis (KIN) that develops as 
a result of FAN1 deficiency. Using human KIN-patient and Fan1-deficient mouse 
cell lines, we show that FAN1 is required for ICL resistance in both human and 
mice. FAN1 possesses ICL repair activity that is independent of the FA pathway, 
yet FAN1 is redundant with SNM1A, another ICL repair nuclease. I will also 
describe Fan1-deficient mouse model that displays characteristics of KIN 
including the presence of kidney and liver karyomegaly. The enlargement of 
nuclei in Fan1-deficient kidney and liver occurs progressively with age and is a 
result of genome endoreduplication. The hematopoietic stem and progenitor cells 
of Fan1-deficient animals are susceptible to crosslink-inducing agent but not to 
ionizing irradiation. Finally, we provide evidence that formaldehyde and 
acetaldehyde are unlikely the endogenous sources of damage that drive the 







Chapter 2: ICL repair functions of FAN1 in 




The contribution of FAN1 to ICL resistance has been firmly established 
(Kratz et al., 2010; Liu et al., 2010; MacKay et al., 2010; Smogorzewska et al., 
2010). It is now clear that mutations in FAN1 lead to kidney disease in humans 
(Zhou et al., 2012), a disease that is distinct from Fanconi anemia.  This chapter 
describes experiments that take advantage of cell lines from KIN patients and a 
mouse model of the human disease, to answer questions that remain about the 
function of FAN1. It explores the significance of FAN1 interaction with the 
FANCD2 for ICL repair, the genetic interaction of FAN1 with other nucleases 
implicated in ICL repair, and the organismal consequences of FAN1 dysfunction 
with and without exogenous DNA damage. 
Results
2.2 Characterization of FAN1’s functions using human KIN patient cells and 
human tissues 
2.2.1 FAN1 deficiency causes cellular sensitivity to DNA crosslink-inducing 
agents in KIN patient cells 
Depletion of FAN1 using siRNA and shRNA has revealed that FAN1 was 
necessary for cellular resistance to ICLs (Kratz et al., 2010; Liu et al., 2010; 
MacKay et al., 2010; Smogorzewska et al., 2010).  To confirm that FAN1 
deficiency identified in the germline of patients with KIN also leads to sensitivity 
to ICL-inducing agents, patient fibroblasts were tested for sensitivity to MMC. 
 33 
Patient cell line (A1170) carrying homozygous FAN1 truncation leading to lack of 
FAN1 protein, exhibited a survival defect and a significant induction of 
micronuclei, a hallmark of chromosomal instability when treated with MMC 
(Figure 2.1A, B). Importantly, the ICL sensitivity of the patient cells was rescued 
when wild-type copy of FAN1 was introduced into the cells (Figure 2.1A). This 
result was consistent with the proposed role of FAN1 in genome maintenance 
and the repair of ICLs.  It is worth noting that KIN patient cells were significantly 
less sensitive to MMC then the Fanconi anemia (FA) patient cells lacking FANCA 
(RA3087) (Figure 2.1A). 
 
2.2.2 Differential expression of FAN1 and FANCD2  
 The distinct phenotypes of KIN and FA could stem from the differential 
expression of FAN1 and FA proteins in a tissue specific manner. FAN1 could 
potentially be highly expressed in the kidney whereas FA proteins might be more 
enriched in the bone marrow, the tissues that are affected in the corresponding 
disorders. The study of FAN1 and FANCD2 gene expression revealed that FAN1 
transcripts could be detected in all tissues, although at different levels of 
expression  (Zhou et al., 2012). FAN1 mRNA was expressed at a higher level 
than FANCD2 in parenchymatous organs, including the kidney, liver and 
neuronal tissues, whereas FANCD2 expression exceeded FAN1 in lymphatic or 
bone marrow-derived tissues as well as in skin and testis (Zhou et al., 2012). The 
fact that FAN1 was expressed at a particularly high level in the parenchymatous 
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organs, raises the possibility that those tissues might depend on FAN1 for its 
normal function. To corroborate the findings from FAN1 gene expression study, 
we examined FAN1 expression at the protein level across multiple tissues 
including the kidney and liver that are affected in KIN. While full-length FAN1 
protein was expressed at a particularly high level in the kidney tissue, a 
significantly lower level was detected in the liver and the bone marrow (Figure 
2.1C, D). However, as will be discussed later, MMC treatment resulted in bone 
marrow failure in Fan1-deficient mice. This observation could be explained if 
FAN1 is expressed in a subset of bone marrow cells (potentially the stem and 
progenitor cells), to protect against ICL-induced bone marrow failure. 
2.2.3 FANCD2 Ubiquitination, G1/S and G2/M checkpoints are intact in 
human FAN1-deficient cells 
To assess if DNA damage signaling and the activation of FA pathway are 
compromised in FAN1-deficient cells, we first tested if FAN1 was required for the 
monoubiquitination of FANCD2 and FANCI in FAN1 patient fibroblasts (A1170) 
and lymphocytes (A4466, A4486, A4385) (Zhou et al., 2012). The loss of function 
mutations of FAN1 did not affect the presence of FANCD2 and FANCI 
monoubiquitination, suggesting that the FA pathway is activated even in the 
absence of FAN1 (Figure 2.2A, B)(Zhou et al., 2012). 
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We next examined whether FAN1 was involved in the regulation of G1/S 
and G2/M checkpoints following DNA damage treatments. To monitor the G1/S 
checkpoint, we analyzed the level of early S-phase cells after the treatment with 
ionizing radiation (IR) by measuring the BrdU+ cells with DNA content close to 2N. 
Cells null for ATM, kinase necessary for DNA damage signaling abated the G1/S 
checkpoint, allowing the progression of the IR-damaged cells into S-phase. In 
contrast, the absence of FAN1 or FA protein did not affect the G1/S checkpoint, 
as cells were effectively blocked in G1 following the IR treatment (Figure 2.2C, D). 
Similarly, the G2/M checkpoint appeared to be intact in cells lacking FAN1 or 
FANCA. FAN1- and FANCA-deficient cells were impeded from entering mitosis 
to the same extent as BJ wild-type cells following IR, unlike the G2/M checkpoint 
deficient ATR-depleted cells (Figure 2.2E, F). 
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Figure 2.1 FAN1 deficiency causes ICL sensitivity in KIN patient cells 
and FAN1 is highly expressed in the kidney tissue. 
(A) Survival of wild-type fibroblasts (BJ), RA3087 FANCA-/-, A1170 FAN1-/-
, and A1170 cells transduced with eV (empty vector), or WT (wild-type) 
FAN1. Cells were treated with MMC. After 6 days, cell numbers were 
determined and normalized to the untreated control to calculate the 
percentage of survival. Error bars indicate SD. (B) Blinded quantification of 
cells with micronuclei following 1 hour of 1 µM MMC treatment. (C-D) FAN1 
expression in human tissues. Lysates from indicated tissues were run and 
immunoblotted with an antibody against FAN1 (RC394) (Left). Loading was 
assessed by a staining with Ponceau dye (Right). 
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Figure 2.2 FANCD2/FANCI ubiquitination and G1/S and G2/M 
checkpoints are not affected in FAN1-deficient KIN patient cells. 
(A-B) Monoubiquitination status of FANCD2 in patient cell lines. Indicated 
cells were treated with 1 µM MMC for 24 hours and collected for western 
blotting with anti-FANCD2 and anti-alpha tubulin antibodies. L indicates 
long, monoubiquitinated form of FANCD2 and S is a short, non-modified 
form. (C) Representative FACS profiles of G1/S checkpoint analysis. Cells 
were analyzed by BrdU and PI (propidium iodide) before and after IR. (D) 
Quantification of early S-phase cells with BrdU+ and DNA content around 
2N. The number of early S-phase cells following IR-treatment was 
normalized to the untreated control to calculate the % of G1/S transition 
inhibition. (E) Representative FACS profiles of G2/M checkpoint analysis. 
Cells were analyzed by phosphorylated H3 and PI (propidium iodide) before 
and after IR. (F) Quantification of mitotic cells that were positive for 
phosphorylated H3 with DNA content close to 4N. The number of mitotic 
cells following IR-treatment was normalized to the untreated control to 
calculate the % of G2/M transition inhibition. 
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2.2.4 FAN1 has ICL repair activity that is non-epistatic with FA factors in 
human cells 
It was previously shown that deletion of FAN1 further sensitizes FANCC- 
and FANCJ- deficient DT40 chicken cells to ICL-inducing agents. This indicates 
that FAN1 has FA pathway-independent function in ICL repair (Yoshikiyo et al., 
2010). To examine whether this aspect of FAN1 function is conserved in human 
cells, we tested whether depletion of the Fanconi anemia factors including 
FANCD2, SLX4 or the SLX4-associated nucleases XPF and MUS81 in the 
FAN1-mutant cells led to increase in ICL sensitivity. FAN1-positive BJ cells were 
used as a control in the experiment.  Depletion of FANCD2, SLX4, XPF, or 
MUS81 in FAN1-deficient cells caused greater MMC sensitivity than the level 
observed in the corresponding FA factor-depleted BJ controls or in the non-
depleted FAN1-/- cells (Figure 2.3A-E). These results suggested that, also in 
human cells, FAN1 could function independently of the Fanconi anemia pathway 
in ICL damage response. 
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Figure 2.3 FAN1 has ICL repair function that is non-epistatic with the 
FA pathway. 
MMC sensitivity in A1170 FAN1-/- fibroblasts transfected with the siRNA 
against genes previously implicated in crosslink repair (A) FANCD2 
depletion, (B) SLX4 depletion, (C) MUS81 depletion, (D) XPF depletion, (E) 
Immunoblot of expression levels of indicated proteins after siRNA-mediated 
depletion in the A1170 cells used in the experiment shown in panel A-D. 
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2.3 Characterization of Fan1 knockout mouse 
2.3.1 Verification of Fan1 knockout in the mouse model 
To investigate the cellular and organismal functions of FAN1, we 
generated Fan1-deficient mice. The Fan1 locus was targeted in embryonic stem 
cells using a conditional Fan1tm1a (KOMP)Wtsi (Fan1stop) construct (Knockout 
Mouse Project [KOMP]) (Figure 2.4A). The correctly targeted clones were used 
to create a mouse with a single Fan1stop allele, which was verified by Southern 
blotting using probes at 5’ and 3’ of the targeted site. (Figure 2.4B, C). 
Fan1+/stop males were crossed with FLPe deleter female mice to generate mice 
carrying Fan1lox allele (Figure 2.4A). Mice carrying the disrupted Fan1 allele -
Fan1Δex3&4, which for ease of labeling, we refer to here as Fan1−, was 
generated from the cross between Fan1+/lox male and E2a-Cre female mice. 
Southern blotting using the probe located 5’ of the targeted locus and PCR 
genotyping were performed to verify the generation of Fan1-/- mice (Figure 2.5A-
D). Deletion of exons 3 and 4 from Fan1 gene resulted in low level of Fan1 
expression with Fan1 transcript reduced to about 50% of the wild-type level in the 
Fan1+/- heterozygotes and lower than 10% in Fan1-/- animals. At the protein 
level, no protein expression could be detected in mouse embryonic fibroblasts 
(MEFs) obtained from homozygous Fan1-/- embryonic day 13.5 (E13.5) embryos 
(Figure 2.5E-G). Together these results suggest that Fan1 expression is 
abrogated in the Fan1 knockout mouse that we engineered. 
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To assess whether FAN1 deficiency recapitulates the phenotypes 
observed in human cells lacking FAN1, we examined the cellular sensitivity of 
Fan1-/- cells to ICL-inducing agent MMC when compared with Fan1+/+ or 
Fan1+/- MEFs. Similar to human cells, Fan1-/- MEFs displayed significant growth 
defects and an increase in the level of chromosome breaks and radial 
chromosomes when cells were treated with MMC (Figure 2.6A-C). Importantly, 
the cellular sensitivity and the increased breakage in Fan1-/- MEFs after MMC 
treatment could be fully rescued when cells were transduced with wild-type 
mouse Fan1 cDNA (Figure 2.6D, E, Figure 2.8C). These experiments show that 
the crosslink repair defect in Fan1-/- MEFs is due to a lack of functional FAN1 
protein. 
Fan1-deficient MEFs were also more sensitive to treatment with 
acetaldehyde and formaldehyde, both of which have been implicated as 
endogenous sources of DNA ICLs (Figure 2.6F, G). However, the level of 
sensitivity to all tested ICL-inducing agents was significantly lower than that of 
MEFs deficient in SLX4 (Slx4f3/f3), a scaffold protein for three nucleases, 
including XPF, which is the major effector of the FA pathway (Figure 2.6A, F, G). 
Consistent with previous reports, Fan1-deficient MEFs did not show 
hypersensitivity to either camptothecin (CPT) or hydroxyurea (HU), suggesting 
that FAN1 is specifically required for the repair of DNA ICLs and no other S-
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phase-associated replication blocks (Figure 2.6H, I; (Kratz et al., 2010; Liu et al., 
2010; MacKay et al., 2010; Smogorzewska et al., 2010). 
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Figure 2.4 Targeting strategy to create the Fan1-deficient mouse. 
(A) Targeting strategy for Fan1-deficient mouse. Coding exons 1-6 of the 
Fan1 genomic locus in wild type (chromosome 7), the Fan1stop, the 
Fan1lox and the Fan1Δex3&4 mutant alleles generated are shown. The 
wild-type Fan1 gene contains a 20.5 kb BamHI restriction fragment that 
hybridizes to the 5’(red) and 3’(dark green) probes. A correctly targeted 
Fan1stop locus contains a 13.8 kb fragment that hybridizes to the 5’ probe 
and 7.5 kb fragment that hybridizes to the 3’ probe. The neomycin cassette 
(pink), the FRT (blue), the LoxP (green), the splice acceptor (SA), and the 
poly A (pA) sites are also shown. The cross between Fan1+/stop and FLP 
deleter mice generated Fan1+/lox. The cross between Fan1+/lox and 
FVB/N-Tg(Ella-cre)C5379Lmgd/J mice to derive Fan1+/-(Δex3&4) are 
shown. The comparison between full-length wild type FAN1 transcript and 
Fan1-(Δex3&4) transcript lacking exon 3 and exon 4 are shown. Red 
asterisk (*), stop codon. The comparison between full-length wild type FAN1 
protein with the domain architecture and the expected truncated FAN1 
protein product expressed from Fan1Δex3&4 allele are shown. (B, C) 5’ and 
3’ Southern blot analyses of BamHI–digested genomic DNA from Fan1+/+ 
and Fan1+/stop mice. CR, cross-reacting band. 
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Figure 2.5 Verification of Fan1 knockout mouse. 
(A) Schematic of the wild-type and Fan1Δex3&4 mutant alleles. The wild-
type Fan1 gene contains a 20.5-kb BamHI restriction fragment that can be 
detected with a 5′probe (red line). A correctly targeted Fan1 locus harbors 
a 3.1-kb deletion, including exons 3 and 4, resulting in a 17.4-kb fragment 
that hybridizes to the same probe. The FRT and LoxP sites are indicated as 
blue and green triangles, respectively. (B) Southern blot analysis of BamHI-
digested gDNA from Fan1+/+, Fan1+/-, and Fan1-/- MEFs. (WT) Wild type; 
(Mut) mutant. (C-D) Schematic showing primer positions used for 
genotyping (top). Genotyping PCR for Fan1+ and Fan1- alleles using DNA 
from MEFs of the indicated genotypes (bottom). (E) Schematic of exons 9-
11 of Fan1, showing exon 10 q-PCR primers used in panel (F). (F) 
Quantification of Fan1 mRNA level in MEFs of indicated genotypes. (G) 
Immunoblot of extracts from MEFs of the indicated genotypes using an 
antibody recognizing mouse FAN1. HAmFAN1 is N-terminally HA-tagged 
mouse FAN1 and is expressed in Fan1-/- MEFs. 
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Figure 2.6 FAN1 is necessary for resistance to DNA ICL damage in 
MEFs. 
(A) Survival of MEFs after treatment with the indicated doses of mitomycin 
C (MMC). MEFs were treated in triplicate with increasing concentrations of 
MMC. After 6 days, cell numbers were determined and normalized to un- 
treated control to calculate the percentage of survival. Error bars indicate 
SD. (B) Examples of metaphase spreads of Fan1+/+ (left) and Fan1-/- 
(right) after exposure to 50 nM MMC for 24 h. Arrowheads indicate radial 
chromosomes shown in the inset. (C) Quantification of chromosome 
breakage of Fan1+/+ and Fan1-/- MEFs shown in B. (∗∗∗∗) P < 0.0001, 
calculated using a t- test. (D) Complementation of MMC sensitivity in Fan1-
/- MEFs. Fan1-/- MEFs stably transduced with empty vector (eV) or vector 
expressing HA-tagged mouse FAN1 (HA-mFAN1) were exposed to different 
levels of MMC, as in A. Error bars indicate SD. (E) Immunoblot showing the 
expression of HA-mFAN1 used in D. (F-G) Sensitivity to aldehydes of the 
indicated MEFs. MEFs were treated in triplicate with increasing 
concentrations of acetaldehyde (0–8 mM) (F) or formaldehyde (0–300 μM) 
(G) for 2 h before being washed three times with PBS and were cultured for 
an additional 6 days in non-drug-containing medium. After 6 days, cell 
numbers were determined and normalized to untreated control to calculate 
the percentage of survival. Error bars indicate SD. (H) Survival of Fan1+/+ 
and Fan1-/- MEFs treated with hydroxyurea (HU). MEFs were treated in 
triplicate with increasing concentrations of HU. Error bars, s.d.. (I) Survival 
of indicated MEFs after camptothecin (CPT) treatment (0-20 nM). MEFs 




2.3.2 FAN1 participates in ICL repair independently of the UBZ domain 
Our earlier work revealed that the UBZ domain was not important for the 
ability of FAN1 to confer resistance to crosslinking agents in human cells (Zhou 
et al., 2012). In that study, the UBZ mutated Cys44AlaCys47Ala human FAN1 
fully rescued the ICL repair defect in the KIN patient cells. To assess which 
domains of mouse FAN1 are important for ICL resistance, we expressed mouse 
FAN1 with mutated UBZ (p.Cys44Ala;Cys47Ala), SAP (p.Leu480Pro), or 
nuclease (p.Asp963Ala) domains in Fan1-/- MEFs and tested complementation 
of ICL sensitivity in a survival assay. Unlike expression of wild-type mouse Fan1 
cDNA, which was able to fully complement the MMC sensitivity of Fan1-deficient 
MEFs, expression of cDNA carrying a mutation in the SAP or nuclease domain 
resulted in no rescue (Figure 2.7A-C, E, F). In agreement with our previous study, 
the UBZ-mutated Fan1 variant (p.Cys44Ala; Cys47Ala) behaved like the wild-
type allele in this assay, indicating that FAN1-conferred ICL resistance is indeed 
independent of its FANCD2/FANCI interaction in mammalian cells (Figure 2.7A-
D). This result was perplexing at the time, since the UBZ domain is critical for 
stable localization of FAN1 to the sites of DNA damage (Smogorzewska et al., 
2010) and implies that a different domain of FAN1 might be important for 
localization of FAN1 to the ICLs. 
51 
Figure 2.7 The UBZ domain is dispensable for FAN1’s function in ICL 
repair. 
(A) Schematic representation of the mouse FAN1 protein indicating the 
mutations in the key functional domains: C44A/C47A in the UBZ domain; 
p.L480P in the SAF-A/B, Acinus, and PIAS (SAP) domain; and p.D963A in
(VRR- NUC) virus-type replication repair nuclease (NUC) domain. (B) MEFs 
stably transduced with empty vector or vector expressing Fan1 variants with 
mutations shown in A were MMC-treated. Error bars indicate SD. (C) 
Immunoblot showing expression of mouse Fan1 mutant cDNAs in MEFs 
used in B. (D) Quantification of chromosome breakage analysis of the 
indicated MEFs treated with 50 nM MMC for 24 hours. (E) MEFs stably 
transduced with vector expressing WT FAN1 or FAN1 D963A variant were 
exposed to MMC (0-100 nM). Error bars, s.d. (F) Immunoblot showing 
expression of WT FAN1 or FAN1 D963A in MEFs used in (E). 
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2.3.3 FAN1 can function independently of the FA pathway 
Having established that FAN1 can repair ICL damage independently of its 
binding to FANCI/D2, we sought to determine whether FAN1 is epistatic with the 
FA pathway. To elucidate this genetic interaction, we generated Fan1-/-Fancd2-/- 
and Fan1-/-Fanca-/- double-knockout MEFs by crossing Fan1+/- mice with 
Fancd2+/- (Houghtaling et al., 2003) or Fanca+/- (INoll et al., 2002) mice. Fan1-/- 
Fancd2-/- animals generated from the intercrosses between Fan1-/-Fancd2+/- 
mice were born at an observed ratio of 0.21, which is not significantly different 
from the expected ratio of 0.25. Fancd2-/- and Fanca-/- MEFs were more 
sensitive to MMC than the Fan1-/- cells (Figure 2.8A, B), confirming that the FA 
pathway deficiency results in more pronounced inability to repair the MMC-
induced damage. No further MMC-induced proliferation defect was apparent in 
the double-mutant MEF cell lines compared with cells lacking Fancd2 or Fanca 
alone (Figure 2.8A, 2.9A). This might be due to difficulty in measuring small 
differences in cellular growth when cells are already very sensitive to DNA 
damage as is the case of FA protein deficient cells.  However, a deficiency in 
Fan1 enhanced the degree of MMC-induced chromosomal abnormalities in 
Fancd2-/- MEFs (Figure 2.8C). FAN1 therefore has a FANCD2-independent 
function in the protection of cells from accruing ICL-induced chromosomal 
instability. To assess the epistasis in human cells, we knocked out FAN1 in 
FANCA or FANCD2 patient cell lines (Kim et al., 2013) using CRISPR/Cas9. 
FAN1 deficiency further sensitized FANCA-/- cells to MMC, which could be 
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complemented back to levels of MMC resistance seen in FANCA-/- cells by 
exogenously expressing wild-type FAN1 (Figure 2.9A-E, H). However, human 
FAN1-/-FANCD2-/- cells did not exhibit significantly greater sensitivity to MMC 
than FANCD2 single mutant cells (Figure 2.9F-H). Collectively, the analysis of 
the UBZ domain mutant and the epistasis analysis supports the conclusion that 
FAN1 has some function in ICL resistance that is independent of the FA pathway. 
This FAN1-specific repair function is more subtle compared with the activity of 
the FA-dependent pathway in mammalian cells, at least when MMC is used to 
introduce ICLs. 
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Figure 2.8 Fan1 and FA genes are non-epistatic in MEFs in 
chromosome breakage assay.  
(A) Survival of single Fan1-/- and Fancd2-/- and double Fan1-/-Fancd2-/- 
MEFs following single treatment with MMC. After 6 days, cell numbers were 
determined and normalized to the untreated control to calculate the 
percentage of survival. (WT) Wild type. Error bars indicate SD. (B) Survival 
of single Fan1-/-, Fanca-/-, and double Fan1-/-Fanca-/- deficient MEFs 
following single treatment with MMC as described in A. Error bars indicate 
SD. (C) Quantification of chromosome breakage analysis of the indicated 
MEFs collected 24 h after 100 nM MMC treatment or left untreated. (∗∗) P < 
0.01; (∗∗∗) P < 0.001, calculated by one- way ANOVA. 
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Figure 2.9 Fan1 and FA genes are non-epistatic in human cells.  
(A) Survival of wild-type fibroblasts (BJ) and A1170-22 FAN1-/-, RA3087 
FANCA-/-, and two clones (1 and 2) of RA3087 FANCA-/-FAN1-/- cells 
obtained by CRISPR/Cas9 gene editing. Cells were treated with MMC. After 
6 days, cell numbers were determined and normalized to the untreated 
control to calculate the percentage of survival. Error bars indicate SD. (B) 
Immunoblot assessing expression of human FAN1 in human fibroblasts 
used in A. (C) Immunoblot assessing expression of human FAN1 
transduced in RA3087 FANCA-/-FAN1-/- clone 1 and clone 2. The clones 
highlighted in red were used for the experiment outlined in (D, E). (D, E) 
Survival of RA3087 FANCA-/-FAN1-/- clone 1 and clone 2 complemented 
with HA-hFAN1. Cells were treated with MMC as described in A. MEFs 
collected 24 h after 100 nM MMC treatment or left untreated. (∗∗) P < 0.01; 
(∗∗∗) P < 0.001, calculated by one-way ANOVA. (F) Survival of wild-type 
fibroblasts (BJ) and A1170-22 FAN1-/-, RA2645 FANCD2-/-, and four 
clones (1, 5, 9 and 10) of RA2645 FANCD2-/-FAN1-/- cells obtained by 
CRISPR/Cas9 gene editing. Cells were treated with MMC. After 6 days, cell 
numbers were determined and normalized to the untreated control to 
calculate the percentage of survival. Error bars indicate SD. (G) Immunoblot 
assessing expression of human FAN1 in human fibroblasts used in F. (H) 
Sequences of the targeted clones RA3087 FANCA-/-FAN1-/- clone 2, 
RA2645 FANCD2-/-FAN1-/- clone 5, 9, and 10 used in A-G. The targeted 
region of RA3087 FANCA-/-FAN1-/- clone 1 and RA2645 FANCD2-/-FAN1-




2.3.4 Genetic interactions of Fan1 with Slx4 and Slx4-associated nuclease 
Mus81 
To determine the genetic interaction between Slx4, Slx4-associated 
nuclease Mus81, and Fan1, we generated Fan1-/-Slx4f3/f3 and Fan1-/-Mus81-/- 
MEFs through appropriate crosses. As shown earlier, Slx4f3/f3 cells were 
significantly more sensitive to ICL-inducing agent compared to Fan1-/- cells 
(Figure 2.6A, 2.10A). Inactivating Fan1 in Slx4f3/f3 cells did not have additive 
effect on cellular sensitivity to MMC, suggesting that Slx4 plays a more dominant 
role in ICL repair and is epistatic with Fan1 in mouse cells (Figure 2.10A). 
Mus81-deficient MEFs were also significantly more sensitive to MMC than 
wild-type cells but less sensitive then Fan1-/- cells (Figure 2.10B). Notably, lack 
of MUS81 did not induce a remarkable increase in MMC-induced chromosomal 
breakage, unlike that seen in Fan1 deficiency (Figure 2.10C). The double-
knockout Fan1-/-Mus81-/- MEFs generated through mouse intercrosses were as 
sensitive to MMC as Fan1-/- cells, suggesting that Fan1 and Mus81 are epistatic. 
Furthermore, Mus81 knockout also did not significantly change the extent of 
chromosomal aberrations in MEFs lacking Fan1 (Figure 2.10C), although there 
was a trend of increased abnormalities in the double-deficient cells. 
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Figure 2.10 Genetic interactions of Fan1 with Slx4 and Mus81. 
(A) Survival of Fan1-deficient, Slx4-deficient, and double-deficient MEFs 
treated with the indicated levels of MMC. After 6 days, cell numbers were 
determined and normalized to the untreated control to calculate the 
percentage of survival. (WT) Wild type. Error bars indicate SD. (B) Survival 
of Fan1-deficient, Mus81-deficient, and double-deficient MEFs treated with 
MMC as described in (A) (WT) Wild type. Error bars indicate SD.  (C) 
Quantification of chromosome breakage analysis of the indicated MEFs 
treated with 50 nM MMC for 24 h. (∗∗∗∗) P < 0.0001; (n.s.) Not significant, 
as determined by one-way ANOVA. 
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2.3.5 FAN1 is functionally redundant with SNM1A 
Recent biochemical analyses revealed that in vitro FAN1 could incise 
close to a crosslink embedded in a variety of DNA substrates. In some cases, the 
processing of crosslink substrates by FAN1 occurred at both the 5′ and 3′ sides 
of the crosslink, leading to complete unhooking of the DNA crosslink (Pizzolato et 
al., 2015; Wang et al., 2014). To date, SNM1A, a homolog of yeast Pso2, is the 
only other known ICL-processing nuclease that is capable of digesting across an 
ICL, leading to the possibility that FAN1 may be functionally redundant with 
SNM1A in DNA ICL repair (Wang et al., 2011). To test this hypothesis, we used 
three different shRNAs to deplete Snm1a in both wild-type and Fan1-/- MEFs. As 
previously reported, Snm1a depletion alone did not cause significant sensitivity to 
MMC in mouse cells (Figure 2.11A, B). However, depletion of Snm1a further 
sensitized Fan1-deficient cells to MMC and the level of MMC sensitization 
correlated with the level of Snm1a mRNA knockdown (Figure 2.11A-C). To 
confirm these results in a cell line that completely lacks both FAN1 and SNM1A, 
we knocked out Snm1a using CRISPR/Cas9. The double-deficient cells were 
more sensitive to MMC than Fan1-/- cells and almost as sensitive as the SLX4-
deficient cells (Figure 2.11D, E). FAN1 with an inactivated UBZ domain was able 
to complement an ICL repair defect in Fan1-/-shSnm1a MEFs to the level of wild-
type cells, indicating that the UBZ domain is also dispensable for ICL resistance 
in this setting. (Figure 2.11F, G). 
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Figure 2.11 FAN1 and SNM1A are redundant in conferring resistance 
to ICL-inducing agents. 
(A) Survival of Fan1+/+ or Fan1-/- stably transduced with control shRNA or 
shRNA targeting the Snm1a gene after treatment with MMC. Slx4f3/f3 was 
used as a control. Error bars indicate SD. (B) Quantitative RT–PCR to 
assess the level of Snm1a transcript depletion in cell lines used in B. (C) 
Blinded quantification of cells with more than 20 γH2AX foci following MMC 
treatment. (D) Survival of wild-type, Fan1-/-, Fan1-/-sgSnm1a.6, and 
Slx4f3/f3 MEFs after MMC. Error bars indicate SD. Fan1-/- sgSnm1a.6 is a 
clonal cell line with a biallelic frameshift mutation in Snm1a generated by 
CRISPR/Cas9 genome editing. (E) Sequencing of the Fan1-/-sgSnm1a.6 
MEF clone used in E. (F) Survival of the indicated MEFs after MMC 
treatment. Fan1-/- MEFs depleted of Snm1a were stably transduced with 
wild-type GFP-FAN1 or GFP-FAN1 C44A/C47A. Error bars indicate SD. (G) 
Immunoblot showing the expression of wild-type GFP-FAN1 or GFP-FAN1 
C44A/C47A in Fan1-/-shSnm1a.3 MEFs used in F. 
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2.3.6 Lack of Fan1 results in progressive kidney and liver karyomegaly and 
liver dysfunction 
In order to assess if Fan1-/- mice are a good model for human KIN, we 
analyzed the phenotypes of these mice.  Fan1-/- mice were born at the expected 
Mendelian ratio with no overt developmental abnormalities (Figure 2.12A). The 
growth of Fan1-/- mice from birth until 12 weeks of age was comparable with 
wild-type and heterozygous littermates (Figure 2.12B). Furthermore, Fan1-/- mice 
were fertile, producing on average eight pups per cross, a number comparable 
with those produced in crosses of heterozygous mice (Figure 2.12C). 
Since one of the most pronounced characteristics of human KIN is the 
presence of karyomegalic nuclei in cells of multiple tissues, we monitored the 
histology of kidney and liver tissues in an aging cohort of mice. At 3 months, we 
did not observe any remarkable differences in the distribution of nuclear areas 
(cross-sectional area of nucleus) in renal tubular cells between Fan1-/- and wild-
type animals (Figure 2.13A, B). Increased nuclear area became detectable in 
Fan1 mice at 6 months of age (Figure 2.13B). The level of renal karyomegaly 
further intensified with age, as the proportion of cells with larger than median 
nuclear area rose more than twofold to ∼29% in 12-month-old Fan1 mice (Figure
2.13B, C). Notably, the number of tubular cells with nuclei larger than the median 
area also went up to ∼10% in 12-month-old wild-type animals. However, the
nuclear area in this cohort did not exceed 1.2 times the median, unlike Fan1-/- 
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animals at an equivalent age, which displayed a significant fraction (17%) that 
were >1.2 of the median. Significant karyomegaly was absent from glomeruli of 
Fan1-/- mice (Figure 2.13D) 
Despite the presence of karyomegaly, we detected no significant elevation 
in the level of blood urea nitrogen, creatinine, phosphorus, and magnesium in 
Fan1-/- mice throughout the experiment (Figure 2.14A-D). These results indicate 
that, even with apparent karyomegaly, the kidneys of the 18-month-old Fan1-/- 
animals still retain sufficient function to support homeostasis. Additional 
experimental manipulations to induce kidney injury may be necessary to elicit 
overt kidney failure in this model. 
Similar to the kidney, there was no discernible difference in the distribution 
of the hepatocyte nuclear area between 3-month-old wild-type and Fan1-/- mice. 
However, in 18-month-old mice without functional FAN1, a large fraction (>50%) 
of nuclei became significantly enlarged (Figure 2.13E, F). In order to determine 
whether the liver morphology had an impact on liver function, we analyzed liver 
enzymes and serum proteins in 3- to 18-month-old animals. Fan1-/- animals 
displayed elevated alanine transaminase and aspartate transaminase while 
exhibiting lowered albumin and globulin levels (Figure 2.14E-H). The rise in 
serum liver enzyme and concurrent reduction in serum proteins synthesized 
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within the liver tissue indicate that the increase in karyomegalic hepatocytes 
coincides with the deterioration of liver function. 
Consistent with the polyploidization of the cells in KIN patients, the 
enlarged cells in the kidney and liver tissue had increased numbers of 
hybridization signals of fluorescence in situ hybridization (FISH) probes 
recognizing three different chromosomes. In contrast, the spleen, which did not 
display karyomegaly, had very few cells with more than two signals (Figure 
2.15A-E). 
Taken together, these results strongly support that FAN1 is required to 
suppress age-dependent development of karyomegaly in the kidney and liver. 
The Fan1-/- mouse model thus phenocopies the KIN conditions observed in 
humans and will be instrumental in understanding human disease and potentially 
the aging-associated changes in these tissues. 
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Figure 2.12 Fan1-deficient mice are born at Mendelian ratio, grow 
normally and are fertile.  
(A) Fan1-/- mice are born at the expected Mendelian ratio. Viability of Fan1-
/-  mice was determined by genotyping the progeny from crosses of Fan1+/- 
female and Fan1+/- male at 21 days of age. p-value was calculated using 
the χ2 -test. (B) Weight of male and female Fan1+/+, Fan1+/-, and Fan1-/- 
mice from 3-12 weeks of age. (C) Fan1-deficient mice are fertile as 
assessed by the comparison of litter size from Fan1+/- x Fan1+/- and 
Fan1-/-x Fan1-/- crosses. 
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Figure 2.13 Fan1 mice develop karyomegaly. 
(A) Hematoxylin and eosin (H&E) staining of kidneys from Fan1+/+ and 
Fan1-/- mice at 3 and 18 months. (B) Quantification of the nuclear area 
(cross-sectional area) of tubular epithelial cells in the cortex of kidneys from 
Fan1+/+ and Fan1-/- mice at 3, 6, 12, and 18 months. The area of each 
nucleus was normalized to the median nuclear area present in the section 
to control for fixation and embed- ding conditions. Data were then plotted 
and grouped according to area. n = 3. Error bars indicate SD. (C) 
Percentage of karyomegalic nuclei larger than the median nuclear area in 
Fan1+/+ and Fan1-/- mice at 3, 6, 12, and 18 months. (∗) P < 0.05; (∗∗) P < 
0.01, calculated by one-way ANOVA. n = 3. Error bars indicate SD. (D) 
Quantification of the nuclear area of glomerular cells in Fan1+/+ and Fan1-/- 
mice at 18 months. The area of each nucleus was normalized to the median 
nuclear area of each section. Data were then plotted and grouped 
according to area. n = 3. Error bars indicate SD. (E) H&E staining of liver 
sections from Fan1+/+ and Fan1-/- animals at 3 and 18 months. (F) 
Quantification of the area of nuclei in the liver isolated from Fan1+/+ and 
Fan1-/- mice at 3 and 18 months. n = 3. Error bars indicate SD. 
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Figure 2.14 Liver function, but not kidney function is abnormal in 
Fan1-deficient mice. 
(A-D) Analysis of serum level of (A) blood urea nitrogen (BUN), (B) 
creatinine, (C) phosphorus, and (D) magnesium to monitor kidney function 
of Fan1+/+ and Fan1-/- mice at indicated ages. (E-H) Analysis of serum 
level of liver enzymes and markers of liver function: (E) alanine 
transaminase (ALT), (F) aspartate transaminase (AST), (G) albumin (ALB), 
and (H) globulin (GLOB). Bars represent mean ± SD; ***p < 0.001, **p < 
0.01 were calculated using F-test. 
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Figure 2.15 Karyomegaly is a result of polyploidization. 
(A) Representative images of fluorescent in situ hybridization (FISH) 
performed with probes against the indicated loci in the kidneys, livers, and 
spleens of 18-month-old Fan1-/- animals. The detail of the probes is given 
in Section 6.1.16. (B) Quantification of the cells with more than two signals 
per nucleus in 18-month-old Fan1-/- animals. The analysis was restricted to 
tubular epithelial cells in the kidney and liver hepatocytes. (C-E) 
Quantification of FISH signals per nucleus in 18 months old Fan1-/- 
animals. Tubular epithelial cells in the kidney (C), liver hepatocytes (D) and 
cells in the spleen (E) were assessed. 
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2.3.7 HSCs are unaffected in Fan1-deficient mice when unchallenged but 
severely affected when Fan1 mice are treated with MMC 
Anemia has been reported in a number of human KIN cases, prompting us 
to investigate the possible hematological dysfunction in Fan1-deficient mice. At 
the peripheral blood level, Fan1-/- mice did not show obvious signs of cytopenia 
at a young age (Figure 2.16A-E). To explore the possibility of bone marrow 
abnormalities in Fan1 animals, we analyzed the hematopoietic stem cell (HSC) 
population in the bone marrow of young (3 month) and old (18 month) mice with 
or without Fan1 deficiency. We could not detect any changes in the level of the 
Lineage (Lin)- Sca-1+ c-Kit+ (LSK) or Lin- Sca-1- c-Kit+ (LK) populations 
between Fan1+/+ and Fan1-/- mice (Figure 2.17A, B). The numbers of long-term, 
short-term, and multipotent HSCs as well as the more differentiated progenitor 
cells-(megakaryocyte/erythroid progenitors, granulocyte/monocyte progenitors, 
and common myeloid progenitors) in Fan1-/- animals were also similar to that of 
the wild-type control in the same age groups (Figure 2.17C, D). Inactivation of 
Fan1 in mice with Fancd2 deficiency did not significantly reduce the level of 
hematopoietic progenitor cells compared with Fancd2 single-mutant mice (Figure 
2.17E, F). Collectively, these results indicated that the activity of FAN1 is not 
required for the protection of early HSCs under unstressed conditions. 
Although the bone marrow was not functionally compromised in Fan1-/- 
mice, we asked whether FAN1 was required upon exogenous treatment with ICL-
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inducing agents. Fan1-/- and control mice were treated with a single 
intraperitoneal injection of 10 mg/kg MMC and were followed over the next 3 
weeks. Some wild-type and heterozygous Fan1+/- mice showed a minor drop in 
body weight after receiving the MMC. Most eventually regained the initial weight 
and tolerated the dose of MMC given until the end of the experiment (20 days 
post injection) (Figure 2.18A). In contrast, all Fan1-/- mice reacted acutely to 
MMC, displaying a significant drop in body weight (10%–30%) following the 
treatment (Figure 2.18A). Ninety percent of Fan1-/- mice tested died within two 
weeks after MMC treatment (Figure 2.18B). On day 7 after treatment with MMC, 
a parallel cohort of Fan1-/- mice displayed depletion of the hematopoietic 
progenitor cells, as shown by a decrease in total cell number in the femurs and a 
complete disappearance of c-Kit+ bone marrow cells following MMC treatment 
(Figure 2.19A-D). Furthermore, MMC-treatment caused significantly greater 
reduction in the level of LSK cells in Fan1-deficient c-Kit+ cells cultured in vitro 
compared to wild-type (Figure 2.19E). In agreement, the histological analysis 
revealed pronounced hypocellularity in the bone marrow and the thymus of Fan1-
/- mice (Figure 2.18C). The effect of ICL repair deficiency on the hematopoietic 
system of Fan1-/- animals was further supported by significant neutropenia and 
thrombocytopenia. Although the red blood cell (RBC) count was largely unaltered 
due to the long half-life of RBCs, the reticulocyte counts of Fan1-/- mice was 
significantly lower than Fan1+/+ mice at day 7 after MMC treatment (Figure 
2.19F-I). These results illustrate the necessity of FAN1 for the maintenance of 
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Figure 2.16 Blood counts are normal in the majority of Fan1-deficient 
mice. 
(A-E) Blood analysis in Fan1+/+ and Fan1-/- mice: (A) platelets (PLT), (B) 
white blood cells (WBC), (C) red blood cells (RBC), (D) reticulocytes (RET), 
and (E) hemoglobin concentration (HGB). 
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Figure 2.17 FAN1 is dispensable for the bone marrow maintenance 
under unstressed condition. 
(A) Representative FACS profiles of HSCs isolated from bone marrow of 
Fan1+/+ and Fan1-/- mice, indicating LSK and LK population. (B) 
Quantification of hematopoietic stem cells (HSCs) isolated from Fan1+/+ 
and Fan1-/- mice assessed by FACS. n = 3 per genotype. Error bars 
indicate SD. (C) Analysis of LT-HSC, ST-HSC and MPP isolated from 
femurs and tibiae of Fan1+/+ and Fan1-/- mice at indicated ages assessed 
by FACS. Error bars, s.d., n = 3 per genotype. (D) Analysis of MEP 
(megakaryocyte/erythroid progenitors), GMP (granulocyte/monocyte 
progenitors), and CMP (common-myeloid progenitors) isolated from femurs 
and tibiae of Fan1+/+ and Fan1-/- mice at indicated ages assessed by 
FACS. Error bars, s.d., n = 3 per genotype. (E) Quantification of HSCs 
isolated from mice of the indicated genotypes, assessed by FACS. n = 3 
per genotype. (WT) Wild type. Error bars indicate SD. (F) D) Analysis of LT-
HSC, ST-HSC, and MPP (left) and MEP, GMP, and CMP (right) isolated 
from femurs and tibiae of 6 months old WT, Fan1-/-, Fancd2-/-, and Fan1-/-
Fancd2-/- mice assessed by FACS. Error bars, s.d., n = 3 per genotype. 
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Figure 2.18 Fan1-deficient mice are hypersensitive to MMC. 
(A) Weight monitoring of mice after treatment with MMC. Following 
intraperitoneal injection of 10 mg of MMC per kg, Fan1+/+, Fan1+/-, and 
Fan1-/- mice were weighed every 2 days for 20 days or until death. Weight 
is expressed as % of original weight on the day of MMC injection. (B) 
Survival of Fan1+/+, Fan1+/-, and Fan1-/- mice (n = 10 per genotype) after 
a single treatment with 10 mg/kg MMC. Mice from each genotype were 
monitored up to 20 days following MMC intraperitoneal injection. Bone 
marrow and thymus histology from Fan1+/+ and Fan1-/- mice treated 1 




Figure 2.19 FAN1 is required to protect the hematopoietic stem and 
progenitor cells from high level of ICL damage. 
(A) Total number of cells per femur of Fan1+/+ and Fan1-/- mice untreated 
or treated 1 week prior with 10 mg/kg MMC. Bars represent mean ± SD. 
(∗∗) P < 0.01, calculated using unpaired t-test. (B) Number of nucleated 
cells per femur of Fan1+/+ and Fan1-/- mice untreated or treated 1 week 
prior with 10 mg/kg MMC. Bars represent mean ± SD; **p < 0.01 were 
calculated using unpaired t-test. (C) Representative FACS profile of bone 
marrow cells that were enriched for c-Kit positive population, determined by 
FSC and 7-ADD (7-amino-actinomycin D) viability gate. The bone marrow 
cells were isolated from Fan1+/+ and Fan1-/- mice untreated or treated 1 
week prior with 10 mg of MMC per kg. (D) Percentage of live bone marrow 
cells that were enriched for c-Kit+ population. The bone marrow cells were 
isolated from Fan1+/+ and Fan1-/- mice untreated or treated 1 week prior 
with 10 mg/kg MMC. Bars represent mean ± SD. (∗∗) P < 0.01, calculated 
using unpaired t-test. (E) Survival of Fan1+/+ and Fan1-/- LSK population 
within the in vitro culture c-Kit+ cells following a single treatment with MMC. 
After 48 hours, LSK frequency were determined and normalized to the 
untreated control to calculate the percentage of survival. Error bars indicate 
SD. (F-I) White blood cell (WBC) (F), platelet (PLT) (G), Red blood cell 
(RBC) (H), and Reticulocyte (RET) (I) counts of Fan1+/+ and Fan1-/- mice 
untreated or treated 1 week prior with 10 mg/kg MMC. Bars represent mean 
± SD. (∗∗) P < 0.01, calculated using unpaired t-test. 
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2.3.8 FAN1 is dispensable for the protection of bone marrow against IR 
induced damage 
To examine whether Fan1 deficiency renders bone marrow sensitivity to 
DNA damaging agents in a non-specific manner, we analyzed the effect of 
ionizing radiation (IR) on the hematopoietic system in wild-type and Fan1-/- 
animals. Mice were treated with a sublethal dose of 450 cGy X-ray that has been 
shown to cause severe bone marrow abnormalities in mice models with defects 
in the repair of IR-induced DNA damage (Nussenzweig et al., 1997). The 
changes in the peripheral blood cells and hematopoietic stem and progenitor cell 
function were monitored to assess the requirement of FAN1 in the protection of 
bone marrow against IR-induced lesions. A significant drop in the body weight 
among wild-type or Fan1-/- cohorts was not observed within 6 weeks following 
the irradiation. However, the body weight of both groups of animals remained 
relatively constant until 3 week following the treatment (Figure 2.20A). As 
previously described, IR treatment induced significant damage to the bone 
marrow progenitor cells, leading to a drastic depletion of WBC, platelets and 
reticulocytes level in the peripheral blood analyzed 1 week after the treatment. 
The level of red blood cell count reduced more gradually, most likely owing to its 
longer half-life. At around week 4-5, most of the blood cell counts in both wild-
type and Fan1-/- mice returned back to one observed in the untreated controls 
(Figure 2.20B-E). These results indicated that the hematopoietic progenitor cells 
were not significantly more damaged in IR-treated Fan1-deficient animals. To 
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specifically assess the level of HSCs in the bone marrow, we analyzed the level 
of c-Kit+ and LSK cells two weeks following IR treatment and found no significant 
alternation in wild-type and Fan1-deficient animals (Figure 2.20F). These results 
suggest that FAN1 is dispensable for the repair of IR-inflicted damage and that 
its role in the protection of the hematopoietic system is specifically against DNA 
crosslinking agents. 
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Figure 2.20 Fan1 deficiency does not cause bone marrow sensitivity to 
IR. 
(A) Weight monitoring of mice after treatment with IR. Following 450 cGy of 
x-ray treatment, Fan1+/+ and Fan1-/- mice were weighed every 3 days for 6 
weeks. Weight is expressed as % of original weight on the day of 
irradiation. (B-E) White blood cell (WBC) (B), platelet (PLT) (C), Red blood 
cell (RBC) (D), and Reticulocyte (RET) (E) counts of Fan1+/+ and Fan1-/- 
mice untreated or IR-treated monitored weekly for 6 weeks following IR 
treatment. Bars represent mean ± SD. (F) Percentage of live bone marrow 
cells that were enriched for c-Kit+ (left) or LSK (right) populations. The bone 
marrow cells were isolated from Fan1+/+ and Fan1-/- mice untreated or 
treated 2 weeks prior with 450 cGy of x-ray. Bars represent mean ± SD.  
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2.4 Summary of the findings 
FAN1 expression could not be detected in fibroblasts of human KIN 
patient or the Fan1 knockout mouse embryonic fibroblasts that were generated 
for the study. Using cells from both species, we showed that FAN1 deficiency 
results in cellular sensitivity to ICL-inducing agents. The level of ICL sensitivity in 
FAN1-negative cells is significantly lower than cells lacking Fanconi anemia 
proteins, suggesting that the ICL repair function of FAN1 and FANC proteins are 
not equivalent. Using the Fan1-deficient MEFs, we showed that the UBZ mutant 
FAN1 could rescue the proliferation defects and suppress chromosomal 
aberration induced by MMC. Therefore, FAN1 can participate in ICL repair 
independently of its interaction with the ID2 complex. This finding is also 
corroborated by the epistasis analysis, which revealed that FAN1 has FANCD2 
independent function in the suppression of MMC-induced chromosomal 
abnormalities. When analyzed for the genetic interactions with other ICL repair 
nucleases, we found that FAN1 and MUS81 are epistatic, whereas FAN1 is 
redundant with SNM1A. The requirement of SNM1A in ICL resistance is only 
apparent when FAN1 is co-inactivated, suggesting that FAN1 can substitute for 
SNM1A in ICL repair. The SNM1A-redundant function of FAN1 does not depend 
on its UBZ domain. 
At the whole organism level, Fan1-deficient mice recapitulate the KIN 
phenotypes including the presence of renal and liver karyomegaly and liver 
87 
dysfunction, both of which are age-dependent. We showed that the karyomegalic 
cells are polyploid, which likely results from genome endoreduplication. 
Nevertheless, the renal function was found to be intact even at 18 months of age, 
potentially due to the high buffering capacity of the kidney. Fan1-deficient mice 
are fertile, display no obvious developmental defects, and show normal bone 
marrow function. However, Fan1-deficient hematopoietic tissues including bone 
marrow and thymus are sensitive to MMC, with Fan1-/- mice developing MMC-
induced bone marrow failure due to hematopoietic stem and progenitor cell 
depletion. The dependency of FAN1 in the protection of bone marrow cells is 
specific to ICL challenge as ionizing radiation failed to inflict more severe 
phenotypes in Fan1-/- than in wild-type animals. 
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Chapter 3: Elucidating the impact of aldehyde 
detoxification defects on Fan1-deficient mice 
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3.1 Introduction 
The pathophysiology of KIN disease development is not understood.  
Fan1-deficient animals develop KIN characteristics despite being accommodated 
in a very controlled environment, with no exposure to exogenous nephrotoxins 
(see section 2.3.6) (Airik et al., 2016; Lachaud et al., 2016b; Thongthip et al., 
2016).  Based on this finding, we hypothesize that it is the endogenously 
produced toxin that is the culprit in KIN pathogenesis.  
 
Recently, endogenous aldehydes have been shown to contribute to the 
pathology of Fanconi anemia, another disorder of ICL repair deficiency 
(Garaycoechea et al., 2012; Langevin et al., 2011; Oberbeck et al., 2014; Pontel 
et al., 2015).  Increased load of acetaldehyde or formaldehyde resulting from 
Aldh2 or Adh5 deficiency dramatically exacerbates Fanconi anemia phenotypes 
in a mouse model of the disease.  Fancd2-/-Adh5-/- mice develop glomerular 
diseases and karyomegaly in the kidney (Pontel et al., 2015).   
 
The direct association between the genotoxic effect of formaldehyde on 
the kidney and liver tissues in humans has not been widely explored. The toxicity 
of formaldehyde and its breakdown product formate is typically attributed to their 
effect on the central nervous system and to their potential as carcinogenic agents 
(Humans, 2006; Songur et al., 2010). The most direct evidence that 
formaldehyde metabolism is critical for the protection of the kidney and liver 
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tissues came from the study of Fancd2-/-Adh5-/- mice (see section 1.6.2) (Pontel 
et al., 2015). The presence of renal and liver karyomegaly in the double mutant 
mice raises a possibility that formaldehyde is a potential in vivo damaging agent 
in the kidney and liver. 
Another connection between aldehydes and human disease is that 
excessive acetaldehyde derived from chronic alcohol consumption causes liver 
damage (Chuang et al., 2009; Mills and Harrison, 2005; Seitz and Becker, 2007; 
Voigt, 2005). Alcohol consumption has also been shown to compromise the 
kidney function by promoting interstitial edema and renal hypertrophy in alcohol-
fed animals (Epstein, 1997; Van Thiel et al., 1977). Additionally, alcohol-induced 
free radical production from the oxidation of acetaldehyde intermediates has 
been linked to deterioration of the Na+/K+-ATPase carrier in the proximal tubular 
epithelial cells (Laitinen et al., 1991; Parenti et al., 1991; Rodrigo et al., 1991; 
Rothman et al., 1992). This phenomenon is potentially linked to the observation 
that some chronic alcoholics have increased urinary levels of beta-2-
microglobulin, N-Acetyl-β-D-glucosaminidase (NAG) and alanine aminopeptidase 
(AAP), markers of proximal tubular damage (Jung et al., 1987; Schardijn and 
Statius van Eps, 1987). Furthermore, prenatal ethanol exposure has detrimental 
effects on postnatal kidney function (De Marchi et al., 1993). Whether any of 
these effects on the renal function are derived from ICL damage caused by 
ethanol or its acetaldehyde intermediate, remains to be determined. 
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Considering the above evidence of potential links between aldehyde-
inflicted ICL damage and blood, kidney, and liver dysfunction, we set out to test if 
increased levels of acetaldehydes or formaldehydes would exacerbate the KIN 
phenotypes of Fan1-/- mice.  We generated Fan1-/-Aldh2-/- and Fan1-/-Adh5-/- 
double mutant mouse models. We hypothesized that by inactivating Aldh2 or 
Adh5, the increased basal level of ICLs may lead to an acceleration or 
exacerbation of KIN phenotypes, particularly in Fan1-deficient mice (Figure 3.1). 
If acetaldehyde and formaldehyde play a role in KIN pathology, Fan1-/-Aldh2-/- 
or Fan1-/-Adh5-/- double-deficient mice would display worsening of the 
phenotypes present in Fan1-deficient mice. 
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Figure 3.1 Putative sources of damage that induce KIN in the absence 
of FAN1. 
The sources of presumed endogenous damage leading to Karyomegalic 
Interstitial Nephritis (KIN) is unknown. Formaldehyde and acetaldehyde are 
two ICL-inducing agents that have been shown to play a role in the 
pathogenesis of Fanconi anemia, which is a disorder of unrepaired ICL-
damage. It is possible that these agents would also be deleterious in the 




3.2 Generation of Fan1-/-Aldh2-/- and Fan1-/-Adh5-/- mice 
To test the hypothesis that lack of detoxification of acetaldehyde or 
formaldehyde would exacerbate the phenotypes of Fan1-deficient mice, the 
Fan1-/- were crossed with Aldh2-/- or Adh5-/- to generate Fan1+/-Aldh2+/- and 
Fan1+/-Adh5+/- double heterozygotes (Figure 3.2A). The double heterozygotes 
were crossed to derive Fan1-/-Aldh2-/- or Fan1-/-Adh5-/- double homozygous 
mutants (Figure 3.2A). The male and female Fan1-/-Aldh2-/- or Fan1-/-Adh5-/- 
double homozygotes were then used to establish the cohorts of double 
homozygotes for subsequent study. In order to enrich animals for the 
experiments, we generated WT, or single mutant animals: Fan1-/-, Aldh2-/-, and 
Adh5-/- through the crosses from the homozygous parental breeding pairs 
(Figure 3.2B). 
The crosses between Fan1-/-Aldh2-/- yielded pups at similar ratios to wild-
type and Fan1 single mutant  breeding pairs, suggesting that deficiency in Aldh2 
did not affect the fertility of the male and female Fan1-deficient animals, nor did it 
impair embryogenesis or fetal viability (Figure 3.3). Interestingly, loss of ADH5 
alone caused a reduction in the number of pups produced in comparison to wild-
type animals (Figure 3.3). This was in contrast to the published data, which 
revealed no differences in terms of the litter size at weaning  (Liu et al., 2004). 
The reason for this difference is unclear. Inactivation of Fan1 in Adh5-/- animals 
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resulted in further decrease in the litter size compared to Adh5-/- single mutant 
(Figure 3.3). Deficiency in Aldh2 did not compromise the growth of mice lacking 
Fan1 as Fan1-/-Aldh2-/- DKO displayed normal growth with the 12-weeks weight 
comparable to wild-type and Fan1-/- animals. Fan1-/-Adh5-/- on the other hand, 
exhibited moderate growth defect when compared with Fan1-/- or Adh5-/- single 
mutants (Figure 3.4A, B). 
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Figure 3.2 Schematic of mouse interbreeding to generate mice for the 
study of the genetic interaction between Fan1 and Aldh2 or Adh5.  
(A) The generation of double knockout Fan1-/-Aldh2-/- or Fan1-/-Adh5-/- 
mice for the study. (B) The generation of wild-type (WT) and single 
knockout Fan1-/-, Aldh2-/-, or Adh5-/- mice for the study. 
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Figure 3.3 Deficiency of Adh5 but not Aldh2 results in reduced pup 
numbers per litter in Fan1 mutant mice.  
The number of pups per litter produced from the crosses between wild-type 
(WT) or Fan1-/-, Aldh2-/- and Adh5-/- single-mutant or Fan1-/-Aldh2-/- and 
Fan1-/-Adh5-/- double-mutant breeding pairs. *p < 0.05, ***p < 0.001, ****p 
< 0.0001, and n.s., not significant, were calculated by one-way ANOVA. 
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Figure 3.4 Deficiency of Adh5 but not Aldh2 results in growth defect in 
Fan1-mutant mice. 
(A-B) Weight of male (A) and female (B) WT, Fan1-/-, Aldh2-/-, Fan1-/-
Aldh2-/-, Adh5-/- and Fan1-/-Adh5-/- mice from 12 weeks of age. Error bars, 
s.d., *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001, and n.s., not
significant, were calculated by Mann-Whitney U test. 
99 
3.3 Analysis of the hematopoietic system in mice lacking Fan1 and Aldh2 
or Adh5 
Aldh2 or Adh5 deficiency did not lead to a significant change in the level of 
peripheral blood cells irrespective of Fan1 status and age (Figure 3.5A-H). We 
next assessed the state of the hematopoietic system in mice with deficiency in 
FAN1 and aldehyde detoxification enzymes by analyzing the level of LSK (Lin- 
Sca1+ cKit+) population in of Fan1-/-Aldh2-/- and Fan1-/-Adh5-/- mice and the 
appropriate corresponding controls. We found that Adh5 but not Aldh2 deficiency 
led to a significant reduction of the LSK population of 3 months old mice under 
Fan1-deficient background (Figure 3.6A). The 12 months old Fan1-/-Aldh2-/- and 
Fan1-/-Adh5-/- mice, however, displayed wild-type level of LSK population 
(Figure 3.6B). 
In order to assess the functionality of HSCs, we adopted the competitive 
repopulation assay to quantify the engraftment potential of the HSCs from WT, 
Fan1-/-, Aldh2-/-, Fan1-/-Aldh2-/-, Adh5-/-, Fan1-/-Adh5-/- animals. The 
transplant was performed from the donor with CD45.2 isotype into the congenic 
recipients with CD45.1 isotype pre-conditioned with lethal dosage of 850 cGy of 
x-ray. By quantifying the frequency of CD45.2/CD45.1 ratio of the leukocytes in 
the recipient animals, we were able to derive the engraftment efficiency of HSCs 
under various combined genetic backgrounds at 1, 2 and 4 months post-
transplant as previously described (Katayama et al., 1999; Morrison et al., 1996). 
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The primary transplant revealed that the engraftment potential was not 
compromised in Fan1-deficient mice (Figure 3.7A-C). Furthermore, inactivating 
Aldh2 or Adh5 did not affect the engraftment of long term HSCs (LT-HSCs) after 
a single transplantation cycle (Figure 3.7A-C). We further challenged the HSCs 
by performing the second round of bone marrow transplant using the total bone 
marrow isolated from the primary recipients two months post-transplant and 
transferred into the secondary recipients that were also pre-conditioned with x-
ray. Notably, mice lacking FAN1 displayed poorer engraftment compared to WT 
control after the secondary transplant experiment (Figure 3.8). This observation 
supports the conclusion that FAN1 is required for the protection of HSCs under 
stressed condition (Section 2.3.7). Aldh2 deficiency also led to a significant 
reduction in the engraftment potential of HSCs in the secondary transplant 
(Figure 3.8) but Aldh2 deficiency did not exacerbate the defect in engraftment in 
Fan1-deficient animals. 
We next assessed whether deficiency in either of the aldehyde 
detoxification enzyme would lead to an increase in the DNA damage level 
manifested as micronuclei in the peripheral RBC or RET. The level of 
micronucleated RBC (MN-RBC) and micronucleated RET (MN-RET) based on 
positive propidium iodine (PI) staining did not increase in Fan1-/-Aldh2-/- or 
Fan1-/-Adh5-/- animals in comparison to the wild-type or single mutant controls. 
This leads us to conclude that FAN1 is dispensable for the protection of the 
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erythropoietic compartment from micronuclei formation under wild-type or 
acetaldehyde/formaldehyde-detoxification deficient conditions (Figure 3.9A-C). 
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Figure 3.5 Deficiency of Fan1 in combination with Aldh2 or Adh5 does 
not cause abnormality in the level of peripheral blood cells.  
(A-H) Blood analysis mice of indicated genotypes at 3 months (A-D) or 12 
months (E-H) of age: (A/E) platelets (PLT), (B/F) white blood cells (WBC), 
(C/G) red blood cells (RBC), (D/H) reticulocytes (RET). Error bars, s.d., 
n=3. 
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Figure 3.6 Deficiency of Adh5 but not Aldh2 compromises HSC 
maintenance in 3 months old Fan1-mutant mice.  
(A-B) Quantification of HSCs isolated from 3 months (A) or 12 months (B) 
WT, Fan1-/-, Aldh2-/-, Fan1-/-Aldh2-/-, Adh5-/- and Fan1-/-Adh5-/- mice 
assessed by FACS. Error bars, s.d., n=6 for (A) and n=3 for (B) per 
genotype.  *p < 0.05 and ***p < 0.001 were calculated by one-way ANOVA. 
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Figure 3.7 Loss of ALDH2 or ADH5 does not affect the engraftment 
potential of Fan1-deficient mice following primary transplant. 
(A-C) Quantification of HSC function based on percent engraftment of 
CD45.2 donor bone marrow cells over the CD45.1 competitor bone marrow 
cells following the primary transplant calculated by the percent of CD45.2 
donor leukocytes (CD45.2/D45.2+CD45.1 or Total reconstitution) of donor 
mice of different genotypes relative to the percent of CD45.2 donor 
leukocytes of WT analyzed at 4-weeks (A), 8-weeks (B), or 12-weeks (C) 
after the transplant. The number of sample (n) is shown in the figure.  
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Figure 3.8 Loss of FAN1 or ALDH2 results in reduced engraftment 
potential of Fan1-deficient mice following the secondary transplant. 
Quantification of HSC function based on percent engraftment of CD45.2 
donor bone marrow cells over the CD45.1 competitor bone marrow cells 
following the secondary transplant. Percentage of CD45.2 donor leukocytes 
(CD45.2/D45.2+CD45.1) of donor mice of different genotypes relative to the 
percent of CD45.2 donor leukocytes of WT at 8-weeks after the transplant is 
shown. The number of sample (n) was as described in the figure. *p < 0.05 
and **p < 0.01 were calculated by one-way ANOVA.   
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Figure 3.9 Deficiency of Fan1 and Aldh2 or Adh5 causes insignificant 
increase in DNA damage in blood cells as assessed by micronuclei in 
normochromatic erythrocytes and reticulocytes.  
(A) Representative FACS profiles of micronucleated (PI+) or non-
micronucleated (PI-) normochromatic erythrocytes (MN-NCE) (CD71-) or 
Reticulocytes (RET) (CD71+) cells isolated from blood. (B-C) Percent of 
MN-NCE (B) or MN-RET analyzed in blood collected from mice of indicated 
genotypes.  
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3.4 Analysis of the liver and kidney function of mice lacking Fan1 and 
Aldh2 or Adh5 
In order to assess the impact of concomitant loss of FAN1 and aldehyde 
detoxifying enzymes on the pathogenesis of KIN in mice, we monitored the level 
of karylomegaly and function of the kidney and liver in aging cohorts at 3 months 
and 12 months of age.  As expected from our earlier study, karyomegaly is 
absent from kidney or liver tissue at 3 months of age (Figure 3.10A,B). Additional 
inactivation of either Aldh2 or Adh5 in Fan1-deficient cohorts did not result in 
significant increase in the proportion of karyomegalic nuclei in either tissues 
(Figure 3.10A,B). Karyomegaly was apparent in 12 months-old Fan1-/- animals, 
but we did not observe an additional increase in the level of enlarged nuclei when 
Aldh2 or Adh5 was inactivated in Fan1-/- mice (Figure 3.11). Furthermore, the 
kidney from Fan1-/-Aldh2-/- and Fan1-/-Adh5-/- mice did not show signs of 
increased level of DNA damage as determine by γH2AX staining or increased 
level of proliferating cells as marked by Ki67 (Figure 3.12A, B). However, we did 
not observe a significant difference in the level of γH2AX positive staining of 
renal tubular epithelium between wild-type and Fan1-/- animals as reported in 
(Lachaud et al., 2016b) (Figure 3.12B). It is unclear why this discrepancy exists. 
It is possible that presence of the nuclease-inactive FAN1 in the other mosue 
model leads to different cellular effects than complete lack of FAN1. 
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In parallel to the histological study, we monitored the function of kidney 
and liver of Fan1 mice lacking ALDH2 or ADH5 by analyzing the serum level of 
their corresponding enzyme and metabolite markers. Again, we failed to notice 
any significant changes in the serum level of liver enzymes or liver-produced 
proteins as well as the serum markers of the kidney function such as BUN, 
creatinine, Mg and Phosphorus (Pi) in Fan1-/-Aldh2-/- or Fan1-/-Adh5-/- mice 
(Figure 3.13A-H). 
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Figure 3.10 Kidney and liver karyomegaly are absent from mice 
lacking Fan1 and Aldh2 or Adh5.  
(A-B) Quantification of the nuclear area (cross-sectional area) of tubular 
epithelial cells (A) or liver hepatocyte (B) in the cortex of kidney from mice 
of indicated genotypes at 3 months. The area of each nucleus was 
normalized to the median nuclear area. Data were then plotted and grouped 
according to area (n=3, Error bars, s.d.). 
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Figure 3.11 Karyomegaly in Fan1-/- animals is not enhanced by 
deficiency of Aldh2 or Adh5.  
Quantification of the nuclear area (cross-sectional area) of tubular epithelial 
cells in mice of indicated genotypes at 12 months. The area of each nucleus 
was normalized to the median nuclear area of each section. Data were then 
plotted and grouped according to area (n=3, Error bars, s.d.). 
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Figure 3.12 Deficiency of Fan1 alone or in combination with Aldh2 or 
Adh5 did not cause an increase in the level of proliferating cells or 
cells with DNA damage.  
(A-B) Representative images of Ki67- or Ki67+ (A, top) or γH2AX- or 
γH2AX+ (B, top) renal tubular epithelial cells and the quantification of Ki67+ 
(A, bottom) or γH2AX+ (B, bottom) renal tubular epithelial cells in mice of 
indicated genotypes at 12 months. The quantification was performed in a 
blinded manner from 35-45 high power field (HPF) (40x) images. Error bars, 
s.d., n=3 per genotype.
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Figure 3.13 Deficiency of Aldh2 or Adh5 did not cause liver and kidney 
dysfunction in young Fan1-deficient mice.  
(A-D) Analysis of serum level of (A) blood urea nitrogen (BUN), (B) 
creatinine, (C) phosphorus, and (D) magnesium to monitor kidney function 
in mice of indicated genotypes at 3-6 months. (F-I) Analysis of serum level 
of liver enzymes and markers of liver function: (F) alanine transaminase 
(ALT), (G) aspartate transaminase (AST), (H) albumin (ALB), and (I) 
globulin (GLOB) in mice of indicated genotypes at 3-6 months. Bars 
represent mean ± SD. 
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3.5 Impact of alcohol treatment on mice lacking Fan1 and Aldh2 or Adh5 
One of the possible explanations for the lack of significant exacerbation of 
KIN phenotypes in Fan1-deficient mice lacking ALDH2 or ADH5 is that the 
increase in the basal level of acetaldehyde or formaldehyde was below the 
threshold required to elicit sufficient damage that would necessitate the repair 
activity of FAN1. To further enhance the level of aldehyde-inflicted damage, we 
performed alcohol feeding experiments in the Aldh2 or Adh5-deficient animals. 
Metabolism of ethanol leads to the formation of acetaldehyde intermediate 
whereas the metabolism of methanol leads to the generation of formaldehyde. 
Therefore, the administration of ethanol or methanol in mice lacking the 
corresponding aldehyde detoxifying enzyme should elicit a greater level of 
damage. This is the case with the Fanconi anemia mouse models, as ethanol or 
methanol ad libitum feeding leads to stronger hematopoietic defect in Aldh2-/- or 
Adh5-/- mice lacking FANCD2 respectively (Langevin et al., 2011; Pontel et al., 
2015). If either of the two aldehydes contribute to the pathogenesis of KIN, this 
strategy could expose the phenotypes previously hidden in the untreated Fan1-/-
Aldh2-/- or Fan1-/-Adh5-/- double mutant mice. 
3.5.1 Short-term ethanol exposure of Fan1/Aldh2 mice 
To test the effect of ethanol-induced acetaldehyde in the expression of 
KIN phenotypes, we employed two separate ethanol treatment schemes. In the 
first regimen, ethanol was added to the drinking water at a final concentration of 
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15% for 5 days before being changed to 20% for another 5 days. The second 
treatment scheme involved supplying 10% of ethanol in the drinking water for 
one month. With the high dose treatment of ethanol, the animals lacking ALDH2 
regardless of Fan1 status exhibited severe sensitivity with their weight being 
drastically reduced to around 80% of the original weight by day 10 of the 
treatment (Figure 3.14A, B). 
High-dose ethanol treatment regimen resulted in a significant deficiency in 
hematopoiesis following ethanol feeding in Aldh2-deficient animals. There was a 
reduction in the level of WBC and RET (reticulocytes) in the treated Aldh2-/- and 
Fan1-/-Aldh2-/- mice, suggesting that hematopoietic progenitors are negatively 
affected by ethanol-induced acetaldehyde (Figure 3.15A, B). Fan1-/-Aldh2-/- 
displayed a greater reduction in the WBC and RET levels then the Aldh2-/- mice 
alone. However, only the difference in the reticulocyte count between Aldh2-/- 
single mutant and Fan1-/-Aldh2-/- double mutants were statistically significant 
(Figure 3.15B). The level of RBC was unchanged most likely due to their longer 
half-life compared to other types of blood cells (Figure 3.15C). The level of 
platelets went up significantly in Aldh2-/- and Fan1-/-Aldh2-/- (Figure 3.15D). The 
cause of thrombocytosis (high platelet count) was unclear, albeit this trend was in 
contrast to the commonly known effect of ethanol in promoting thrombocytopenia 
symptom in human with alcoholism (Ballard, 1997; Girard et al., 1987). 
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Ethanol treatment led to a significant depletion of the LSK population in 
Aldh2-/- and Fan1-/-Aldh2-/- animals (Figure 3.15E). However, the difference in 
the LSK frequencies between Aldh2-/- and Fan1-/-Aldh2-/- was not statistically 
significant. We conclude that the absence of Aldh2 was driving hematopoietic 
defect following high dose of ethanol treatment. Furthermore, we were able to 
detect a significant increase in the level of micronucleated normochromatic 
erythrocytes (MN-NCE) in Aldh2-/- and Fan1-/-Aldh2-/- animals compared to 
wild-type or Fan1-/- mutant mice (Figure 3.15F). Yet again, the difference 
between the micronuclei level of Aldh2-/- and Fan1-/-Aldh2-/- was not statistically 
significant, indicating that the observed DNA damage phenotype was caused by 
deficiency in Aldh2 not Fan1. With these results, we can conclude that the 
ethanol-induced damage on the hematopoietic system in the Fan1/Aldh2 cohorts 
was primarily driven by the absence of Aldh2 not Fan1. 
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Figure 3.14 Aldh2-deficient mice displayed ethanol sensitivity.  
(A) Schematic of ethanol treatment regimen. Mice were treated with 15% 
ethanol for 5 days and 20% for another 5 days before being sacrificed for 
analysis. (B) Weight of mice measured after the ethanol treatment scheme 
in (A). Weight is expressed as % of original weight before the treatment. 
Bars represent mean ± SD. 
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Figure 3.15 Short-term ethanol treatment affects the hematopoietic 
system in Aldh2-deficient mice. Fan1-/-Aldh2-/- animals have slight 
decrease in the reticulocyte counts compared to Aldh2-/- animals. 
(A-D) White blood cell (WBC) (A), Reticulocyte (RET) (B), Red blood cell 
(RBC) (C), and platelet (PLT) (D) counts from mice of indicated genotypes 
after the ethanol treatment (Figure 3.12A). Bars represent mean ± SD; *p < 
0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001, n.s., not significant were 
calculated by one-way ANOVA.  (E) Quantification of HSCs isolated from 3-
month-old mice of indicated genotypes treated with ethanol as in (A-D) 
assessed by FACS. Error bars, s.d., n=3. **p < 0.01, ***p < 0.001, n.s., not 
significant, were calculated by one-way ANOVA. (F) Percent of total MN 
(MN-NCE + MN-RET) analyzed in blood collected from mice of indicated 
genotypes treated with ethanol as in (A-D). Error bars, s.d., n=3. *p < 0.05, 
**p < 0.01, n.s., not significant, were calculated by one-way ANOVA. 
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3.5.2 Long-term ethanol exposure for Fan1/Aldh2 mice 
To assess the effect of increased acetaldehyde production in the 
Fan1Aldh2 cohorts over longer treatment time, drinking water was replaced with 
10% ethanol solution for 1 month (Figure 3.16A). At week 4, mice with deficiency 
in Aldh2 lost weight to 80% of the starting weight (Figure 3.16B). The use of 
reduced ethanol concentration caused a mild increase in the level of RET and 
PLT in mice lacking Aldh2. This was likely a prolonged response to ethanol-
induced anemia. However, the differences in the RET and PLT levels between 
Aldh2-/- single mutants and Fan1-/-Aldh2-/- double mutants were not statistically 
significant. (Figure 3.17A, B). The differences in the level of WBC and RBC 
counts between Fan1Aldh2 cohorts were not statistically significant (Figure 
3.17C, D). 
Next, we analyzed the histology of kidney and liver under long-term 
ethanol treatment. We did not detect a significant difference in the number of 
karyomegalic nuclei in kidney epithelial or liver cells among mice regardless of 
Fan1 and Aldh2 status (Figure 3.18A, B). The ethanol-treated Fan1-/-Aldh2-/- 
double mutant mice displayed normal kidney and liver functions compared to WT 
and single mutant animals (Figure 3.19A-H). Additionally, we did not detect an 
increase in the level of Ki67+ renal tubular epithelial cells in the alcohol treated 
kidney irrespective of Fan1 or Aldh2 status (Figure 3.18C), indicating that the 
ethanol treatment employed in the study did not stimulate cell division in the 
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kidney tissue as was reported with the treatment with crosslink-inducing agent 
cisplatin (Airik et al., 2016). 
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Figure 3.16 Aldh2-deficient mice lose more weight after four weeks of 
ethanol treatment.  
(A) Schematic of ethanol treatment scheme. Mice were treated with 10% 
ethanol for 4 weeks, and then sacrificed for analysis. (B) Weight of mice 
measured weekly after the ethanol treatment scheme in (A). Weight is 
expressed as % of original weight before the treatment. 
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Figure 3.17 Long-term ethanol treatment moderately affects the 
hematopoietic system in Aldh2-deficient mice. No significant 
differences between the peripheral blood cell levels in Aldh2-/- and 
Fan1-/-Aldh2-/- deficient animals. 
(A-D) Platelet (PLT) (A), Reticulocyte (RET) (B), Red blood cell (RBC) (C), 
and white blood cell (WBC) (D) counts from mice of indicated genotypes 
after the ethanol treatment (Figure 3.14A). Bars represent mean ± SD; *p < 
0.05, **p < 0.01, n.s., not significant was calculated by one-way ANOVA. 
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Figure 3.18 Long-term ethanol treatment did not increase the level of 
kidney and liver karyomegaly in Fan1/Aldh2 double-deficient mice.  
(A-B) Quantification of the nuclear area of tubular epithelial cells (A) or liver 
hepatocyte (B) in the cortex of kidney from 4 months old mice of indicated 
genotypes at 1 month after the ethanol treatment (Figure 3.14A). The area 
of each nucleus was normalized to the median nuclear area. Data were 
then plotted and grouped according to area (n=3, Error bars, s.d.). (C) The 
quantification of Ki67+ tubular epithelial cells after the alcohol treatment as 
in (Figure 3.14A) performed in a blinded manner from 35-45 high power 
field (HPF) (40x) images. Error bars, s.d., n=3 per genotype. 
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Figure 3.19 Long-term treatment with ethanol did not cause liver and 
kidney dysfunction in Fan1/Aldh2 -deficient mice.  
(A-D) Analysis of serum level of (A) blood urea nitrogen (BUN), (B) 
creatinine, (C) phosphorus, and (D) magnesium to monitor kidney function 
in 4 months mice of indicated genotypes after 1 months of ethanol 
treatment. (F-I) Analysis of serum level of liver enzymes and markers of 
liver function: (F) alanine transaminase (ALT), (G) aspartate transaminase 
(AST), (H) albumin (ALB), and (I) globulin (GLOB) in 4 months mice of 
indicated genotypes after 1 months of ethanol treatment. Bars represent 
mean ± SD. 
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3.6 Summary of the findings 
Concomitant lack of Aldh2 in Fan1 did not affect growth or fertility of the 
animals. In contrast, Fan1/Adh5 double deficiency caused significant growth 
defect and reduced number of pups produced per litter. This result underlines a 
possible requirement of FAN1 to counteract the damage inflicted by increased 
formaldehyde due to the absence of ADH5 to maintain normal growth and 
embryonic development. The LSK population in 3 month-old Fan1/Adh5 double 
mutant animals was decreased compared to levels in wild-type animals, however 
the remaining level of LSK in Fan1-/-Adh5-/- was sufficient to support the 
production of peripheral blood cells. The reduction in LSK level was not observed 
in Fan1-/-Adh5-/- animals at 12 months. This could be due to an age-related 
increase in the cycling activity of hematopoietic stem cells as previously reported 
(Rossi et al., 2007). Deficiency of Fan1 alone or in combination with Aldh2 or 
Adh5 did not result in reduced engraftment potential after the first transplant. 
Secondary transplant revealed that combination of Aldh2 and Fan1 deficiency 
resulted in decreased HSC engraftment. Secondary engraftment was not yet 
tested in Fan1-/-Adh5-/- animals. 
We did not observe a significant increase in the level of karyomegaly in 
the kidney or liver tissues in 3 month-old animals lacking FAN1 and ALDH2 or 
ADH5. FAN1 status appeared to be a determinant on the level of renal 
karyomegaly in 12 months old animals as the deficincy of Aldh2 or Adh5 did not 
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lead to increased karyomegaly in kidney or liver. In line with tissue histology, the 
concomitant absence of FAN1 and ALDH2 or ADH5 did not cause further 
functional decline in the kidney and liver. When treated with ethanol, lack of 
FAN1 caused a stronger peripheral blood abnormality in Aldh2-deficient animals, 
although the severity was much less compared to that observed in Fancd2/Aldh2 
double-mutant animals (Langevin et al., 2011). This result suggests that FAN1 
functions in the repair of ethanol-induced damage in the bone marrow, although 
to a lesser extent than the proteins of the Fanconi anemia pathway. The ethanol 
treatment failed to exacerbate kidney and liver karyomegaly phenotype in Fan1-/- 
or Fan1-/-Aldh2-/- double-deficient animals in our experiments suggesting that 
acetaldehyde may not be the endogenous agent that leads to karyomegaly in the 
absence of FAN1.  Experiments with methanol treatment of Fan1-/-Adh5-/- 
animals will be necessary to further assess possible role of increased 
formaldeyde levels on the pathogenesis of karyomegalic interstitial nephritis. 
Overall our data highlight the fact that increased level of formaldehyde but 
not acetaldehyde could moderately compromise the maintenance of HSC level in 
young Fan1-deficient animals. However, under stressed condition, for instance 
through successive bone marrow transplantations, the presence of FAN1 or 
ALDH2 is necessary for the protection of HSCs from the transplant-induced 
stress. In terms of the KIN phenotypes, we conclude that the heightened level of 
endogenous acetaldehyde or formaldehyde present due to Aldh2 or Adh5 
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deficiency, is insufficient to enhace the level of tissue karyomegaly or to incite 
kidney and liver dysfunctions in Fan1-deficient animals. Acetaldehyde and 
formaldehyde are unlikely to be the endogenous sources of damage that 
promote KIN-associated phenotypes in the absence of FAN1. 
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Chapter 4: Interplay between the Fanconi anemia 




Several recent studies suggest that ICL sensitivity and genomic instability, 
two major hallmarks of Fanconi anemia are a result of inappropriate repair 
activity of another DNA repair pathway, the non-homologous end joining (NHEJ). 
It was shown that suppression of NHEJ could rescue ICL hypersensitivity and 
chromosomal aberration in FA-deficient cells in multiple model organisms 
(Adamo et al., 2010; Bouwman et al., 2010; Pace et al., 2010). There are; 
however, a number of conflicting reports among the results from different model 
systems, with paucity of data from the human Fanconi anemia patient cells 
(reviewed in (Kottemann and Smogorzewska, 2013). This prompted us to 
analyze whether inactivating NHEJ can suppress ICL repair defects in FA patient 
cells. 
4.1.1 Double strand break repair pathway choice: homologous 
recombination (HR) vs non-homologous end joining (NHEJ)
DSBs are repaired by one of two repair processes – homologous 
recombination (HR) or non-homologous end joining (NHEJ). Several FA proteins, 
including BRCA1/FANCS, BRCA2/FANCD1, PALB2/FANCN, RAD51/FANCR 
and SLX4/FANCP, are key regulators of important steps during the process 
(Howlett et al., 2002; Vaz et al., 2010; Wang et al., 2015; Xia et al., 2007). 
BRCA1 is required for the resection of DSB, to promote HR by preparing DNA 
ends for the BRCA2-dependent loading of RAD51. RAD51, a recombinase, 
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forms RAD51-ssDNA nucleoprotein filaments to facilitate homology search and 
strand invasion. Some of the D-loop structures formed following the strand 
invasion can be resolved by SLX4-associated nucleases SLX1 and MUS81 
(Garner et al., 2013; Li and Heyer, 2008; Wyatt et al., 2013). In addition, FA 
proteins of the core and the ID2 complexes have been shown to have a 
modulatory role in the control of HR proficiency, although the mechanism is still 
unclear (Nakanishi et al., 2005; Smogorzewska et al., 2007). Homology directed
repair is considered to be an error-free process since the template for the repair 
is a sister chromatid. 
In the NHEJ pathway, DSB ends are captured by the Ku70/80 
heterodimers (Blier et al., 1993; Falzon et al., 1993; Mimori and Hardin, 1986). 
DNA-dependent protein kinase catalytic subunit (DNA-PKcs), a serine/threonine 
kinase is recruited and its kinase activity promotes endonucleolytic processing of 
DSB ends by Artemis and subsequent ligation by DNA Ligase IV (LIG4)/XRCC4 
complex with the help of a stimulatory factor XLF (Ciccia and Elledge, 2010; 
Goodarzi et al., 2006; Grawunder et al., 1997; Yannone et al., 2008). The 
endonucleolytic processing and the ability of NHEJ machinery to directly rejoin 
two broken DNA ends together regardless of the sequence homology, make the 
repair outcome error-prone, leading to accumulation of genomic mutations and
chromosomal translocations (Chiruvella et al., 2013; Lieber, 2008, 2010). 
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4.1.2 Aberrant NHEJ is implicated in causing genome instability in Fanconi 
anemia 
The repair of ICL-induced DSBs generated by ICL unhooking have been 
shown to depend on homologous recombination (Long et al., 2011). This 
preference for repair via HR instead of NHEJ is thought to be a consequence of 
the activity of FA pathway and HR during S/G2 phases (Moore and Haber, 1996; 
Sonoda et al., 2006), as well as the type of substrate that is created during ICL 
repair. Recent studies suggest the FA pathway may play an active role in 
inhibiting aberrant NHEJ activity at the ICL-induced DSBs and protect cells from 
accumulating chromosomal abnormalities (Adamo et al., 2010; Pace et al., 2010; 
Zhang et al., 2016). Suppression of NHEJ has been shown to relieve ICL 
sensitivity in a number of FA-deficient model systems. In Caenorhabditis elegans 
with a germline defects in fcd-2 (FANCD2), sensitivity to crosslinking agents and 
abnormal meiotic crossovers can be ameliorated after the deletion of lig-4 
(Adamo et al., 2010). A knockout of Ku70 in FANCC-deficient DT40 chicken cells 
as well as depletion of Ku80 in human FA-D2 or FA-C patient cells using RNAi 
also result in a partial rescue of ICL hypersensitivity (Adamo et al., 2010; Pace et 
al., 2010). Furthermore, treatment with DNA-PKcs inhibitor fully or partially 
alleviated sensitivity to ICL-inducing compounds in FANCA or FANCD2-depleted 
human HeLa cells and Fanca or Fancc mutant mouse embryonic fibroblasts 
(MEFs). Depletion of FANCD2 failed to sensitize DNA-PKcs-deficient M059J 
human glioblastoma cells to ICL-inducing agents (Adamo et al., 2010). More 
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recently, inhibition of TGF-β signaling was shown to promote ICL resistance of 
FA patient cell lines and to suppress hematopoietic stem cell (HSC) defects in FA 
mouse and human cells. This inhibition was correlated with up-regulation of HR 
factors and down-regulation of NHEJ factors (Zhang et al., 2016). 
The finding of NHEJ inhibition rescuing phenotypes of Fanconi anemia 
deficiency, raised a number of interesting questions.  One would want to know 
the mechanism of how the FA pathway functions to counteract the inappropriate 
engagement of NHEJ proteins and a more profound question of how the ICL 
repair proceeds in the absence of FA and NHEJ pathways.  Mutagenicity of such 
a process would be of interest.  Therapeutically, it would be important to 
determine whether NHEJ inhibition could be a potential medical treatment for the 
patients with Fanconi anemia, even in the short term while a patient is awaiting a 
bone marrow transplant, and whether the effect of NHEJ inhibition is specific to 
particular crosslinking agents, or complementation groups of FA patients. 
The implication that NHEJ underlies the ICL sensitivity and chromosomal 
aberration in FA-deficient cells has, however, been challenged by contradicting 
results of other studies. Knockout of LIG4 or DNA-PKcs does not rescue of 
crosslink sensitivity in DT40 cell lines (Pace et al., 2010). In very convincing 
genetic knockout studies, MEFs lacking FANCD2 and Ku80, DNA-PKcs, or 
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53BP1 were as sensitive to ICL-inducing agents as FANCD2-deficient cells alone 
(Bunting et al., 2012; Houghtaling et al., 2005).  
The disparity between results of different studies that assessed the 
genetic interaction of FA and NHEJ pathways prompted our studies that use 
human patient cell lines. In this study, we assessed whether disrupting 
components of NHEJ with chemical inhibitors, RNAi or CRISPR-Cas9 could 
rescue the ICL hypersensitivity of human FANCA-/- patient fibroblasts. All of our 
experiments led to a conclusion that abrogation of major NHEJ factors does not 
alleviate crosslink repair defect phenotypes of FANCA-/- cells. 
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Figure 4.1 Schematic showing proteins in the non-homologous end 
joining pathway. 
Ku70/Ku80 heterodimer complex recruited to DSB ends activates DNA-
PKcs. In parallel, 53BP1 is recruited to promote NHEJ by suppressing 
extensive DNA end resection and enhancing DNA end mobility. DNA-PK 
regulates the stability of DSB ends through phosphorylation of Artemis and 
other protein substrates. Artemis facilitates DNA end processing and, 
subsequently, LIG4/XRCC4 complex and XLF catalyze the ligation of the 




4.2 Inactivation of DNA-PKcs does not rescue MMC-induced proliferation 
defects in cells lacking FA pathway function. 
FANCA-/- (RA3087) human patient fibroblasts with biallelic deletion of 
FANCA (Kim et al., 2013), were used for studies to examine whether 
suppressing essential NHEJ factors could rescue crosslink repair defects in FA 
patient cells. We first used RNAi-mediated knockdown to deplete DNA-PKcs in 
RA3087 cells (Figure 4.2A). Three independent hairpins to DNA-PKcs efficiently 
suppressed NHEJ activity as determined by increased sensitization of shDNA-
PKcs expressing RA3087 cells to ionizing irradiation (IR) (Figure 4.2A, B). 
However, these cells were still as sensitive to MMC as the control FANCA-/- cells 
expressing control shRNA (Figure 4.2C). We next chemically inhibited DNA-PKcs 
activity in RA3087 cells using DNA-PKcs inhibitors. Both DNA-PKcs inhibitors, 
NU7026 and NU7441, efficiently inhibited NHEJ as demonstrated by dosage-
dependent IR-induced survival defect in inhibitor-treated RA3087 cells (Figure 
4.2D). RA3087 cells treated with the inhibitors at dosages that induced NHEJ 
suppression without significant growth defects (10 μM for NU7026 or 1 μM for 
NU7441) did not exhibit resistance to MMC (Figure 4.2E, F). DNA-PKcs inhibitor 
NU7026 treatment also failed to reduce MMC sensitivity of FA patient cells 
lacking FANCD2 or SLX4, FA proteins that act downstream of FANCA (Figure 
4.2G). These results show that shRNA-depletion or chemical inhibition of DNA-
140 
PKcs to inactivate NHEJ did not restore crosslink repair proficiency in FA patient 
cells. 
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Figure 4.2 Suppression of DNA-PKcs does not rescue MMC sensitivity 
in FANCA-deficient cells. 
(A) Survival of RA3087 FANCA-deficient patient cells stably transduced with 
shRNA targeting Luciferase (control) or DNA-PKcs after IR treatment (0-8 
Gy). FA-A patient cells with siRNA treatment against ATM was used as IR 
sensitive-control. Error bars, s.d.. (B) Survival of RA3087 cells stably 
transduced with shRNA targeting Luciferase (control) or DNA-PKcs and 
RA3087 cells complemented with FANCA after MMC treatment (0-100 nM). 
Error bars, s.d.. (C) Immunoblot showing the expression of DNA-PKcs in 
the shRNA transduced RA3087 cells used in A and B. (D) Survival of 
RA3087 cells under untreated or treated with 2 Gy IR after the pretreatment 
with NU7026 (0-10 μM) or NU7441 (0-10 μM). Error bars, s.d.. (E) Survival 
of RA3087 cells stably transduced with empty vector or with FANCA under 
chronic treatment with MMC (0-100 nM). The cells were pretreated with 10 
μM NU7026 or DMSO. Error bars, s.d.. (F) Survival of RA3087 cells stably 
transduced with empty vector or with FANCA after treatment with MMC (0-
100 nM). The cells were pretreated with 1 μM NU7441 or DMSO. Error 
bars, s.d.. (G) Survival of wild type fibroblasts (BJ), RA2645 FANCD2-
deficient cells, RA3331 SLX4-deficient cells after treatment with MMC (0-




4.3 Inactivation of DNA Ligase IV or DNA Ligase III does not rescue MMC-
induced proliferation defects in cells lacking FA pathway 
 We next examined whether suppression of DNA Ligase IV would rescue 
ICL hypersensitivity in FANCA-deficient cells. FANCA depletion in LIG4+/+, 
LIG4+/-, or LIG4-/- HCT116 cell lines (Oh et al., 2013) led to a significant 
reduction of FANCA protein level and a disappearance of FANCI 
monoubiquitination in all shFANCA transduced HCT116 cell lines, indicating a 
successful inhibition of the FA pathway. FANCA depletion in all cell lines, 
regardless of the LIG4 status resulted in no change to MMC sensitivity from the 
parental cell lines expressing control shRNA (Figure 4.3A, B), leading to 
conclusion that absence of Ligase IV could not rescue sensitivity to MMC in the 
setting of FA pathway deficiency.  We have noted, however, that cells lacking 
one allele of LIG4 were more sensitive to MMC than the LIG4+/+ HCT116 cells 
and that the LIG4-/- HCT116 were even more sensitive than the LIG4+/- HCT116 
cells. This finding will have to be confirmed in other, non-HCT116 cells.   
 
 In parallel, we assessed impact of DNA Ligase III deficiency on MMC 
sensitivity in the setting of FANCA deficiency. Ligase III function is essential in 
mitochondria (Simsek et al., 2011). To examine the impact of LIG3 and 
alternative NHEJ suppression on the outcome of ICL repair in FA-deficient cells, 
we used FANCA shRNAs in HCT116 cell lines with LIG3 being inactivated in the 
nucleus but active in the mitochondria (Jones et al., 2014; Oh et al., 2014). 
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Absence of nuclear LIG3 did not rescue the MMC sensitivity of FANCA-depleted 
HCT116, indicating that alternative end joining pathway is unlikely to be 
responsible for ICL-inflicted genomic instability in cells deficient in FA pathway 
(Figure 4.3C, D). 
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Figure 4.3 LIG4 or LIG3 inactivation does not rescue MMC sensitivity 
in the setting of FANCA depletion.  
(A) Survival of LIG4+/+, LIG4+/-, and LIG4-/- HCT116 cells stably 
transduced with shRNA targeting Luciferase (control) or FANCA after MMC 
treatment (0-75 nM). Error bars, s.d.. (B) Immunoblot showing expression of 
FANCA and FANCI in the shRNA transduced cells used in A with or without 
24 hours 1 μM MMC treatment. (C) Survival of LIG3+/+, LIG3-/-, LIG3-/- 
+WT LIG3, and LIG3-/- +ΔBRCT LIG3 HCT116 cells stably transduced with 
shRNA targeting Luciferase (control) or FANCA after MMC treatment (0-75 
nM). Error bars, s.d.. (D) Immunoblot showing expression of FANCA and 
FANCI in the shRNA cells used in C with or without 24 hours 1 μM MMC 
treatment. 
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4.4 Inactivation of DSB repair choice factor, 53BP1, does not rescue MMC-
induced proliferation defects in FANCA-/- cells 
 We next assessed if 53BP1, factor that functions upstream of the core 
NHEJ machinery to promote the choice between NHEJ and HR in DNA DSB 
repair, would rescue MMC sensitivity of FANCA-/- cells.  There are conflicting 
reports on whether 53BP1 inactivation could rescue the ICL-repair defect in 
BRCA1-deficient mouse cells (Bouwman et al., 2010; Bunting et al., 2012). 
Notably, 53BP1 deletion cannot rescue ICL-induced chromosomal aberrations in 
Fancd2-deficient MEFs (Bunting et al., 2012). As all of these studies were 
performed in mouse cells, we generated an equivalent human system with 
FANCA/53BP1 double deficiency. In agreement with published data, which 
suggests that 53BP1 does not play a major role in resistance to IR-induced DSBs, 
we did not observe a significant IR sensitivity in 53BP1-depleted FA-A patient cell 
lines despite efficient protein depletion (Figure 4.4A) (Chapman et al., 2012; 
Iwabuchi et al., 2006; Nakamura et al., 2006; Riballo et al., 2004; Ward et al., 
2004). 53BP1 knockdown did not lead to a suppression of MMC sensitivity in 
human FANCA-deficient cells (Figure 4.4B, C). These results provide strong 
support for the finding in the mouse system that loss of 53BP1 is not sufficient to 
rescue defective ICL repair in FA deficient cells.  
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Figure 4.4 Depletion of 53BP1 does not rescue MMC sensitivity in 
FANCA-deficient cells. 
(A) Survival of RA3087 FANCA-deficient patient cells stably transduced with 
shRNA targeting Luciferase (control) or 53BP1 after IR treatment (0-6 Gy). 
RA3087 cells transfected with siRNA against ATM were used as positive 
control for outcome after IR treatment. Error bars, s.d.. (B) Survival of 
RA3087 cells stably transduced with shRNA targeting Luciferase (control) 
or 53BP1 or RA3087 cells complemented with FANCA after MMC treatment 
(0-100 nM). Error bars, s.d.. (C) Immunoblot showing the expression of 
53BP1 in the shRNA transduced RA3087 cells used in A and B. 
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4.5 Partial inactivation of Ku70 or Ku80 does not rescue ICL-induced 
proliferation defects in FANCA-deficient cells 
We analyzed the possibility of suppressing ICL sensitivity of FANCA-
deficient human cells by Ku70 (XRCC6) and Ku80 (XRCC5) inactivation. By 
stably expressing three independent shRNA hairpins and their combinations to 
target Ku70 or Ku80 in FA-A patient cells, we were able to partially but never 
completely deplete Ku70 and Ku80. We found that RA3087 cells with Ku70 or 
Ku80 knockdown grew slower than control cells (Figure 4.5A-D). This growth 
arrest induced upon Ku70 or Ku80 depletion in consistent with data showing that 
Ku70 and Ku80 are essential genes for human but not mouse cells (Fattah et al., 
2008b; Li et al., 2002). Ku70 and Ku80 have been shown to be required for 
telomere maintenance and their absence leads to genomic instability and cell 
death (Myung et al., 2004; Wang et al., 2009). We used cells with the best Ku70 
depletion and did not detect a significant suppression of MMC sensitivity in Ku70-
depleted RA3087 cells (Figure 4.5E).
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Figure 4.5 Ku70 and Ku80 are essential in human cells and their partial 
suppression does not rescue ICL sensitivity in FANCA-deficient cells. 
(A) Growth of RA3087 FANCA-/- cells stably transduced with shRNA 
targeting Luciferase (control) or Ku70 or complemented with FANCA. Error 
bars, s.d.. (B) Immunoblot showing the expression of Ku70 in cells used in 
A. (C) Growth of RA3087 cells stably transduced with shRNA targeting 
Luciferase (control) or Ku80 or complemented with FANCA. Error bars, s.d.. 
(D) Immunoblot showing the expression of Ku80 in cells used in C. (E) 
Survival of FANCA-/- patient cells stably transduced with shRNA targeting 
Luciferase (control) or Ku70 and FANCA-/- patient cells complemented with 
FANCA after MMC treatment (0-100 nM). Error bars, s.d.. 
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4.6 Complete inactivation of NHEJ factors by CRISPR-Cas9 mediated 
genome-editing does not rescue MMC proliferation defects in FA cells 
To eliminate the possibility that lack of rescue of MMC sensitivity in FA-
pathway-deficient cells was due to the residual NHEJ activity after shRNA-
mediated knockdown or chemical inhibition, Clustered Regularly Interspaced 
Short Palindromic Repeat (CRISPR)-Cas9-dependent gene engineering was 
employed to completely inactivate components of NHEJ including DNA-PKcs, 
LIG4, and 53BP1 in FANCA-/- patient cells. Successful inactivation of the three 
NHEJ factors was verified at the protein level as the expressions of DNA-PKcs, 
LIG4, and 53BP1 were not detected in the isolated clones (Brooke Conti, Figure 
4.6 A, D, G). Furthermore, as expected, the DNA-PKcs (Clone 1 and 4) and LIG4 
(Clone 1, 2, and 3) knockout cells exhibited sensitivity to IR, confirming that 
NHEJ was abrogated in these clones (Brooke Conti, Figure 4.6B, E). Similar to 
the shRNA-mediated depletion experiment (Figure 4.4A), full removal of 53BP1 
by genome editing did not result in significant IR sensitivity (Brooke Conti, Figure 
4.6H). Nonetheless, CRISPR-Cas9-mediated complete removal of DNA-PKcs, 
LIG4, or 53BP1 did not improve the MMC-induced survival defect in RA3087 
cells (Brooke Conti, Figure 4.6C, F, I). These experiments are consistent with the 
conclusion that NHEJ suppression does not rescue ICL repair defect in Fanconi 
anemia patient cells. 
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Figure 4.6 Full inactivation of NHEJ factors by genome-editing does 
not rescue MMC sensitivity in FANCA-/- cells.  
(A) Immunoblot showing expression of DNA-PKcs in RA3087 FANCA-/- 
cells and the RA3087 FANCA-/-DNA-PKcs-/- clones obtained by 
CRISPR/Cas9 gene editing. Sequences at the targeting site of clone 1 and 
4 are shown. (B) Survival of wild type fibroblasts (BJ), FANCA-/-, and 2 
clones (1 and 4) of FANCA-/-DNA-PKcs-/- cells after IR treatment (0-4 Gy). 
Error bars, s.d.. (C) Survival of wild type fibroblasts (BJ), FANCA-/-, and 2 
clones (1 and 4) of FANCA-/-DNA-PKcs-/- cells after MMC treatment (0-100 
nM). Error bars, s.d.. (D) Immunoblot showing expression of LIG4 in 
RA3087 FANCA-/- cells and the RA3087 FANCA-/-LIG4-/- clones. 
Sequences around the targeting site of clone 1 and 2 are shown. (E) 
Survival of FANCA-/-, FANCA-/- complemented with FANCA, and 3 clones 
of FANCA-/-LIG4-/- cells (1, 2, and 3) after IR treatment (0-5 Gy). Error 
bars, s.d.. (F) Survival of FANCA-/-, FANCA-/- complemented with FANCA, 
and 3 clones of FANCA-/-LIG4-/- cells (1, 2, and 3) after MMC treatment (0-
100 nM). Error bars, s.d.. (G) Immunoblot showing expression of 53BP1 in 
FANCA-/- cells and the FANCA-/-53BP1-/- clones. Sequences around the 
targeting site of clone 5 and 6 are shown.  (H) Survival of wild type 
fibroblasts (BJ), FANCA-/-, and 2 clones (5 and 6) of FANCA-/-53BP1-/- 
cells after IR treatment (0-4 Gy). FANCA-/-DNA-PKcs-/-.1 CRISPR-targeted 
clone from (A-C) was used as IR sensitive-control. Error bars, s.d.. (I) 
Survival of wild type fibroblasts (BJ), FANCA-/-, and 2 clones (5 and 6) of 
FANCA-/-53BP1-/- cells after MMC treatment (0-100 nM). Error bars, s.d.. 
All experiments shown in the figure were performed by Brooke Conti, a 
fellow student in the lab. 
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4.7 Summary of findings and discussion 
 The observation that NHEJ inhibition could suppress ICL-inducing agent 
sensitivity in FA deficient cells has triggered excitement for potential new 
therapeutic avenues for FA and novel mechanistic insight into ICL repair. 
However, there have been inconsistencies between published studies (Adamo et 
al., 2010; Bunting et al., 2012; Chapman et al., 2012; Houghtaling et al., 2005; 
Kottemann and Smogorzewska, 2013; Pace et al., 2010). Here we performed an 
extensive analysis in cells derived from FA patients to identify whether 
inactivating NHEJ factors could rescue ICL-induced proliferation defects. We 
found that inactivation of classical NHEJ proteins, including DNA-PKcs, DNA 
Ligase IV, and Ku70/80, as well as pathway choice protein 53BP1 or Ligase III 
necessary for alternative NHEJ, do not alleviate the ICL sensitivity in FA patient 
cells. 
 
 Our findings directly contradict published studies including the observation 
that DNA-PKcs deficiency could suppress ICL-inducing agent sensitivity in FA 
pathway-deficient human cells.  The rescue of MMC sensitivity with DNA-PKcs 
inhibitor was previously illustrated in HeLa cells with RNAi to deplete FANCA or 
FANCD2 (Adamo et al., 2010). However, we failed to rescue MMC sensitivity of 
FANCA-/- patient cells by shRNA-mediated depletion of DNA-PKcs or through 
chemical inhibitors of DNA-PKcs. It is possible that this inconsistency was a 
result of different experimental set-ups. The rescue effect observed in the 
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previous studies could be a non-specific effect of the DNA-PKcs inhibitor or 
incomplete depletion of the FA transcripts by RNAi treatment. We did not attain 
similar observation, despite using the same type and treatment of DNA-PKcs 
inhibitor. As evidenced by the pronounced IR sensitivity upon depletion or 
chemical inhibition of DNA-PKcs, we are confident that inactivation of DNA-PKcs 
does not rescue ICL repair defects in the human FA patient cells. Yet there 
remains a possibility that the remnant DNA-PKcs activity from incomplete 
depletion or inhibition could still contribute to the MMC sensitivity observed. To 
discard that possibility, we characterized the CRISPR/Cas9-generated full 
genetic knockout of DNA-PKcs in FA-A patient cells and observed no rescue of 
MMC sensitivity (Brooke Conti, Figure 4.6A-C), leading us to conclude that DNA-
PKcs suppression does not promote ICL resistance in FANCA-deficient human 
patient cells.  Our findings are consistent with mouse genetic data that showed 
that ICL sensitivity of Fancd2 mutant MEFs could not be rescued by DNA-PKcs 
deficiency (Houghtaling et al., 2005).  
  
 Divergent relationship between NHEJ and ICL repair among experimental 
systems appears to be a common theme. This is well illustrated by the 
contradictory effects of LIG4 suppression on ICL-induced drug resistance in C. 
elegans and chicken DT-40 cells, reflecting potential differential regulations of 
DSB repair pathway choice and the FA pathway in different organisms (Adamo et 
al., 2010; Pace et al., 2010). Our analysis provides the first genetic evidence 
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against a rescue of crosslink repair defects by LIG4 inactivation in human cells. 
Ablation of LIG4 did not promote ICL resistance in FANCA-depleted HCT116 
cells. It should be noted that the HCT116 cells lack functional MLH1 and MSH3 
proteins, whose role in ICL repair remains incompletely understood. We thus 
tested the effect of CRISPR-mediated LIG4 inactivation directly in FANCA-/- 
patient cell lines and observed no evidence for a rescue of ICL sensitivity (by 
Brooke Conti, Figure 4.6D-F).  
   
In this study, we showed that 53BP1 inactivation did not restore ICL repair 
proficiency in FANCA-deficient cells, in agreement with the previous study in the 
mouse (Bunting et al., 2012). This observation indicates that a potential increase 
in DSB end resection with 53BP1 deficiency, which disfavors NHEJ could not 
compensate for the lack of FANCA-dependent ICL repair (Bunting et al., 2012; 
Knipscheer et al., 2009; Raschle et al., 2008).  
 
 The analysis of rescue of FA cellular phenotypes by Ku70/Ku80 
inactivation in human cells is challenging, as Ku70 and Ku80 function is essential 
at human telomeres (Fattah et al., 2008a; Li et al., 2002). Depletion of Ku80 was 
nonetheless shown previously to partially rescue ICL sensitivity in FA-C and FA-
D2 patient cells (Adamo et al., 2010; Pace et al., 2010). In mouse cells, Ku80 is 
not essential and its knockout leads not only to lack of rescue, but to an increase 
in sensitivity to ICL-inducing agents when combined with Fancd2 deficiency 
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(Bunting et al., 2012). Here, we did not observe a rescue of ICL sensitivity in 
FANCA-deficient cells when Ku70 or Ku80 were partially depleted.   Until Ku70 or 
Ku80 mutants that retain the telomere protection function but lose specifically the 
NHEJ activity are identified, we will not know for sure if full inhibition of the KU 
complex would lead to rescue of FA phenotypes. 
 
 It should be noted that in most of our experiments, we focused our 
attention on the effect of NHEJ suppression on the proliferation of FA-patient 
cells under ICL treatment without additional analysis on the state of crosslinking-
induced chromosomal abnormality, which is a diagnostic feature of FA cells. 
NHEJ is thought to contribute to the chromosomal translocation and the 
formation of radial chromosomes. Therefore, there is a possibility that NHEJ 
inactivation could rescue the radial chromosomes phenotype or could change the 
types of chromosomal aberrations without rescuing the proliferation defect in ICL-
treated FA-patient cells. There is in fact some recent evidence in support of such 
phenomenon that chromosomal translocation/radial chromosomes may not be 
the direct cause of cellular sensitivity to crosslinks or defective DSB repair 
(Bunting et al., 2010). This merits further investigation in the future. 
 
 It should also be noted that our genetic experiments were mostly 
undertaken in FANCA-/- fibroblasts because as a member of the core complex its 
abrogation leads to a full inactivation of FA pathway. We also took into 
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consideration that majority of FA patients carry FANCA mutations. While it is 
possible that other members of the FA pathway may have unique relationships 
with NHEJ, we showed that DNA-PKs inhibitors did not rescue the ICL sensitivity 
of human patient cells lacking FANCD2 or SLX4, the downstream components of 
the FA pathway. Aberrant NHEJ activity is thereby unlikely to be responsible for 
the ICL-inducing agent sensitivity of FA-deficient cells. In addition, our study was 
performed on human patient fibroblasts rather than hematopoietic stem cells 
(HSCs), which may be more relevant to FA-associated bone marrow failure. A 
recent report proposes a correlation between the effect of NHEJ down-regulation 
and a rescue of HSCs defects in FA-deficient mouse and human models via an 
inhibition of TGF-β signaling (Zhang et al., 2016). Whether direct NHEJ 
suppression would produce a similar rescue effect on FA-deficient HSCs needs 
to be explored. 
 
 Together our findings have significant implications for the care of FA 
patients. With our current results, we conclude that inhibition of NHEJ would not 
be able to suppress cellular sensitivity to crosslinking agents in FA-patient cells 
and hence it would not be a viable treatment option for FA patients. It is still 
important to continue to identify and understand the pathways that may crosstalk 
with FA pathway and which could be involved in the aberrant processes in FA-















Chapter 5: Discussion 
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5.1 The role of FAN1 in DNA interstrand crosslink repair  
 In this study, we analyzed FAN1 function in human and mouse cells. Cell 
lines derived from KIN patients and Fan1-deficient mouse embryos, provide a 
powerful genetic tool to study the molecular mechanisms of FAN1 function in 
DNA interstrand crosslink (ICL) repair. Our work demonstrates that FAN1 is 
necessary for cellular resistance to DNA ICL-inducing agents as FAN1-deficient 
cells display decreased proliferation and aberrant chromosomal structures after 
treatment with them. Our study also highlights that the ICL repair function of 
FAN1 is independent of the FA pathway and is not contingent upon interaction 
with the ID2 complex. This finding provides a plausible explanation for the 
phenotypic differences observed between FA and KIN patients.  
 
5.1.1 The mechanism of FAN1 in ICL repair 
 Our study demonstrates that the sensitivity of cells derived from KIN 
patients to ICL-inducing agents can be complemented by ectopic expression of 
wild-type FAN1. Further analysis revealed that KIN patient cells have intact DNA 
damage G1/S and G2/M checkpoints, as well as robust FANCD2 ubiquitination 
especially following ICL treatment. These results suggest that FAN1 might 
function downstream of DNA damage response and FA pathway activation. To 
further characterize the mechanism of FAN1 in ICL repair, we generated Fan1-
deficient mouse embryonic fibroblasts. The study showed that Fan1-knockout 
mouse cells recapitulate the behavior of human cells deficient for FAN1. Namely, 
 161 
the nuclease activity of FAN1 proved necessary for protection against various 
ICL inducing agents - MMC, acetaldehyde and formaldehyde, but not to non-
crosslink replication stress inducers such as hydroxyurea or camptothecin. Our 
analysis also suggests that FAN1 is not haploinsufficient for ICL repair as MEFs 
heterozygous for the Fan1-deficient allele were resistant to the same drug 
treatments. These findings are consistent with karyomegalic interstitial nephritis 
(KIN) being a recessive disease in humans (Zhou et al., 2012).  
 
 The UBZ domain-mediated interaction between FAN1 and the ID2 
complex is believed to be crucial for the recruitment of FAN1 to the sites of 
crosslinked DNA and its involvement in ICL repair (Kratz et al., 2010; Liu et al., 
2010; MacKay et al., 2010; Smogorzewska et al., 2010). However, our data 
indicate that FAN1 can facilitate ICL repair independently of the UBZ domain. 
Our work in collaboration with the Seidman lab demonstrates that the UBZ 
domain is not necessary for the localization of FAN1 to the site of crosslinks 
(Thongthip et al., 2016).  The recruitment of FAN1 relies primarily on the SAP 
domain, with the UBZ domain playing an auxiliary role in the additional 
enrichment of FAN1 at the site of damage. Based on the structural analysis of 
FAN1, the direct interaction of the SAP domain with crosslinked DNA provides 
proper structural remodeling of the DNA substrate, which is required for 
appropriate incision by the nuclease domain of FAN1 and subsequent ICL repair 
(Gwon et al., 2014; Wang et al., 2014; Zhao et al., 2014). Consistent with the 
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SAP domain being important for recruitment to the ICL, we found that ectopic 
expression of FAN1 with mutations in its SAP domain failed to rescue ICL repair 
defect in Fan1-deficient mouse cells. The observation that the SAP domain is 
sufficient for the efficient recruitment of FAN1 to the damage site raises the 
possibility that FAN1 could function in cellular contexts where the FA proteins are 
unable to act efficiently; for example, in the G0 or G1 stage of the cell cycle or at 
a subset of DNA lesions that have structures other than convergent replication 
forks.  
 
The fact that the UBZ of FAN1 is not necessary for resistance to ICL 
inducing agents, prompts a question of the significance and function of the UBZ 
domain and the FAN1- FANCD2 interaction. It is possible that the UBZ domain is 
required for the functions of FAN1 and the ubiquitinated FANCD2/FANCI that are 
unrelated to the repair of ICLs. The UBZ domain is a more recent evolutionary 
extension of FAN1 protein architecture (MacKay et al., 2010; Smogorzewska et 
al., 2010). In yeast, Fan1 is capable of conferring ICL repair activity in the 
absence of the UBZ domain (Fontebasso et al., 2013).  Study from John Rouse  
laboratory showed that the UBZ domain of FAN1 is essential for processing 
replication forks and for protection against chromosomal instability after 
treatment with HU and MMC (Lachaud et al., 2016a). Our experimental 
conditions however, did not reveal a similar requirement for UBZ domain in 
maintenance of chromosomal stability after MMC treatment. One potential 
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difference is that we are working with a knockout model of FAN1 and the Rouse 
lab works with a nuclease dead allele of FAN1. Nevertheless, it remains to be 
determined whether defects in the fork-protective function of FAN1 could 
contribute to KIN development.  Another possibility that remains to be explored is 
the role of the UBZ domain in the potential functions of FAN1 in regulation of 
DNA mismatch repair (MMR) and nucleotide repeat expansion pathways, which 
are associated with diseases like hereditary colorectal cancer (CRC) and 
Huntington’s disease (HD) (Bettencourt et al., 2016; Segui et al., 2015) (see 
section 5.2.3). 
 
 Consistent with the UBZ domain not being necessary for ICL resistance, 
we showed that FAN1 has ICL repair functions outside of the FA pathway. Our 
data are consistent with studies in DT40 chicken cells, which report that FAN1 is 
not epistatic with FANCC and FANCJ in ICL resistance (Yoshikiyo et al., 2010). 
Based on the MMC-induced proliferation defect, the FA protein network 
represents the predominant ICL repair pathway in mammalian cells (Lachaud et 
al., 2016b; Thongthip et al., 2016; Zhou et al., 2012).  However, we found that 
FAN1 depletion/inactivation can further enhance the ICL-induced sensitivity of 
FANCD2-depleted BJ cells, SLX4-depleted BJ cells, and FANCA-patient cells. 
Similarly, we observed that FAN1 depletion could also exacerbate chromosomal 
aberrations in MEF cells lacking FANCD2 upon exposure to a high level of ICLs. 
These results firmly establish the presence of an FA pathway-independent 
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functions of FAN1 that can protect cells from accruing extensive genomic 
alterations upon exposure to ICL agents. 
 
5.1.2 Genetic interaction between FAN1 and other nucleases in ICL repair 
 In vitro biochemical analyses of SLX4/FANCP and XPF/FANCQ-
dependent processing of the crosslinks and the ICL unhooking studies from 
Xenopus egg extracts, strongly support the major involvement of the 3’ flap 
endonuclease activity of XPF/FANCQ, but not FAN1, in performing ICL 
unhooking (Douwel et al., 2014; Hodskinson et al., 2014). Lack of SLX4-
interacting XPF sensitizes human cells to ICL-inducing agents to a greater extent 
than the depletion of FAN1. However, it is evident from the published 
biochemical analyses as well as from our own unpublished data, that FAN1 is 
very effective in incising and unhooking different types of crosslink substrates in 
vitro through its endonuclease and exonuclease activities (Pizzolato et al., 2015; 
Zhao et al., 2014)(A. Wang, L. Timashev, and A. Smogorzewska, unpublished).   
This suggests that the true function of FAN1 has not yet been identified.  FAN1 
may be involved in repair at stalled forks, which do not look like the converging 
replication forks formed on plasmids in the Xenopus egg extracts. It is also 
possible that FAN1 predominantly works in G1 unlike typical FA-associated 
proteins that function in S phase as illustrated by the experiments in Xenopus 
(Raschle et al., 2008).  Another explanation for the lack of a discernible ICL 
unhooking defect in egg extracts depleted of FAN1, could be the presence of 
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redundant nucleases in the extracts.  In our study, we identified SNM1A as being 
redundant with FAN1 during the ICL damage response. Unlike FAN1, SNM1A 
deficiency alone exhibits very mild crosslink sensitivity in mammalian cells 
(Ahkter et al., 2005; Dronkert et al., 2000). In fact, our analysis demonstrated that 
depletion of SNM1A in fibroblasts did not elicit any significant sensitization to 
ICLs. On the other hand, cells lacking both FAN1 and SNM1A became as 
sensitive to crosslinking agents as cells lacking the FA proteins such as SLX4 or 
FANCD2. This result suggests that the ICL repair could be severely 
compromised when both SNM1A and FAN1 are absent. The analysis of ICL 
incision and repair after co-depletion of FAN1 and SNM1A in the Xenopus egg 
extracts could shed further light on the unhooking of the ICLs.  The long-term in 
vivo effects of a combined SNM1A and FAN1 deficiency have not been studied. 
It is possible that the redundant functions of the two nucleases contribute to the 
protection of kidney and liver tissues. It will be interesting to determine if the 
Snm1a knockout animals develop KIN and whether combined inactivation of 
Fan1 and Snm1a could exacerbate KIN phenotypes.   
 
5.2 The role of FAN1 in the protection of tissue function and human disease 
 The Fan1 knockout mouse model exhibits karyomegaly in the kidney and 
liver. This phenomenon demonstrates age-dependence, as stronger phenotypes 
become more apparent in the older mice. Moreover, even though the Fan1-
deficient mice display normal hematopoiesis under unstressed conditions, they 
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develop acute bone marrow dysfunction when challenged with MMC, which 
severely affects animal survival. Overall, our mouse model recapitulates the 
pathology of human KIN in which FAN1 mutations have been identified (Zhou et 
al., 2012).  Although FAN1 mutations in the general population are rare, patients 
with such mutations are predicted to have an adverse reaction if they were 
treated ICL-inducing chemotherapeutics. 
 
5.2.1 The role of FAN1 in the suppression of KIN pathogenesis 
 FAN1 protein appears to be ubiquitously expressed in various human 
tissues with a significant level detected in the kidney and liver, two of the tissues 
affected in KIN patients. Fan1-deficient mice display karyomegaly in epithelial 
cells lining the renal tubules in the kidney as well as in the hepatocytes in the 
liver, as early as at six months of age. Moreover, the number as well as the 
average area of the enlarged nuclei increases with time, suggesting that this 
phenomenon is a continuous and chronic process. The FISH analysis of 18-
month-old mice revealed increased ploidy at three independent genomic loci 
consistent with reduplication of the genome in the karyomegalic nuclei. This 
observation implies that affected cells undergo replication cycles, which are not 
followed by successful mitoses.  It is unclear at this point if the whole genome, or 
only parts of the genome are reduplicated in the absence of FAN1. In KIN 
patients, the karyomegalic nuclei in kidney tissue have also been to shown to 
contain polyploid DNA. This supports our finding in Fan1-deficient mice, that the 
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enlargement of nuclei is a result of polyploidization that takes place in the 
absence of FAN1 (Bhandari et al., 2002; Spoendlin et al., 1995). 
 
 One possible reason for endoreduplication is exit from prolonged cell cycle 
arrest in the setting of persistent DNA damage. The arrest may not last 
permanently and is eventually overcome by mitosis and/or cytokinesis bypass 
with a new round of replication licensing and initiation cycle (Davoli et al., 2010). 
Alternatively, the absence of FAN1 may directly interfere with chromosome 
segregation or cytokinesis preventing the division of the duplicated genomes and 
cells, leading to an increase in ploidy level. More work is needed to understand 
the polyploidization of different tissues affected in KIN patients. The question of 
how polyploidization is allowed to take place in Fan1-deficient animals despite 
the presence of p53 also merits further investigation. The extensive karyomegaly 
seen in the liver in this mouse model could be useful for understanding the 
mechanism of polyploidization in normal hepatic tissue during aging.   
 
 Analysis of 18 months old Fan1-deficient mice revealed that, similar to KIN 
patients, the mice exhibit liver function abnormality as determined by an increase 
in AST and ALT and a reduction in the level of serum albumin and globulin, 
which are synthesized in the liver.  Hepatocytes are especially prone to 
increasing their ploidy during development and in response to insults including 
DNA damage (reviewed in (Gentric and Desdouets, 2014).  The proportion of 
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karyomegalic polyploid hepatocytes is significantly higher in livers of Fan1-
deficient mice compared to that of wild-type animals at 18 months. Based on our 
observation that the polyploidization is a progressive event and that there is a 
strong correlation between ploidy increase and functional decline of the animals, 
it is highly likely that polyploidization is a pathogenic and not an adaptive event in 
Fan1-deficient animals. 
 
 Although both the liver and the kidney of the Fan1-deficient mice display 
karyomegaly at 18 months, we only observe liver but not kidney dysfunction. The 
serum level of urea nitrogen, creatinine and electrolytes that we measured are 
more representative of glomerular function and are not specialized markers of 
proximal tubule function, the primary subtype of kidney tissues affected in Fan1-
deficient mice (Hall et al., 2014; Labarga et al., 2009; Norden et al., 2000). Other 
markers that more accurately correspond with changes in proximal tubule 
function such as the urine level of glucose, amino acids and tubular proteins (e.g. 
retinol-binding protein) might be more appropriate for future assessment of 
functional impairment (Hall et al., 2014).  
 
The kidney is a very resilient organ with high buffering capacity of tissue 
function and usually its functional decline only becomes apparent upon loss of 
the majority of kidney tissue.  Our study was done in mice with C57BL/6J genetic 
background, and this strain is known to be less susceptible to developing kidney 
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deficiency.  Another factor is a relatively short lifespan of mice which might not 
have allowed for sufficient kidney impairment despite the absence of FAN1. 
Additional insults including nephrectomy of one kidney or increase in the 
endogenous DNA damage load (see section 5.3), may be necessary to see 
effects of FAN1 deficiency on kidney function. Alternately, the genetic differences 
between mice and humans might be responsible for the less severe phenotypes 
exhibited by Fan1-deficient mice. It is possible that additional gene inactivation of 
a redundant nuclease such as SNM1A might expose kidney dysfunction in mice.    
 
5.2.2 The role of FAN1 in the protection of bone marrow stem cells 
 In contrast to patients with Fanconi anemia, KIN patients do not develop 
pancytopenia at a young age (Zhou et al., 2012). However, when diagnosed with 
kidney failure, some KIN patients exhibit mild anemia of a presently unknown 
origin (Godin et al., 1996). The anemic phenotype observed in KIN patients could 
be an outcome of prolonged kidney dysfunction or alternatively a direct 
consequence of bone marrow abnormalities, prompting us to evaluate the bone 
marrow function of Fan1-/- mice. These mice at either young or old age, display 
normal levels of peripheral blood cells compared to wild-type animals. The 
analysis of bone marrow histology and quantification of hematopoietic stem cell 
(HSC) frequency in 3 and 18 months old Fan1-/- mice do not reveal a discernible 
change from the wild type levels. In competitive reconstitution experiments, LT-
HSCs derived from bone marrow of Fan1-/- mice were able to engraft with the 
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same efficiency as their wild-type counterparts. This result suggests that the 
function of hematopoietic stem cells is not compromised in Fan1-deficient mice. 
Additionally, we also determined that Fan1 deficiency does not significantly 
enhance the HSC defect observed in Fancd2-/- animals. Taken together, these 
data imply that the activity of FAN1 is dispensable for the protection of 
hematopoietic stem cells from DNA damage under unperturbed conditions.  
 
 Only one Fan1-/- mouse in our study cohort exhibited signs of blood 
cytopenia during the first 18 months of life, which is most likely a sporadic event. 
Despite not being required under unstressed conditions, FAN1 is essential for the 
maintenance of hematopoiesis when animals are challenged with doses of 
crosslinking agents that can be well tolerated by the wild type animals. We 
determined that the bone marrow and thymus were particularly prone to ICL-
induced toxicity in Fan1-deficient animals and that injection of these animals with 
MMC resulted in 90% mortality. Moreover, analysis of the c-Kit+ cells, which 
represent the hematopoietic stem cell population, revealed that the frequency of 
these cells, including the LSK and the LK populations is severely affected by the 
treatment with MMC. This result indicates that FAN1 is indispensable for the 
protection of both the stem and progenitor cells in the bone marrow upon 
exposure to an ICL-challenge. The sensitivity of the HSCs was specific to the 
ICL-induced damage, as ionizing radiation did not elicit the same level of 
pathology. Defects in the kidney and liver were not detected under the acute 
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MMC treatment used in this study. More chronic, low dose treatments might be 
necessary to induce kidney and liver dysfunction in young Fan1-/- animals.  
 
5.2.3 FAN1 and other human diseases 
 Other than KIN, mutations in FAN1 have been implicated as a pathogenic 
factor in a number of diseases including polyglutamine diseases such as 
Huntington’s disease (HD) and multiple spinocerebellar ataxias (SCAs), 
hereditary colorectal cancer (CRC) and high-risk pancreatic cancer (PC) 
(Bettencourt et al., 2016; Segui et al., 2015; Smith et al., 2015). Occurrences of 
pulmonary carcinoma and hepatic lymphoma have also been reported in Fan1 
knockout mice at 20 months of age (Lachaud et al., 2016a). Additionally, a 
deletion of 15q13.2-13.3 which includes FAN1 and 4 other genes, has been 
identified in patients with Schizophrenia (SZ) (Chen et al., 2016; Forsingdal et al., 
2016).  
 
It is unclear how FAN1 variants are involved in the pathogenesis of these 
diseases. In the case of hereditary CRC, mutations associated are either 
truncation mutations such as p.Cys47* and p.Arg952* or missense mutations 
including p.Asp140Thr, p.Pro340Ser, and p.Arg591Trp. FAN1+/- heterozygous 
cells with p.Cys47* variant were reported to have almost wild-type level of ICL 
resistance whereas among all the missense mutations, the p.Asp140Thr FAN1 
variant was the only one to display ICL-repair defects as shown by its failure to 
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complement the ICL sensitivity of FAN1-deficient 293T cells (Segui et al., 2015). 
The ICL repair efficiency of cells carrying the pancreatic cancer variant 
p.Met50Arg of FAN1 has yet to be assessed (Smith et al., 2015). Nonetheless, 
this is the first time that the UBZ domain of FAN1 has been implicated to be 
functionally significant in human studies. To date, there is no evidence indicating 
the loss of heterozygosity or reduced level of FAN1 expression in CRC or PC 
tumor samples that harbor FAN1 variants (Broderick et al., 2017; Segui et al., 
2015; Smith et al., 2015). These observations suggest a possibility that the FAN1 
variants act as dominant alleles. Alternatively, the mutations could potentially 
affect the function of FAN1 outside of ICL repair, which may be affected by a 
haploinsufficiency of FAN1.  
 
DNA mismatch repair (MMR) is one of the likely cellular processes that 
may require the activity of FAN1 for the protection against CRC and Huntington’s 
disease (Bettencourt et al., 2016; Segui et al., 2015). The function of FAN1 in 
MMR has not been formally demonstrated, however, FAN1 was shown by 
multiple labs to be able to interact with MMR components including MLH1, MLH3, 
PMS2 and PMS1 (Kratz et al., 2010; Liu et al., 2010; MacKay et al., 2010; 
Smogorzewska et al., 2010). In accordance with this idea, mutations in MMR 
factors have been implicated in the control of DNA repeat stability that is known 
to underlie CRC and polyglutamine disease predisposition syndromes (Iyer et al., 
2015; Mirkin, 2007; Tome et al., 2013; Wheeler et al., 2003). Given that the type 
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of CRC described in patients with FAN1 variants is MMR proficient, FAN1 might 
not be directly involved in the main MMR pathway (Segui et al., 2015). However, 
its function might be important for the modulation of the pathway to ensure that 
faithful DNA replication and repair occur, especially within the repetitive regions 
of the genome. In order to verify the plausible function of FAN1 in MMR and in 
the protection against repeat-instability disorders, more data need to be collected 
with larger control populations and the hypothesized functions of FAN1 need to 
be tested in cellular and animal models.  
 
5.3 The endogenous source of ICL damage that requires FAN1’s repair 
activity 
 The major unanswered question in the pathophysiology of KIN is the 
nature of lesions that FAN1 repairs. Given the recent data implicating 
acetaldehyde and formaldehyde in the pathogenesis of Fanconi anemia 
(Garaycoechea et al., 2012; Hira et al., 2013; Langevin et al., 2011; Pontel et al., 
2015), aldehydes are attractive candidates as endogenous sources of damage 
that could promote KIN in the absence of FAN1. Based on the sensitivity of 
Fan1-deficient MEFs to aldehydes, there was a possibility that FAN1 was 
involved in the repair of acetaldehyde- or formaldehyde- induced damage, 
particularly in the kidney and liver that are affected in KIN patients.  
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Our data indicate a mild growth defect in Fan1-/-Adh5-/- double-deficient 
animals, which implies that an increased basal formaldehyde level in Adh5-
deficient mice could lead to the accumulation of formaldehyde-induced DNA 
damage that affects growth. The absence of ADH5 also results in smaller 
number of pups produced per litter, a phenotype which is slightly worsened upon 
inactivation of FAN1. Given that the testis and ovary from Fan1-/-Adh5-/- animals 
are within normal limits histologically (data not shown), we hypothesize that 
FAN1 might be required to maintain normal embryonic development, protecting 
developing embryos from formaldehyde insults, which arise in the absence of 
ADH5. 
 
 Kidney and liver function in Fan1 mutant animals with Aldh2 or Adh5 
inactivation are no different than in the wild-type or other single mutant control 
mice. The histology of kidney and liver from 3-month-old Fan1-/-Aldh2-/- or Fan1-
/-Adh5-/- animals is within normal limits with no significant presence of 
karyomegalic cells. This result suggests that KIN phenotypes cannot be 
accelerated by ablating either acetaldehyde or formaldehyde detoxification in 
Fan1-deficient animals. Moreover, we can attribute the karyomegaly phenotype 
primarily to the absence of FAN1. At 12 months of age, Fan1 single or the DKO 
mice lacking both Fan1 and Aldh2 or Adh5 mice displayed similar levels of renal 
karyomegaly. Also, there was no sign of enhanced proliferation or DNA damage 
in the kidney tissue of Fan1-/-Aldh2-/- or Fan1-/-Adh5-/- animals. The fact that 
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suppression of Aldh2 or Adh5 in Fan1-deficient mice did not promote tissue 
karyomegaly and tissue damage, challenges the idea that acetaldehyde and 
formaldehyde contribute to KIN pathogenesis. Furthermore, even when Fan1-/-
Aldh2-/- animals were additionally stressed with increased levels of acetaldehyde 
due to ethanol feeding in the absence of the detoxification pathway, no renal 
karyomegaly or kidney/liver functional decline was observed. The stress-
enhancing experiment with Fan1/Adh5 series is still on-going.  
 
Lack of synergy between Fan1 and Adh5 in promoting kidney disease was 
unexpected. Recent work demonstrated that inactivation of ADH5, which is 
responsible for formaldehyde detoxification, resulted in tissue karyomegaly, 
kidney failure, and abnormal liver function when combined with Fancd2 
deficiency (Pontel et al., 2015).  It is possible that the synergy was not seen 
because the etiology of karyomegaly in the absence of FANCD2 is different from 
its etiology in the absence of FAN1. Fancd2-/-Adh5-/- mice develop glomerular 
damage before they develop karyomegaly and this damage is absent in KIN 
patients and Fan1-deficient mice.  Future experiments will be required to identify 
the mechanism of karyomegaly in both genetic backgrounds. 
 
Besides effects on growth, ADH5 deficiency also had an adverse effect on 
the maintenance of the hematopoietic stem and progenitor populations in young 
3 months old Fan1-/-Adh5-/-. This effect was not seen in Fancd2-/-Aldh2-/- mice. 
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The stronger phenotypes observed in Fan1-/- mice lacking ADH5 when 
compared to mice lacking ALDH2, are reminiscent of the effects of these two 
aldehyde detoxification deficiencies in Fanconi anemia mice with Fancd2-/-Adh5-
/- mice exhibiting more severe defects compared with Fancd2-/-Aldh2-/-. This 
could stem from the more severe nature of formaldehyde induced lesions or 
alternatively due to the increased number of lesions when ADH5 was absent.  
 
 Despite a reduction in the LSK frequency, the remaining Fan1-/-Adh5-/- 
HSCs can effectively function to support sufficient production of peripheral blood 
cells. We further assessed HSC function by testing the ability of the long-term 
HSCs to reconstitute hematopoiesis after serial transplantation. While there is no 
discernible functional compromise in the engraftment efficiency of the bone 
marrow lacking FAN1 in combination with ADH5 or ALDH2 after the first 
transplant, the secondary transplant revealed that both FAN1 and ALDH2 are 
required for long-term reconstitution of blood cells. Secondary transplant studies 
are still ongoing with Fan1-/-Adh5-/-  mice.  
 
Taken together, our results show that FAN1 contributes very subtly, to the 
protection of the bone marrow against acetaldehyde and formaldehyde-induced 
damage in the bone marrow. It is possible that in the bone marrow, nucleases 
associated with the Fanconi anemia pathway such as XPF are more active at 
clearing out aldehyde-induced crosslinks. Furthermore, SNM1A, a redundant 
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nuclease may be able to efficiently compensate for the lack of FAN1 in the bone 
marrow, masking the contribution of FAN1 to the repair of aldehyde-induced 
crosslinks. The generation and characterization of Fan1-/-Snm1a-/-Aldh2-/- and 
Fan1-/-Snm1a-/-Adh5-/- triple mutant mice would be of interest to examine such 
hypothesis. 
 
Several questions regarding the contributions of FAN1 to KIN 
pathophysiology remain unanswered. We still do not know the endogenous 
source of lesions that leads to KIN pathogenesis.  Based on our studies, it is 
unlikely that these are acetaldehyde or formaldehyde. It is still possible that 
FAN1 is required for the repair of damage inflicted by other reactive aldehydes. 
Therefore, investigating the contributions of other members of the aldehyde 
dehydrogenase/alcohol dehydrogenase family might of value. In addition, other 
metabolites that cause ICLs are possible candidates. To address this possibility, 
performing an unbiased screen for metabolic genes whose inactivation in 
combination with FAN1 deficiency produces a synthetic lethality or a synthetically 
reduced fitness at the cellular level and an acceleration of KIN phenotypes at the 
whole organism level, may prove to be a fruitful approach. Furthermore, the 
possibility of KIN being driven by lesions other than ICLs should not be 
overlooked.  For instance, ischemia reperfusion model, which induces significant 
oxidative damage, could be used to stress the kidney to examine its impact on 
the maintenance of renal tubular cells and kidney function in the presence and 
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absence of FAN1.  Identification of the endogenous lesion that needs FAN1 for 
its removal will be important not only for the basic understanding of FAN1 
function but may also lead to therapeutic strategies to protect liver and kidney 















Chapter 6: Materials and Methods 
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6.1 General procedures 
6.1.1 Mammalian cell culture 
 Human patient fibroblasts were transformed by HPV16 E6E7 and 
immortalized by expression of catalytic subunit of human telomerase (hTERT). 
Cells were cultured at 3% oxygen and maintained in DMEM containing 15% FBS, 
100 U/mL penicillin, 0.1 μg/mL streptomycin, 0.1 mM nonessential amino acids, 
and 0.1 mM glutamax (Life Technologies).  
 
 Primary MEFs were isolated from E13.5 embryos using standard 
techniques and cultured at 3% oxygen and in DMEM containing 15% FBS, 100 
U/mL penicillin, 0.1 μg/mL streptomycin, 0.1 mM non-essential amino acids and 
glutamax (Life Technologies). MEFs were immortalized at passage 2 using 
pMSCVNeo HPV16E6E7. 
 
6.1.2 Viral transduction of mammalian cells 
 For viral infections, 293T cells plated in 10 cm dishes the day before were 
transfected with 6 μg of plasmid DNA and the viral packaging vectors using 
TransIT reagent (Mirus). The media was changed once, 24 hours after 
transfection. The virus-containing supernatants were harvested at 24 hours and 
48 hours later and filtered (0.45 μM filter). Polybrene was added at a final 
concentration of 4 μg/mL before used to infect the targeted cells. Cells were 
infected 2-3 at 12 hours intervals for each experimental condition. 24 hours after 
the infection, the infected cells were put under selection with the appropriate 
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antibiotic (puromycin (2 μg/mL), blasticidin (500 μg/mL), hygromycin (100 μg/mL) 
or neomycin (600 μg/mL). Selection was deemed completed after all uninfected 
control cells had died in the present of antibiotic. 
 
6.1.3 DNA damage sensitivity assays 
 Analyses of cell survival under DNA damaging agent treatment were 
performed in a 6-well plate format (except the experiments from Figure 4.2B-E, 
Figure 4.4A-B, and Figure 4.5E that were performed in a 96-well plate format) as 
previously described (Kim et al., 2013). Cells were seeded in triplicate at a 
density of 3.5-4 × 104 per well in a 6-well plate or 500 cells per well in a 96-well 
plate (Opaque White MicrotestTM plate (BD, 353296)) before treatment with 
DNA damaging drugs (MMC (0-75 nM), HU (0-100 nM), CPT (0-20 nM)) 24 
hours later. For cell survival assay following ionizing radiation, cells were first 
irradiated in suspension before plating. In the case of NU7026 or NU7441 pre-
treatment for inhibition of DNA-PKcs, cells were first pre-treated with 10 μM 
NU7026 or 1 μM NU7441 for 3 hours before being subjected to MMC treatment 
in a media containing the corresponding DNA-PKcs inhibitor for the duration of 
the survival assay.  
 
 In the 6-well plate format, the cells were split once after 3 days of drug 
treatment. After additional 3–4 days of further culturing, cell numbers were 
determined using the Z2 Coulter Counter (Beckman Coulter). For the 96-well 
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plate format, cell viability was determined after 5 days in culture using the 
CellTiter-Glo reagent (Promega).  500 cells were plated per well in a 96-well 
plate (Opaque White MicrotestTM plate (BD, 353296) and allowed to grow 
following the DNA damaging agent treatment for 4-5 days until the most 
confluent well reached ~ 80-90% confluency. 50 μl CellTiter-Glo reagent were 
added to each well, which contained 100 μl of media, mixed well by repeated 
pipetting and allowed to incubate at room temperature for 15 minutes before the 
luminescence signals were read.  Luminescence signal/cell viability post-
treatment were normalized to Luminescence signal /cell viability of the untreated 
samples to give the percentage of survival. 
 
6.1.4 Cell proliferation assays 
 Cell proliferation was determined using the 96-well plate format. 500 cells 
were plated per well in a 96-well plate (Opaque White MicrotestTM plate (BD, 
353296)). Cell viability as determined by the luminescence signal was measured 
daily for 6 days using the CellTiter-Glo reagent (Promega). The luminescence 
signals were normalized to the luminescence signals measured on day 1 to give 
the percentage of cell proliferation. 
 
6.1.5 siRNA-mediated knockdown  
 For siRNA transfection, cells were subjected to reverse transfection, using 
RNAiMax (Thermo Fisher). siRNAs were prepared at a final concentration of 25 
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nM in 500 μl of Opti-MEM medium (Gibco) before mixing with 5 μl of 
Lipofectamine RNAimax (Thermo) and transferred to empty 6-well plate. After 20 
minutes of incubation at RT, ~ 150,000 cells diluted in 2 mL of media with no 
added antibiotic were added on top of the RNAi complexes per well. The media 
was changed once 24 hours later, and the RNAi-transfected cells were used at 
72 hours following the transfection for each experiment. 
 
6.1.6 shRNA-mediated knockdown  
 DNA-PKcs, 53BP1, Ku70 and Ku80 shRNA targeting sequences were 
amplified from ssDNA template using miRXhoF (cagaaggctcgagaaggtat-
attgctgttgacagtgagcg) and miREcoRIR (ctaaagtagccccttgaattccgaggcagtagca) 
primers. The original shRNA expression vector pAHM - (pALPS-Hygro-miR30) 
vector was mutagenized to remove the EcoRI site within the hygromycin gene to 
leave only a unique EcoRI cut site within the miR30 cassette of the vector. The 
XhoI/EcoRI-digested amplified products were then ligated to the XhoI/EcoRI 
digested pAHM vector. FANCA was stably knocked down using pAHM-UltramiR 
generated by inserting MluI-HpaI fragments of shFANCA pGipz-UltramiR 
(Transomics) into pAHM. Sequences of shRNAs are given in 6.2.4. Cells were 
transduced with shRNA-expressing lentiviruses and selected for 1 week with 200 
μg/mL hygromycin until the selection was deemed completed after all uninfected 




6.1.7 Gene targeting 
 RA3087 FANCA-/- human fibroblasts and Fan1-/- MEFs were transduced 
with lentivirus expressing of pCW-Cas9 vector encoding dox-inducible Cas9 
expression cassette (Wang et al. 2014b) (plasmid 50661, Addgene, originally 
from Lander and Sabatini labs, MIT). After selection with 50 μg/mL hygromycin 
(for MEFs) or 3 μg/mL puromycin (for human fibroblasts), a single clone with 
undetected basal level of pCW-Cas9 but showed increased in expression 
following dox-induction was selected before being transduced with lentivirus 
expressing single guide RNA (sgRNA) (Sanjana et al. 2014; Wang et al. 2015) 
targeting FAN1 in FANCA-/- human fibroblasts or Snm1a in the Fan1-/- MEFs.  
Following selection in 3 μg/mL puromycin (for MEFs) or 5 μg/mL blasticidin (for 
human fibroblasts), cells were treated with 100 ng/mL doxycyclin for 48 hours 
before single cells were plated in 96-well plates. Isolated clones were screened 
for CRISPR-mediated genome editing at target region by sequencing of genomic 
DNA. The reduction of the corresponding mRNA transcripts determined by RT-
PCR or protein level was used to validate knockout.  Sequences of sgRNAs are 
listed in 6.2.5. 
 
6.1.8 G1/S and G2/M Checkpoint analysis 
G1/S checkpoint 
 Cells were treated with 10 Gy IR. After resting for 10 hours, cells were 
pulsed by 10 µM BrdU for 30 minutes. The cells were then trypsinized and 
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harvested for fixation and analysis. Cells were fixed in ice-cold 100% methanol 
slowly while vortexing. After fixation, the fixed cells were stored at -20 oC at least 
24 hours before staining. Methanol were then replaced by 1 mL 2 N HCl plus 0.2 
mg/mL of pepsin and cells were incubated for 30 minutes at room temperature. 
To neutralized HCL, 3 mL of 0.1 M sodium tetraborate (pH 8.5) were added. 
Cells were then washed once in PBS before a second washed with 1%BSA/0.5% 
Tween-20/PBS. The staining was done with 1:20 FITC-conjugated anti-BrdU 
antibody (BD) in 1%BSA/0.5% Tween-20/PBS at room temperature for 30 
minutes in the dark. Cells were washed once with PBS before resuspended in 
500 µl of PBS/PI (20µg/mL)/RNase (200µg/mL) solution, incubated for 15-20 
minutes at 37 oC and analyzed by LSRII flow cytometer (BD Pharmingen). 
 
G2/M checkpoint 
 Cells were treated with 10 Gy IR and rested for 1 hour before arrested 
with 100 ng/µl nocodazole for 18 hours. The cells were then trypsinized and 
harvested for fixation and analysis. Cells were fixed in ice-cold 70% ethanol 
solution slowly while vortexing. After fixation, the fixed cells were stored at -20 oC 
at least 24 hours before staining. Cells were washed once with PBS before being 
permeabilized with 0.2%Triton X-100 in PBS for 10 minutes. Cells were then 
washed once in PBS before being blocked in 1%FBS/PBS for 30 minutes. After 
blocking cells were stained with 1 µg/ml anti-phospho H3 antibody (Upstate 
Rabbit) for 1 hour at 4 oC. Cells were washed once with PBS before being 
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stained with 1:1000 Secondary antibody 30 minutes at 4 oC in the dark. Cells 
were washed once with PBS before resuspended in 500 µL of PBS/PI 
(20µg/mL)/RNase (200µg/mL) solution, incubated for 15-20 minutes at 37 oC and 
analyzed by LSRII flow cytometer (BD Pharmingen). 
 
6.1.9 Southern blotting 
 Cells were collected by trypsinization, washed once in PBS and processed 
for genomic DNA isolation. Genomic DNA was extracted as previously described 
(de Lange et al., 1990). Genomic DNA was digested by a restriction enzymes 
BamHI overnight before being run on a 0.7% agarose gel overnight. The gels 
were depurinated with 0.25N HCl, denatured and neutralized using standard 
Southern blotting protocol and transferred to nitrocellulose membrane. The 
probes were synthesized by Klenow-based labeling using random hexamers and 
α-32P-dCTP. Membranes were exposed to PhosphorImager screens and 
quantified with ImageQuant software. 
 
6.1.10 Quantitative reverse transcription-polymerase chain reaction (qRT-
PCR) 
 RNA was isolated using the RNeasyPlus extraction kit (Qiagen). cDNA 
was synthesized using the SuperScript III First-Strand Synthesis System (Life 
Technologies) and qRT-PCR was performed using the Platinum SYBR Green 
qPCR SuperMix-UDG (Life Technologies) on an Applied Biosystems 7900HT 
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Sequence Detection System. All steps were carried out as per the manufacturers’ 
instructions. Differences between samples calculated using QuantStudio 
software (Applied Biosystems) using the ΔCT method and were normalized to 
actin. Primers used for qRT-PCR are listed in 6.2.3. 
 
6.1.11 Mutagenesis 
 Mouse Fan1 cDNA was prepared by SuperScript III Reverse 
Transcriptase (Thermo)-mediated cDNA synthesis using wild type mouse 
embryonic fibroblasts (MEFs) RNA extract. The cDNA was cloned into 
pENTR™/D-TOPO (Lifetechnologies). Mutagenesis was performed using the 
QuikChange Multi Site-Directed mutagenesis kit (Agilent) as per the 
manufacturer’s instructions using oligonucleotides listed in 6.2.2. 
 
6.1.12 Cell lysates and immunoblotting 
 Cells were lysed in 2X Laemmli buffer (125 mM Tris-HCl, pH 6.8, 200 mM 
DTT, 4% SDS, 20% glycerol, 0.02% bromophenol blue) at 106 cells per 100 μl, 
sonicated at Amplitude 20 for 30 seconds (S-4000, MISONIX), and boiled for 5 
minutes at 100 oC. The processed lysates were loaded at the equivalent of 1.5-2 
105 cells per lane. Protein samples were separated by SDS-PAGE and blotted 
onto PVDF blotting membranes (GE healthcare Life Sciences). Membranes were 
blocked in 3% milk in t-BST (0.1% Tween-20 in 50mM Tris, 150mM NaCl, pH 
7.6) for 1 hour at RT and incubated with primary antibody in 3% milk containing t-
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BST overnight at 4 oC or for 2-3 hours at RT. Membranes were washed 3 times in 
t-BST, 10 minutes each and incubated with secondary antibody in t-BST for 1 
hour at RT, and washed 3 times 10 minutes each with t-BST at RT. Blots were 
developed with enhanced chemiluminescence (Perkin Elmer) on MultiImage II 
FlourChem HD2 Imaging system (Alpha Innotech). 
 
6.1.13 Immunofluorescence 
 Cells were grown on autoclaved-round coverslips. Cells were rinsed once 
with PBS, before being fixed with 3.7% formaldehyde in PBS for 10 minutes at 
RT and washed three times with PBS. Cells were blocked with PBG (0.2% (w/v) 
cold water fish gelatin (Sigma), 0.5% (w/v) BSA (Sigma) in PBS) for 20 minutes 
at RT, before being incubated with primary antibody diluted in PBG for 2 h at RT 
or overnight at 4 oC. Afterwards, cells were washed 3 times with PBG at RT, 
incubated with secondary antibody diluted 1:500 in PBG for 1 hour at RT, and 
washed 2 times with PBG and 1 time with PBS. Coverslips were sealed onto 
glass sides with mounting medium (VECTASHIELD with DAPI, Vector). Images 
were captured with a Zeiss Axio Observer A1 microscope using Axiovision 
software. 
 
6.1.14 Chromosome breakage analysis 
 Cells were plated at around 75% confluency before being exposed to 50-
100 nM MMC 12 hours later for 24 hours. Afterwards, cells were arrested                                                                                 
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for 2 hours with 0.167 μg/mL of colcemid (EMD) (without media change). Cells 
were harvested, incubated in 0.075 M KCl for 15 minutes at 37°C, and fixed in 
freshly prepared methanol:glacial acidic acid (3:1). Metaphase spreads were 
prepared by dropping cells onto pre-wetted microscope slides. Slides were air-
dried overnight at 40°C before staining with 6% Karyomax Giemsa (Life 
Technologies) in Gurr buffer (Life Technologies) for 3 min. After rinsing with fresh 
Gurr buffer and distilled water, slides were fully dried at room temperature and 
scanned using the Metasystems Metafer. One-way ANOVA test was used to 
determine the statistical significance. The quantification was blinded. 
 
6.1.15 Histology 
 Tissues were harvested and fixed in 10% neutral buffered formalin for 20 
hours at 4 °C. They were then washed twice with water before transferred to 70% 
ethanol solution. The bone decalcification (femur/tibia), paraffin embedding, 
sectioning and hematoxylin & eosin (H&E) staining were performed at the Center 
for Comparative Medicine and Pathology at MSKCC. Quantification of nuclear 
area in tissues was performed blinded to the genotype of the sample. Images 
were captured at 40X objective on a Zeiss Axiovert 40 microscope and then 
analyzed in ImageJ. The area (cross-sectional area) of at least 150 nuclei from 
renal tubular epithelial cells or glomerular cells were measured and normalized to 
the median nuclear area of each section. Data were then plotted and grouped 
according to area.  
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6.1.16 Fluorescent in situ hybridization (FISH)  
 FISH analysis was performed by the MSKCC Molecular Cytogenetics 
Core. It is analyzed on a 5 μm-thick formalin fixed paraffin section using an in-
house 3-color probe for chromosomal regions: 12qA1.1, 16qA and 17qA1. The 
probe mix consisted of the following BAC clones: 12qA1.1 (clones RP23-168O9, 
RP23-54G4 & RP23-41E22; labeled with Green dUTP); 16qA (clones RP23-
290E4, RP23-356A24 & RP23-258J4; labeled with Red dUTP); and 17qA1 
(clones RP23-73N16, RP23-354J18 & RP23-202G20; labeled with Orange 
dUTP). Probe labeling, hybridization, post-hybridization washing, and 
fluorescence detection were performed according to standard procedures. Slides 
were scanned using a Zeiss Axioplan 2i epifluorescence microscope equipped 
with a megapixel CCD camera (CV-M4+CL, JAI) controlled by Isis 5.5.9 imaging 
software (MetaSystems Group Inc, Waltham, MA). 
 
6.1.17 Generation of Fan1-deficient mouse strain 
 All of the animals were handled according to the Rockefeller University 
institutional animal care and use committee (IACUC) protocols. Fan1 gene 
targeting construct (Fan1tm1a(KOMP)Wtsi; MGI code: 4940765) was generated 
by the Knockout Mouse Project KOMP. The construct was electroporated into 
albino B6 mice-derived embryonic stem cells (ES) and the targeted ES cells were 
injected into C57BL/6J blastocyst to generate chimeric animals by the Gene 
Targeting and the Transgenic services at the Rockefeller University. Germline 
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transmission of the targeted allele - Fan1(stop) was verified by the 5′ and 3′ 
probes on Southern blots (Figure 2.4) and used to generate Fan1lox from the 
cross with FLPe deleter mouse stain (Jackson Labs). Fan1Δex3&4 allele was 
generated from the cross between Fan1+/lox and E2a-Cre mice (Jackson Labs). 
Fanca and Fancd2-deficient mice of 129SV background were obtained from 
Marcus Grompe (Noll et al. 2002; Houghtaling et al. 2003). Slx4 and Mus81-
deficient mice of C57/Bl6 background were obtained from Paula Cohen 
(Dendouga et al. 2005; Holloway et al. 2011).  Aldh2- and Adh5- deficient mice of 
C57/Bl6 background were obtained from KJ Patel (Langevin et al. 2011; Pontel 
et al. 2015). 
 
6.1.18 Genotyping 
 Genotyping was carried out by PCR on DNA isolated from mouse tail 
samples digested overnight in 250 μl Direct PCR Lysis reagent (Yolk Sac, 
Viagenbiotech supplemented with 0.4 mg/mL Proteinase K.  PCR was performed 
in 20 μl reaction containing 1.5 μl of DNA extract, 10x PCR buffer (Qiagen), 0.2 
mM dNTP, 1% DMSO, 0.15 U of Taq polymerase (Qiagen) and 0.25/0.5 μM of 
each individual primer. Genotyping primers are shown in 6.2.1. 
 
6.1.19 Whole-animal MMC sensitivity  
 12 weeks old mice were injected intraperitoneally with a single dose of 10 
mg of MMC per kg of body weight. Survival and body weight measurements were 
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recorded daily. The percentage of survival was calculated according to the 
Kaplan and Meier method (Kaplan and Meier 1958). Differences in survival 
between the different genotypes were tested for significance by the Log-Rank 
test. The hematopoietic analyses were done seven days following MMC 
treatment in an independent cohort of mice. The blood was collected by cardiac 
puncture and analyzed for complete blood count (CBC) and serum level of liver 
and kidney marker analytes at the Center for Comparative Medicine and 
Pathology at MSKCC. The bone marrow cells were collected for LSK analysis. 
 
6.1.20 Alcohol administration in mice 
 Ethanol was provided to mice ad libitum in two different administration 
schemes. For short-term exposure, water supply was replaced by a 15% Ethanol 
solution for 5 days, followed by a 20% ethanol solution for another 5 days. 
Alternatively, a 10% ethanol solution was provided to mice for 1 month in a long-
term treatment scheme. To administer methanol, mice were gavage-fed with 
methanol solution to a final dose of 80 mg/kg, 5 days per week for 4 weeks. 
Following the treatments, mice were sacrificed for histological examination, 
hematopoietic and genome instability analysis.  
 
6.1.21 LSK analysis 
 Bone marrow cells were isolated from the femurs and tibiae of mice by 
crushing the bone in FACs buffer (2% FBS in 1X PBS) followed by an additional 
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wash in FACs buffer, before being filtered through a 40-mm cell strainer. The 
early progenitor cells (c-Kit+) were enriched by a 30-minute incubation with 
CD117 (c-Kit) microbeads (Miltenyi Biotec) before passing through the LS 
column (Miltentyl Biotec) placed under magnetic field. The column was washed 
once with FACs buffer, followed by an elution outside of the magnetic field. The 
c-Kit+ enriched cells were stained for 1 hour at 4 °C with the following antibodies 
– PerCP-Cyanine5.5-conjugated lineage cocktail with antibodies anti-CD4 
(Clone: RM4-5 eBioscience), CD3e (Clone: 145-2C11 eBioscience), Ly-6G/Gr-1 
(RB6-8C5 eBioscience), CD11b/Mac-1 (Clone: M1/70 eBioscience), 
CD45R/B220 (RA3-6B2 eBioscience), CD8a (Clone: 53-6.7 eBioscience), and 
TER-119 (eBioscience), anti-c-Kit (APC, Clone: 2B8 eBioscience), anti-Sca-1 
(BV421, Clone: D7 biolegend), anti-CD150 (SLAM) (PE, Clone: TC15-12F12.2 
biolegend) and anti-CD34 (FITC, Clone: RAM34 eBioscience) and anti- CD16/32 
(AF700, Clone: 93 ebioscience) (Frascoli et al. 2012). After one wash with FACs 
buffer, the samples were resuspended in FACs buffer with 7-AAD (ebioscience) 
before run on a LSRII flow cytometer (BD Pharmingen) and the data were 
analyzed with the FlowJo software. 
 
6.1.22 Long-term bone marrow reconstitution analysis 
 The bone marrow cells were isolated from donor animals (CD45.2) and 
prepared as described in 6.1.21. To count the number of live nucleated cells, a 
fraction of cells was treated with ACK lysing buffer (Life technologies) for 10 
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minutes, followed by Trypan blue staining, and counted using a Countess Cell 
counter (Life Technologies). 5x105 (primary transplant) or 2x106 (secondary 
transplant) total bone marrow cells from femur/tibia of donor (CD45.2) mixed with 
2.5x105 total bone marrow competitor cells (CD45.1) in PBS were transplanted to 
the recipient animals (CD45.1) through retro-orbital injection. The recipient 
animals were pre-conditioned with 2 doses of 450 cGy x-ray irradiation with a 3-
hour resting interval. The level of reconstitution efficiency was determined by the 
ratio of CD45.2 to CD45.1 white blood cells using the following antibodies 
cocktail – anti-Ter119 (APC eBioscience), anti-Gr-1 (PE eBioscience), anti-Mac1 
(PB Biolegend), anti-B220 (BV521 Biolegend), anti-CD3 (APC-Cy7 Biolegend), 
anti-CD45.1 (PE-Cy7 eBioscience), anti-CD45.2 (Pecp-Cy5.5 eBioscience), and 
Propidium iodide (PI Sigma) and analyzed with before run on a LSRII flow 
cytometer (BD Pharmingen) at 1, 2, or 4 months. 
 
6.1.23 Micronuclei analysis of genome instability 
 The analysis was done as described in (Balmus et al., 2015). The blood 
was collected through retro-orbital bleeding by heparinized capillary tubes 
(Fisher) or cardiac puncture (if the animals were sacrificed) into the EDTA-coated 
tubes (Greiner Bio-One). The blood was then resuspended in heparin solution 
before fixed in cold methanol and stored directly at -80 oC for at least 12 hours. 
After one wash with bicarbonate buffer, the cells were stained with anti-CD71 
(FITC SouthernBiotech) in a solution containing 5 mg/mL RNase (Sigma). After 1 
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wash with bicarbonate buffer, the cells were resuspended in bicarbonate buffer 
containing 5 mg/mL PI and analyzed with a LSRII flow cytometer (BD 
Pharmingen). 
 
6.1.24 In vitro analysis of hematopoietic stem cell sensitivity to MMC 
 c-Kit+ enriched cells were isolated as described in 6.1. The cells were 
then cultured in DMEM/F12 (Gibco) containing 100 U/mL penicillin, murine 
recombinant cytokines including TPO (100 ng/mL Peprotech), SCF (100 ng/mL 
Peprotech), FLT-3 (100 ng/mL Peprotech), IL-3 (20 ng/mL Peprotech), IL-6 (20 
ng/mL Peprotech). 24 hours later, the MMC were added at different 
concentrations (0 nM, 100 nM, 200 nM) and the cells were cultured for additional 
48 hours. The cells were then harvested and washed once with FACs buffer 
before stained for the LSK markers as described in 6.1.21. 
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6.2 List of primers 
6.2.1 Genotyping primers 
Mouse genotyping primers 
Genotype Primer sequences Amplicon size (bp) 
Fan1+ 5’-AAGGTCTGTGGTCATCGTGTCAG-3’ 5’-AAACGATCCCTGTCTGGCTGA-3’ 292 
Fan1- 5’-TGAGACAGCTCAACTGGCACT-3’ 5’-AAACGATCCCTGTCTGGCTGA-3’ 543 
Fancd2+ 5’-TCAGCCTCACATGGAGTTTAACG-3’ 5’-AA TTCGCCAATGACAAGACGC-3’ 300 
Fancd2- 5’-TCAGCCTCACATGGAGTTTAACG-3’ 5’-CAGGGATGAAAGGGTCTTACGC-3’ 550 






Slx4+ 5’-CACTGAGCCATCTCACCAGC-3’ 5’-GGAGCCCAGTCTGGGACTCTG-3’ 475 
Slx4f3 5’-CACTGAGCCATCTCACCAGC-3’ 5’-TCGTGGTATCGTTATGCGCC-3’ 298 
Mus81+ 5’-CTAGCCGCTTGCGTTCCACAATGT-3’ 5’-GGAGCTAAGGCCTAGCGAGTACAG-3’ 418 
Mus81- 5’-GGTGTGGCCCTGATGGAAGAG-3’ 5’-GGAGCTAAGGCCTAGCGAGTACAG-3’ 380 
Aldh2+ 5’-AAACTTTGCACACACTGTCCC-3’ 5’-CCCAGATCCAACTGTTAGGAATAC-3’ 212 
Aldh2- 5’-AAACTTTGCACACACTGTCCC-3’ 5’-GCTTCACTGAGTCTCTGGCATCTC-3’ 441 
Adh5+ 5’-TCAAGAGGTGAGGCTACAAGTT-3’ 5’-GGCATGTCTTCATTTAGCTCAC-3’ 200 










FAN1 L480P 5’-TCTGCTCCTGAGCCGAAAGCCCTGGCC-3’ 




Gene Primer sequences 
Mouse Fan1 5’-CACAGTCCTGTGTTCTGTGGA-3’ 5’-TCAAAGCCACTCTGCCTGTA-3’ 
Mouse Snm1a 5’-GCAAAGTCCACACACTGTTCC-3’ 5’-CTGCTGTGACGGGAAGGTAT-3' 
Mouse Actin 5’-CTAAGGCCAACCGTGAAAAG-3’ 5’-ACCAGAGGCATACAGGGACA-3’ 
 
 
6.2.4 List of shRNAs 
shRNA target sequences 
shRNA Target sequences 
Mouse Snm1a.1 5’-TGACTCTTTTCTGCTTCT-3’ 
Mouse Snm1a.2 5’-CAGAATCTGTTGAAAAATCA-3’ 
Mouse Snm1a.3 5’-CATGTCCGTTCTATAAGAGA-3’ 
Human  






Human Ku70.1 5’-AACGGATCTGACTACTCACTC-3’ 
Human Ku70.2 5’-ACAGGTTAAAGCTGAAGCTCA-3’ 
Human Ku70.3 5’-CAGGGAAAGTTACCAAGAGAA-3’ 
Human Ku80.1 5’-CCAGCTGGATATTATAATTCAT-3’ 
Human Ku80.2 5’-CCCCGCTGAGGTGACAACAAA-3’ 
Human Ku80.3 5’-CAAGAGAGAAAGTTTCGTTAT-3’ 
Human 53BP1.1 5’-CAAGGATGTACATGTTGTAAA-3’ 
Human 53BP1.2 5’-AAAGGAGAAGAGGAGAAAGAA-3’ 
Human 53BP1.3 5’-AACGATTATGTTTCTCACTAA-3’ 
Human FANCA.1 5’-CCTGCAGAGAATGCTGATTTT-3’ 
Human FANCA.2 5’-AACAGTATGTTCTCCCGTCTT-3’ 
 
6.2.5 List of sgRNAs  
sgRNA target sequences 
Gene Target sequences 
Mouse Snm1a 5’-CGAAGGTGCGCCCTGTTTAT-3’ 




6.3 List of Antibodies  
Antigen ID Source Uses 
mFAN1 S101D John Rouse lab WB 
mFANCD2 EPR2302 Abcam  WB 
HA MMS-101R Covance WB, IF 
hFAN1 AP394 In-house WB 
GFP Clones 7.1 and 13.1 Roche WB, IF 
γH2AX JBW301/05-636 Upstate WB, IF 
H2AX A300-082A Bethyl WB 
hDNA-PKcs Clone: 25-4 Fisher WB 
h53BP1 NB100-304 Novus WB, IF 
hKu70 N3H10 NeoMarkers WB 
hKu80 C-ter Ku80 Lisa Postow Funabiki lab WB 
hFANCA A301-980A Bethyl WB 
hFANCI AP583 In-house WB 
hFANCD2 NB100-182 Novus WB, IF 
hXPF/ERCC4 Bethyl A301-315A WB 
hMUS81 M1445 Sigma WB 




6.4 List of cell lines  
Cell lines Organism 
BJ Human, Fibroblasts 
A1170-22 (KIN patients) Human, Fibroblasts 
A4466 (KIN patients) Human, Lymphocytes 
A4486 (KIN patients) Human, Lymphocytes 
A4385 (KIN patients) Human, Lymphocytes 
RA3087 (FA-A patients) Human, Fibroblasts 
RA2645 (FA-D2 patients) Human, Fibroblasts 
RA3331 (FA-P/SLX4 patients) Human, Fibroblasts 
RA3087 pcwCAS9 Human, Fibroblasts 
RA2645 pcwCAS9 Human, Fibroblasts 
RA3087sgFAN1 Human, Fibroblasts 
RA2645sgFAN1 Human, Fibroblasts 
WT HCT 116 Human, Colorectal carcinoma 
LIG4+/- HCT 116 Human, Colorectal carcinoma 
LIG4-/- HCT 116 Human, Colorectal carcinoma 
LIG3-/- 








Human, Colorectal carcinoma 
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Cell lines Organism 
Fan1+/+ Mouse, E13.5 MEFs 
Fan1+/- Mouse, E13.5 MEFs 
Fan1-/- Mouse, E13.5 MEFs 
Fancd2-/- Mouse, E13.5 MEFs 
Fan1-/-Fancd2-/- Mouse, E13.5 MEFs 
Fanca-/- Mouse, E13.5 MEFs 
Fan1-/-Fanca-/- Mouse, E13.5 MEFs 
Fan1-/-sgSnm1a.6 Mouse, E13.5 MEFs 
Slx4f3/f3 Mouse, E13.5 MEFs 
Fan1-/-Slx4f3/f3 Mouse, E13.5 MEFs 
Mus81-/- Mouse, E13.5 MEFs 





















Chapter 7: References 
  
 203 
Adamo, A., Collis, S.J., Adelman, C.A., Silva, N., Horejsi, Z., Ward, J.D., 
Martinez-Perez, E., Boulton, S.J., and La Volpe, A. (2010). Preventing 
nonhomologous end joining suppresses DNA repair defects of Fanconi anemia. 
Mol Cell 39, 25-35. 
Ahkter, S., Richie, C.T., Zhang, N., Behringer, R.R., Zhu, C., and Legerski, R.J. 
(2005). Snm1-Deficient Mice Exhibit Accelerated Tumorigenesis and 
Susceptibility to Infection. Mol Cell Biol 25, 10071-10078. 
Airik, R., Schueler, M., Airik, M., Cho, J., Porath, J.D., Mukherjee, E., Sims-Lucas, 
S., and Hildebrandt, F. (2016). A FANCD2/FANCI-Associated Nuclease 1-
Knockout Model Develops Karyomegalic Interstitial Nephritis. J Am Soc Nephrol 
27, 3552-3559. 
Alter, B.P. (2003). Cancer in Fanconi anemia, 1927-2001. Cancer 97, 425-440. 
Alter, B.P., Giri, N., Savage, S.A., Peters, J.A., Loud, J.T., Leathwood, L., Carr, 
A.G., Greene, M.H., and Rosenberg, P.S. (2010). Malignancies and survival 
patterns in the National Cancer Institute inherited bone marrow failure syndromes 
cohort study. Br J Haematol 150, 179-188. 
Auerbach, A.D. (2009). Fanconi anemia and its diagnosis. Mutation 
Research/Fundamental and Molecular Mechanisms of Mutagenesis 668, 4-10. 
 204 
Auerbach, A.D., Rogatko, A., and Schroeder-Kurth, T.M. (1989). International 
Fanconi Anemia Registry: relation of clinical symptoms to diepoxybutane 
sensitivity. Blood 73, 391-396. 
Auerbach, C. (1949). The Mutagenic Mode of Action of Formalin. Science 110, 
419-420. 
Ballard, H.S. (1997). The hematological complications of alcoholism. Alcohol 
Health Res World 21, 42-52. 
Balmus, G., Karp, N.A., Ng, B.L., Jackson, S.P., Adams, D.J., and McIntyre, R.E. 
(2015). A high-throughput in vivo micronucleus assay for genome instability 
screening in mice. Nat Protoc 10, 205-215. 
Bettencourt, C., Hensman-Moss, D., Flower, M., Wiethoff, S., Brice, A., Goizet, 
C., Stevanin, G., Koutsis, G., Karadima, G., Panas, M., et al. (2016). DNA repair 
pathways underlie a common genetic mechanism modulating onset in 
polyglutamine diseases. Ann Neurol 79, 983-990. 
Bhandari, S., Kalowski, S., Collett, P., Cooke, B.E., Kerr, P., Newland, R., 
Dowling, J., and Horvath, J. (2002). Karyomegalic nephropathy: an uncommon 
cause of progressive renal failure. Nephrol Dial Transplant 17, 1914-1920. 
 205 
Bird, R.P., Draper, H.H., and Basrur, P.K. (1982). Effect of malonaldehyde and 
acetaldehyde on cultured mammalian cells. Production of micronuclei and 
chromosomal aberrations. Mutat Res 101, 237-246. 
Blier, P.R., Griffith, A.J., Craft, J., and Hardin, J.A. (1993). Binding of Ku protein 
to DNA. Measurement of affinity for ends and demonstration of binding to nicks. J 
Biol Chem 268, 7594-7601. 
Bluteau, D., Masliah-Planchon, J., Clairmont, C., Rousseau, A., Ceccaldi, R., 
Dubois d'Enghien, C., Bluteau, O., Cuccuini, W., Gachet, S., Peffault de Latour, 
R., et al. (2016). Biallelic inactivation of REV7 is associated with Fanconi anemia. 
J Clin Invest 126, 3580-3584. 
Bouwman, P., Aly, A., Escandell, J.M., Pieterse, M., Bartkova, J., van der Gulden, 
H., Hiddingh, S., Thanasoula, M., Kulkarni, A., Yang, Q., et al. (2010). 53BP1 
loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-
mutated breast cancers. Nat Struct Mol Biol 17, 688-695. 
Broderick, P., Dobbins, S.E., Chubb, D., Kinnersley, B., Dunlop, M.G., Tomlinson, 
I., and Houlston, R.S. (2017). Validation of Recently Proposed Colorectal Cancer 
Susceptibility Gene Variants in an Analysis of Families and Patients-a Systematic 
Review. Gastroenterology 152, 75-77 e74. 
 206 
Bunting, S.F., Callen, E., Kozak, M.L., Kim, J.M., Wong, N., Lopez-Contreras, 
A.J., Ludwig, T., Baer, R., Faryabi, R.B., Malhowski, A., et al. (2012). BRCA1 
functions independently of homologous recombination in DNA interstrand 
crosslink repair. Mol Cell 46, 125-135. 
Bunting, S.F., Callen, E., Wong, N., Chen, H.T., Polato, F., Gunn, A., Bothmer, A., 
Feldhahn, N., Fernandez-Capetillo, O., Cao, L., et al. (2010). 53BP1 inhibits 
homologous recombination in Brca1-deficient cells by blocking resection of DNA 
breaks. Cell 141, 243-254. 
Burry, A.F. (1974). Extreme dysplasia in renal epithelium of a young woman 
dying from hepatocarcinoma. J Pathol 113, 147-150. 
Butturini, A., Gale, R.P., Verlander, P.C., Adler-Brecher, B., Gillio, A.P., and 
Auerbach, A.D. (1994). Hematologic abnormalities in Fanconi anemia: an 
International Fanconi Anemia Registry study. Blood 84, 1650-1655. 
Cannavo, E., Gerrits, B., Marra, G., Schlapbach, R., and Jiricny, J. (2007). 
Characterization of the interactome of the human MutL homologues MLH1, 
PMS1, and PMS2. J Biol Chem 282, 2976-2986. 
 207 
Casanova-Schmitz, M., and Heck, H.D. (1983). Effects of formaldehyde 
exposure on the extractability of DNA from proteins in the rat nasal mucosa. 
Toxicol Appl Pharmacol 70, 121-132. 
Castor, D., Nair, N., Déclais, A.-C., Lachaud, C., Toth, R., MacArtney, T.J., Lilley, 
D.M.J., Arthur, J.S.C., and Rouse, J. (2013). Cooperative control of holliday 
junction resolution and DNA repair by the SLX1 and MUS81-EME1 nucleases. 
Mol Cell 52, 221-233. 
Cattell, E., Sengerova, B., and McHugh, P.J. (2010). The SNM1/Pso2 family of 
ICL repair nucleases: from yeast to man. Environ Mol Mutagen 51, 635-645. 
Ceccaldi, R., Parmar, K., Mouly, E., Delord, M., Kim, J.M., Regairaz, M., Pla, M., 
Vasquez, N., Zhang, Q.S., Pondarre, C., et al. (2012). Bone marrow failure in 
Fanconi anemia is triggered by an exacerbated p53/p21 DNA damage response 
that impairs hematopoietic stem and progenitor cells. Cell Stem Cell 11, 36-49. 
Ceccaldi, R., Sarangi, P., and D'Andrea, A.D. (2016). The Fanconi anaemia 
pathway: new players and new functions. Nat Rev Mol Cell Biol 17, 337-349. 
Chapman, J.R., Taylor, M.R., and Boulton, S.J. (2012). Playing the end game: 
DNA double-strand break repair pathway choice. Mol Cell 47, 497-510. 
 208 
Chen, J., Calhoun, V.D., Perrone-Bizzozero, N.I., Pearlson, G.D., Sui, J., Du, Y., 
and Liu, J. (2016). A pilot study on commonality and specificity of copy number 
variants in schizophrenia and bipolar disorder. Transl Psychiatry 6, e824. 
Chiruvella, K.K., Liang, Z., and Wilson, T.E. (2013). Repair of double-strand 
breaks by end joining. Cold Spring Harb Perspect Biol 5, a012757. 
Chuang, S.C., La Vecchia, C., and Boffetta, P. (2009). Liver cancer: descriptive 
epidemiology and risk factors other than HBV and HCV infection. Cancer Lett 
286, 9-14. 
Ciccia, A., and Elledge, S.J. (2010). The DNA damage response: making it safe 
to play with knives. Mol Cell 40, 179-204. 
Clauson, C., Scharer, O.D., and Niedernhofer, L. (2013). Advances in 
understanding the complex mechanisms of DNA interstrand cross-link repair. 
Cold Spring Harb Perspect Biol 5, a012732. 
Crossan, G.P., van der Weyden, L., Rosado, I.V., Langevin, F., Gaillard, P.-H.L., 
McIntyre, R.E., Gallagher, F., Kettunen, M.I., Lewis, D.Y., Brindle, K., et al. 
(2011). Disruption of mouse Slx4, a regulator of structure-specific nucleases, 
phenocopies Fanconi anemia. Nat Genet 43, 147-152. 
 209 
Davoli, T., Denchi, E.L., and de Lange, T. (2010). Persistent telomere damage 
induces bypass of mitosis and tetraploidy. Cell 141, 81-93. 
de Lange, T., Shiue, L., Myers, R.M., Cox, D.R., Naylor, S.L., Killery, A.M., and 
Varmus, H.E. (1990). Structure and variability of human chromosome ends. Mol 
Cell Biol 10, 518-527. 
De Marchi, S., Cecchin, E., Basile, A., Bertotti, A., Nardini, R., and Bartoli, E. 
(1993). Renal tubular dysfunction in chronic alcohol abuse--effects of abstinence. 
N Engl J Med 329, 1927-1934. 
Deans, A.J., and West, S.C. (2011). DNA interstrand crosslink repair and cancer. 
1-14. 
Dellarco, V.L. (1988). A mutagenicity assessment of acetaldehyde. Mutat Res 
195, 1-20. 
Douwel, D.K., Boonen, R.A.C.M., Long, D.T., Szypowska, A.A., Räschle, M., 
Walter, J.C., and Knipscheer, P. (2014). XPF-ERCC1 Acts in Unhooking DNA 
Interstrand Crosslinks in Cooperation with FANCD2 and FANCP/SLX4. Mol Cell, 
1-12. 
 210 
Dronkert, M.L., de Wit, J., Boeve, M., Vasconcelos, M.L., van Steeg, H., Tan, 
T.L., Hoeijmakers, J.H., and Kanaar, R. (2000). Disruption of mouse SNM1 
causes increased sensitivity to the DNA interstrand cross-linking agent mitomycin 
C. Mol Cell Biol 20, 4553-4561. 
Dunnick, J.K., Forbes, P.D., Davies, R.E., and Iverson, W.O. (1987). Toxicity of 
8-methoxypsoralen, 5-methoxypsoralen, 3-carbethoxypsoralen, or 5-
methylisopsoralen with ultraviolet radiation in the hairless (HRA/Skh) mouse. 
Toxicol Appl Pharmacol 89, 73-80. 
Dutta, S., Chowdhury, G., and Gates, K.S. (2007). Interstrand cross-links 
generated by abasic sites in duplex DNA. J Am Chem Soc 129, 1852-1853. 
Eastman, A. (1983). Characterization of the adducts produced in DNA by cis-
diamminedichloroplatinum(II) and cis-dichloro(ethylenediamine)platinum(II). 
Biochemistry 22, 3927-3933. 
Epstein, M. (1997). Alcohol's impact on kidney function. Alcohol Health Res 
World 21, 84-92. 
Falzon, M., Fewell, J.W., and Kuff, E.L. (1993). EBP-80, a transcription factor 
closely resembling the human autoantigen Ku, recognizes single- to double-
strand transitions in DNA. J Biol Chem 268, 10546-10552. 
 211 
Fanconi, G. (1967). Familial constitutional panmyelocytopathy, Fanconi's anemia 
(F.A.). I. Clinical aspects. Semin Hematol 4, 233-240. 
Fattah, F.J., Lichter, N.F., Fattah, K.R., Oh, S., and Hendrickson, E.A. (2008a). 
Ku70, an essential gene, modulates the frequency of rAAV-mediated gene 
targeting in human somatic cells. Proc Natl Acad Sci U S A 105, 8703-8708. 
Fattah, K.R., Ruis, B.L., and Hendrickson, E.A. (2008b). Mutations to Ku reveal 
differences in human somatic cell lines. DNA Repair (Amst) 7, 762-774. 
Fekairi, S., Scaglione, S., Chahwan, C., Taylor, E.R., Tissier, A., Coulon, S., 
Dong, M.-Q., Ruse, C., Yates, I., John R, Russell, P., et al. (2009). Human SLX4 
Is a Holliday Junction Resolvase Subunit that Binds Multiple DNA 
Repair/Recombination Endonucleases. Cell 138, 78-89. 
Fontebasso, Y., Etheridge, T.J., Oliver, A.W., Murray, J.M., and Carr, A.M. 
(2013). The conserved Fanconi anemia nuclease Fan1 and the SUMO E3 ligase 
Pli1 act in two novel Pso2-independent pathways of DNA interstrand crosslink 
repair in yeast. DNA repair 12, 1011-1023. 
Forsingdal, A., Fejgin, K., Nielsen, V., Werge, T., and Nielsen, J. (2016). 15q13.3 
homozygous knockout mouse model display epilepsy-, autism- and 
schizophrenia-related phenotypes. Transl Psychiatry 6, e860. 
 212 
Fricke, W.M., and Brill, S.J. (2003). Slx1-Slx4 is a second structure-specific 
endonuclease functionally redundant with Sgs1-Top3. Genes Dev 17, 1768-1778. 
Garaycoechea, J.I., Crossan, G.P., Langevin, F., Daly, M., Arends, M.J., and 
Patel, K.J. (2012). Genotoxic consequences of endogenous aldehydes on mouse 
haematopoietic stem cell function. Nature 489, 571-575. 
Garcia-Higuera, I., Taniguchi, T., Ganesan, S., Meyn, M.S., Timmers, C., Hejna, 
J., Grompe, M., and D'Andrea, A.D. (2001). Interaction of the Fanconi anemia 
proteins and BRCA1 in a common pathway. Mol Cell 7, 249-262. 
Gargiulo, D., Kumar, G.S., Musser, S.S., and Tomasz, M. (1995). Structural and 
function modification of DNA by mitomycin C. Mechanism of the DNA sequence 
specificity of mitomycins. Nucleic Acids Symp Ser, 169-170. 
Garner, E., Kim, Y., Lach, F.P., Kottemann, M.C., and Smogorzewska, A. (2013). 
Human GEN1 and the SLX4-associated nucleases MUS81 and SLX1 are 
essential for the resolution of replication-induced Holliday junctions. Cell Rep 5, 
207-215. 
Gentric, G., and Desdouets, C. (2014). Polyploidization in liver tissue. Am J 
Pathol 184, 322-331. 
 213 
Girard, D.E., Kumar, K.L., and McAfee, J.H. (1987). Hematologic effects of acute 
and chronic alcohol abuse. Hematol Oncol Clin North Am 1, 321-334. 
Godin, M., Francois, A., Le Roy, F., Morin, J.P., Creppy, E., Hemet, J., and 
Fillastre, J.P. (1996). Karyomegalic interstitial nephritis. Am J Kidney Dis 27, 166. 
Goedde, H.W., and Agarwal, D.P. (1990). Pharmacogenetics of aldehyde 
dehydrogenase (ALDH). Pharmacol Ther 45, 345-371. 
Goodarzi, A.A., Yu, Y., Riballo, E., Douglas, P., Walker, S.A., Ye, R., Harer, C., 
Marchetti, C., Morrice, N., Jeggo, P.A., et al. (2006). DNA-PK 
autophosphorylation facilitates Artemis endonuclease activity. EMBO J 25, 3880-
3889. 
Goodman, L.S., Wintrobe, M.M., and et al. (1946). Nitrogen mustard therapy; use 
of methyl-bis (beta-chloroethyl) amine hydrochloride and tris (beta-chloroethyl) 
amine hydrochloride for Hodgkin's disease, lymphosarcoma, leukemia and 
certain allied and miscellaneous disorders. J Am Med Assoc 132, 126-132. 
Grawunder, U., Wilm, M., Wu, X., Kulesza, P., Wilson, T.E., Mann, M., and 
Lieber, M.R. (1997). Activity of DNA ligase IV stimulated by complex formation 
with XRCC4 protein in mammalian cells. Nature 388, 492-495. 
 214 
Gwon, G.H., Kim, Y., Liu, Y., Watson, A.T., Jo, A., Etheridge, T.J., Yuan, F., 
Zhang, Y., Kim, Y., Carr, A.M., et al. (2014). Crystal structure of a Fanconi 
anemia-associated nuclease homolog bound to 5 ′  flap DNA: basis of 
interstrand cross-link repair by FAN1. Genes Dev 28, 2276-2290. 
Hall, A.M., Bass, P., and Unwin, R.J. (2014). Drug-induced renal Fanconi 
syndrome. QJM 107, 261-269. 
Hazrati, A., Ramis-Castelltort, M., Sarkar, S., Barber, L.J., Schofield, C.J., 
Hartley, J.A., and McHugh, P.J. (2008). Human SNM1A suppresses the DNA 
repair defects of yeast pso2 mutants. DNA repair 7, 230-238. 
Hejna, J., Philip, S., Ott, J., Faulkner, C., and Moses, R. (2007). The hSNM1 
protein is a DNA 5&apos;-exonuclease. Nucleic Acids Res 35, 6115-6123. 
Herskowitz, I.H. (1950). The differential induction of lethal mutations by formalin 
in the two sexes of Drosophila. Science 112, 302-303. 
Hira, A., Yabe, H., Yoshida, K., Okuno, Y., Shiraishi, Y., Chiba, K., Tanaka, H., 
Miyano, S., Nakamura, J., Kojima, S., et al. (2013). Variant ALDH2 is associated 
with accelerated progression of bone marrow failure in Japanese Fanconi 
anemia patients. Blood 122, 3206-3209. 
 215 
Hodskinson, M.R.G., Silhan, J., Crossan, G.P., Garaycoechea, J.I., Mukherjee, 
S., Johnson, C.M., Schärer, O.D., and Patel, K.J. (2014). Mouse SLX4 Is a 
Tumor Suppressor that Stimulates the Activity of the Nuclease XPF-ERCC1 in 
DNA Crosslink Repair. Mol Cell, 1-33. 
Hoeijmakers, J.H. (2009). DNA damage, aging, and cancer. N Engl J Med 361, 
1475-1485. 
Hofmann, K. (2009). Ubiquitin-binding domains and their role in the DNA damage 
response. DNA Repair (Amst) 8, 544-556. 
Houghtaling, S., Newell, A., Akkari, Y., Taniguchi, T., Olson, S., and Grompe, M. 
(2005). Fancd2 functions in a double strand break repair pathway that is distinct 
from non-homologous end joining. Hum Mol Genet 14, 3027-3033. 
Houghtaling, S., Timmers, C., Noll, M., Finegold, M.J., Jones, S.N., Meyn, M.S., 
and Grompe, M. (2003). Epithelial cancer in Fanconi anemia complementation 
group D2 (Fancd2) knockout mice. Genes Dev 17, 2021-2035. 
Howlett, N.G., Taniguchi, T., Olson, S., Cox, B., Waisfisz, Q., De Die-Smulders, 
C., Persky, N., Grompe, M., Joenje, H., Pals, G., et al. (2002). Biallelic 
inactivation of BRCA2 in Fanconi anemia. Science 297, 606-609. 
 216 
Huang, H., Kozekov, I.D., Kozekova, A., Wang, H., Lloyd, R.S., Rizzo, C.J., and 
Stone, M.P. (2010). DNA cross-link induced by trans-4-hydroxynonenal. Environ 
Mol Mutagen 51, 625-634. 
Huang, J., Liu, S., Bellani, M.A., Thazhathveetil, A.K., Ling, C., de Winter, J.P., 
Wang, Y., Wang, W., and Seidman, M.M. (2013). The DNA translocase 
FANCM/MHF promotes replication traverse of DNA interstrand crosslinks. Mol 
Cell 52, 434-446. 
Humans, I.W.G.o.t.E.o.C.R.t. (2006). Formaldehyde, 2-butoxyethanol and 1-tert-
butoxypropan-2-ol. IARC Monogr Eval Carcinog Risks Hum 88, 1-478. 
INoll, M., Battaile, K.P., Bateman, R., Lax, T.P., Rathbun, K., Reifsteck, C., 
Bagby, G., Finegold, M., Olson, S., and Grompe, M. (2002). Fanconi anemia 
group A and C double-mutant mice: functional evidence for a multi-protein 
Fanconi anemia complex. Exp Hematol 30, 679-688. 
Ishiai, M., Kimura, M., Namikoshi, K., Yamazoe, M., Yamamoto, K., Arakawa, H., 
Agematsu, K., Matsushita, N., Takeda, S., Buerstedde, J.-M., et al. (2004). DNA 
cross-link repair protein SNM1A interacts with PIAS1 in nuclear focus formation. 
Mol Cell Biol 24, 10733-10741. 
 217 
Ishiai, M., Kitao, H., Smogorzewska, A., Tomida, J., Kinomura, A., Uchida, E., 
Saberi, A., Kinoshita, E., Kinoshita-Kikuta, E., Koike, T., et al. (2008). FANCI 
phosphorylation functions as a molecular switch to turn on the Fanconi anemia 
pathway. Nat Struct Mol Biol 15, 1138-1146. 
Isnard, P., Rabant, M., Labaye, J., Antignac, C., Knebelmann, B., and Zaidan, M. 
(2016). Karyomegalic Interstitial Nephritis: A Case Report and Review of the 
Literature. Medicine (Baltimore) 95, e3349. 
Iwabuchi, K., Hashimoto, M., Matsui, T., Kurihara, T., Shimizu, H., Adachi, N., 
Ishiai, M., Yamamoto, K., Tauchi, H., Takata, M., et al. (2006). 53BP1 contributes 
to survival of cells irradiated with X-ray during G1 without Ku70 or Artemis. 
Genes Cells 11, 935-948. 
Iyer, L.M., Babu, M.M., and Aravind, L. (2006). The HIRAN domain and 
recruitment of chromatin remodeling and repair activities to damaged DNA. Cell 
Cycle 5, 775-782. 
Iyer, R.R., Pluciennik, A., Napierala, M., and Wells, R.D. (2015). DNA triplet 
repeat expansion and mismatch repair. Annu Rev Biochem 84, 199-226. 
 218 
Jackson, B., Brocker, C., Thompson, D.C., Black, W., Vasiliou, K., Nebert, D.W., 
and Vasiliou, V. (2011). Update on the aldehyde dehydrogenase gene (ALDH) 
superfamily. Hum Genomics 5, 283-303. 
Jacobsen, E. (1950). Is acetaldehyde an intermediary product in normal 
metabolism? Biochim Biophys Acta 4, 330-334. 
Jensen, R.P., Luo, W., Pankow, J.F., Strongin, R.M., and Peyton, D.H. (2015). 
Hidden formaldehyde in e-cigarette aerosols. N Engl J Med 372, 392-394. 
Jones, R.E., Oh, S., Grimstead, J.W., Zimbric, J., Roger, L., Heppel, N.H., 
Ashelford, K.E., Liddiard, K., Hendrickson, E.A., and Baird, D.M. (2014). Escape 
from telomere-driven crisis is DNA ligase III dependent. Cell Rep 8, 1063-1076. 
Jung, K., Schulze, B.D., and Sydow, K. (1987). Diagnostic significance of 
different urinary enzymes in patients suffering from chronic renal diseases. Clin 
Chim Acta 168, 287-295. 
Katayama, Y., Mahmut, N., Takimoto, H., Maeda, Y., Yano, T., Kojima, K., 
Azuma, T., Hara, M., Imajyo, K., Takahashi, S., et al. (1999). Hematopoietic 
progenitor cells from allogeneic bone marrow transplant donors circulate in the 
very early post-transplant period. Bone Marrow Transplant 23, 659-665. 
 219 
Kelly, P.F., Radtke, S., Kalle, C.V., Balcik, B., Bohn, K., Mueller, R., Schuesler, 
T., Haren, M., Reeves, L., Cancelas, J.A., et al. (2007). Stem Cell Collection and 
Gene Transfer in Fanconi Anemia. Mol Ther 15, 211-219. 
Kim, Y., Lach, F.P., Desetty, R., Hanenberg, H., Auerbach, A.D., and 
Smogorzewska, A. (2011). Mutations of the SLX4 gene in Fanconi anemia. Nat 
Genet 43, 142-146. 
Kim, Y., Spitz, G.S., Veturi, U., Lach, F.P., Auerbach, A.D., and Smogorzewska, 
A. (2013). Regulation of multiple DNA repair pathways by the Fanconi anemia 
protein SLX4. Blood 121, 54-63. 
Kinch, L.N., Ginalski, K., Rychlewski, L., and Grishin, N.V. (2005). Identification 
of novel restriction endonuclease-like fold families among hypothetical proteins. 
Nucleic Acids Res 33, 3598-3605. 
Kirchner, J.J., Sigurdsson, S.T., and Hopkins, P.B. (1992). Interstrand Cross-
Linking of Duplex DNA by Nitrous-Acid - Covalent Structure of the Dg-to-Dg 
Cross-Link at the Sequence 5'-Cg. J Am Chem Soc 114, 4021-4027. 
Klyosov, A.A., Rashkovetsky, L.G., Tahir, M.K., and Keung, W.M. (1996). 
Possible role of liver cytosolic and mitochondrial aldehyde dehydrogenases in 
acetaldehyde metabolism. Biochemistry 35, 4445-4456. 
 220 
Knipscheer, P., Raschle, M., Smogorzewska, A., Enoiu, M., Ho, T.V., Scharer, 
O.D., Elledge, S.J., and Walter, J.C. (2009). The Fanconi Anemia Pathway 
Promotes Replication-Dependent DNA Interstrand Cross-Link Repair. Science 
326, 1698-1701. 
Kosinski, J., Feder, M., and Bujnicki, J.M. (2005). The PD-(D/E)XK superfamily 
revisited: identification of new members among proteins involved in DNA 
metabolism and functional predictions for domains of (hitherto) unknown function. 
BMC Bioinformatics 6, 172. 
Kottemann, M.C., and Smogorzewska, A. (2013). Fanconi anaemia and the 
repair of Watson and Crick DNA crosslinks. Nature 493, 356-363. 
Kratz, K., Schöpf, B., Kaden, S., Sendoel, A., Eberhard, R., Lademann, C., 
Cannavó, E., Sartori, A.A., Hengartner, M.O., and Jiricny, J. (2010). Deficiency of 
FANCD2-Associated Nuclease KIAA1018/FAN1 Sensitizes Cells to Interstrand 
Crosslinking Agents. Cell 142, 77-88. 
Kutler, D.I., Auerbach, A.D., Satagopan, J., Giampietro, P.F., Batish, S.D., Huvos, 
A.G., Goberdhan, A., Shah, J.P., and Singh, B. (2003a). High incidence of head 
and neck squamous cell carcinoma in patients with Fanconi anemia. Arch 
Otolaryngol Head Neck Surg 129, 106-112. 
 221 
Kutler, D.I., Singh, B., Satagopan, J., Batish, S.D., Berwick, M., Giampietro, P.F., 
Hanenberg, H., and Auerbach, A.D. (2003b). A 20-year perspective on the 
International Fanconi Anemia Registry (IFAR). Blood 101, 1249-1256. 
Labarga, P., Barreiro, P., Martin-Carbonero, L., Rodriguez-Novoa, S., Solera, C., 
Medrano, J., Rivas, P., Albalater, M., Blanco, F., Moreno, V., et al. (2009). 
Kidney tubular abnormalities in the absence of impaired glomerular function in 
HIV patients treated with tenofovir. AIDS 23, 689-696. 
Lachaud, C., Moreno, A., Marchesi, F., Toth, R., Blow, J.J., and Rouse, J. 
(2016a). Ubiquitinated Fancd2 recruits Fan1 to stalled replication forks to prevent 
genome instability. Science. 
Lachaud, C., Slean, M., Marchesi, F., Lock, C., Odell, E., Castor, D., Toth, R., 
and Rouse, J. (2016b). Karyomegalic interstitial nephritis and DNA damage-
induced polyploidy in Fan1 nuclease-defective knock-in mice. Genes Dev 30, 
639-644. 
Laitinen, K., Lamberg-Allardt, C., Tunninen, R., Karonen, S.L., Tahtela, R., 
Ylikahri, R., and Valimaki, M. (1991). Transient hypoparathyroidism during acute 
alcohol intoxication. N Engl J Med 324, 721-727. 
 222 
Langevin, F., Crossan, G.P., Rosado, I.V., Arends, M.J., and Patel, K.J. (2011). 
Fancd2 counteracts the toxic effects of naturally produced aldehydes in mice. 
Nature 475, 53-58. 
Levran, O., Attwooll, C., Henry, R.T., Milton, K.L., Neveling, K., Rio, P., Batish, 
S.D., Kalb, R., Velleuer, E., Barral, S., et al. (2005). The BRCA1-interacting 
helicase BRIP1 is deficient in Fanconi anemia. Nat Genet 37, 931-933. 
Li, G., Nelsen, C., and Hendrickson, E.A. (2002). Ku86 is essential in human 
somatic cells. Proc Natl Acad Sci U S A 99, 832-837. 
Li, X., and Heyer, W.D. (2008). Homologous recombination in DNA repair and 
DNA damage tolerance. Cell Res 18, 99-113. 
Lieber, M.R. (2008). The mechanism of human nonhomologous DNA end joining. 
J Biol Chem 283, 1-5. 
Lieber, M.R. (2010). The mechanism of double-strand DNA break repair by the 
nonhomologous DNA end-joining pathway. Annu Rev Biochem 79, 181-211. 
Lindahl, T. (1993). Instability and decay of the primary structure of DNA. Nature 
362, 709-715. 
 223 
Lindahl, T., and Barnes, D.E. (2000). Repair of endogenous DNA damage. Cold 
Spring Harb Symp Quant Biol 65, 127-133. 
Liu, L., Yan, Y., Zeng, M., Zhang, J., Hanes, M.A., Ahearn, G., McMahon, T.J., 
Dickfeld, T., Marshall, H.E., Que, L.G., et al. (2004). Essential roles of S-
nitrosothiols in vascular homeostasis and endotoxic shock. Cell 116, 617-628. 
Liu, T., Ghosal, G., Yuan, J., Chen, J., and Huang, J. (2010). FAN1 Acts with 
FANCI-FANCD2 to Promote DNA Interstrand Cross-Link Repair. Science 329, 
693-696. 
Loenarz, C., and Schofield, C.J. (2008). Expanding chemical biology of 2-
oxoglutarate oxygenases. Nat Chem Biol 4, 152-156. 
Long, D.T., Raschle, M., Joukov, V., and Walter, J.C. (2011). Mechanism of 
RAD51-dependent DNA interstrand cross-link repair. Science 333, 84-87. 
Lu, K., Collins, L.B., Ru, H., Bermudez, E., and Swenberg, J.A. (2010). 
Distribution of DNA adducts caused by inhaled formaldehyde is consistent with 
induction of nasal carcinoma but not leukemia. Toxicol Sci 116, 441-451. 
MacKay, C., Déclais, A.-C., Lundin, C., Agostinho, A., Deans, A.J., MacArtney, 
T.J., Hofmann, K., Gartner, A., West, S.C., Helleday, T., et al. (2010). 
 224 
Identification of KIAA1018/FAN1, a DNA Repair Nuclease Recruited to DNA 
Damage by Monoubiquitinated FANCD2. Cell 142, 65-76. 
Magana-Schwencke, N., and Ekert, B. (1978). Biochemical analysis of damage 
induced in yeast by formaldehyde. II. Induction of cross-links between DNA and 
protein. Mutat Res 51, 11-19. 
Marchitti, S.A., Brocker, C., Stagos, D., and Vasiliou, V. (2008). Non-P450 
aldehyde oxidizing enzymes: the aldehyde dehydrogenase superfamily. Expert 
Opin Drug Metab Toxicol 4, 697-720. 
Marietta, C., Thompson, L.H., Lamerdin, J.E., and Brooks, P.J. (2009). 
Acetaldehyde stimulates FANCD2 monoubiquitination, H2AX phosphorylation, 
and BRCA1 phosphorylation in human cells in vitro: implications for alcohol-
related carcinogenesis. Mutat Res 664, 77-83. 
Matsuda, T., Terashima, I., Matsumoto, Y., Yabushita, H., Matsui, S., and 
Shibutani, S. (1999). Effective utilization of N2-ethyl-2'-deoxyguanosine 
triphosphate during DNA synthesis catalyzed by mammalian replicative DNA 
polymerases. Biochemistry 38, 929-935. 
 225 
McGhee, J.D., and von Hippel, P.H. (1977). Formaldehyde as a probe of DNA 
structure. 3. Equilibrium denaturation of DNA and synthetic polynucleotides. 
Biochemistry 16, 3267-3276. 
Mechilli, M., Schinoppi, A., Kobos, K., Natarajan, A.T., and Palitti, F. (2008). DNA 
repair deficiency and acetaldehyde-induced chromosomal alterations in CHO 
cells. Mutagenesis 23, 51-56. 
Mihatsch, M.J., Gudat, F., Zollinger, H.U., Heierli, C., Tholen, H., and Reutter, 
F.W. (1979). Systemic karyomegaly associated with chronic interstitial nephritis. 
A new disease entity? Clin Nephrol 12, 54-62. 
Mills, S.J., and Harrison, S.A. (2005). Comparison of the natural history of 
alcoholic and nonalcoholic fatty liver disease. Curr Gastroenterol Rep 7, 32-36. 
Mimori, T., and Hardin, J.A. (1986). Mechanism of interaction between Ku protein 
and DNA. J Biol Chem 261, 10375-10379. 
Mirkin, S.M. (2007). Expandable DNA repeats and human disease. Nature 447, 
932-940. 
Moldovan, G.-L., and D’Andrea, A.D. (2009). How the Fanconi Anemia Pathway 
Guards the Genome. In Genetics, pp. 223-249. 
 226 
Montes de Oca, R., Andreassen, P.R., Margossian, S.P., Gregory, R.C., 
Taniguchi, T., Wang, X., Houghtaling, S., Grompe, M., and D'Andrea, A.D. (2005). 
Regulated interaction of the Fanconi anemia protein, FANCD2, with chromatin. 
Blood 105, 1003-1009. 
Moore, J.K., and Haber, J.E. (1996). Cell cycle and genetic requirements of two 
pathways of nonhomologous end-joining repair of double-strand breaks in 
Saccharomyces cerevisiae. Mol Cell Biol 16, 2164-2173. 
Morrison, S.J., Wandycz, A.M., Akashi, K., Globerson, A., and Weissman, I.L. 
(1996). The aging of hematopoietic stem cells. Nat Med 2, 1011-1016. 
Munoz, I.M., Hain, K., Declais, A.C., Gardiner, M., Toh, G.W., Sanchez-Pulido, L., 
Heuckmann, J.M., Toth, R., Macartney, T., Eppink, B., et al. (2009). Coordination 
of structure-specific nucleases by human SLX4/BTBD12 is required for DNA 
repair. Mol Cell 35, 116-127. 
Myung, K., Ghosh, G., Fattah, F.J., Li, G., Kim, H., Dutia, A., Pak, E., Smith, S., 
and Hendrickson, E.A. (2004). Regulation of telomere length and suppression of 
genomic instability in human somatic cells by Ku86. Mol Cell Biol 24, 5050-5059. 
Nakamura, K., Sakai, W., Kawamoto, T., Bree, R.T., Lowndes, N.F., Takeda, S., 
and Taniguchi, Y. (2006). Genetic dissection of vertebrate 53BP1: a major role in 
 227 
non-homologous end joining of DNA double strand breaks. DNA Repair (Amst) 5, 
741-749. 
Nakanishi, K., Yang, Y.G., Pierce, A.J., Taniguchi, T., Digweed, M., D'Andrea, 
A.D., Wang, Z.Q., and Jasin, M. (2005). Human Fanconi anemia 
monoubiquitination pathway promotes homologous DNA repair. Proc Natl Acad 
Sci U S A 102, 1110-1115. 
Norden, A.G., Scheinman, S.J., Deschodt-Lanckman, M.M., Lapsley, M., Nortier, 
J.L., Thakker, R.V., Unwin, R.J., and Wrong, O. (2000). Tubular proteinuria 
defined by a study of Dent's (CLCN5 mutation) and other tubular diseases. 
Kidney Int 57, 240-249. 
Nussenzweig, A., Sokol, K., Burgman, P., Li, L., and Li, G.C. (1997). 
Hypersensitivity of Ku80-deficient cell lines and mice to DNA damage: the effects 
of ionizing radiation on growth, survival, and development. Proc Natl Acad Sci U 
S A 94, 13588-13593. 
Oberbeck, N., Langevin, F., King, G., de Wind, N., Crossan, G.P., and Patel, K.J. 
(2014). Maternal aldehyde elimination during pregnancy preserves the fetal 
genome. Mol Cell 55, 807-817. 
 228 
Ogawa, H., Gomi, T., and Fujioka, M. (2000). Serine hydroxymethyltransferase 
and threonine aldolase: are they identical? Int J Biochem Cell Biol 32, 289-301. 
Oh, S., Harvey, A., Zimbric, J., Wang, Y., Nguyen, T., Jackson, P.J., and 
Hendrickson, E.A. (2014). DNA ligase III and DNA ligase IV carry out genetically 
distinct forms of end joining in human somatic cells. DNA Repair (Amst) 21, 97-
110. 
Oh, S., Wang, Y., Zimbric, J., and Hendrickson, E.A. (2013). Human LIGIV is 
synthetically lethal with the loss of Rad54B-dependent recombination and is 
required for certain chromosome fusion events induced by telomere dysfunction. 
Nucleic Acids Res 41, 1734-1749. 
Pace, P., Mosedale, G., Hodskinson, M.R., Rosado, I.V., Sivasubramaniam, M., 
and Patel, K.J. (2010). Ku70 corrupts DNA repair in the absence of the Fanconi 
anemia pathway. Science 329, 219-223. 
Parenti, P., Giordana, B., and Hanozet, G.M. (1991). In vitro effect of ethanol on 
sodium and glucose transport in rabbit renal brush border membrane vesicles. 
Biochim Biophys Acta 1070, 92-98. 
Park, J.Y., Virts, E.L., Jankowska, A., Wiek, C., Othman, M., Chakraborty, S.C., 
Vance, G.H., Alkuraya, F.S., Hanenberg, H., and Andreassen, P.R. (2016). 
 229 
Complementation of hypersensitivity to DNA interstrand crosslinking agents 
demonstrates that XRCC2 is a Fanconi anaemia gene. J Med Genet 53, 672-680. 
Patel, K.J., and Joenje, H. (2007). Fanconi anemia and DNA replication repair. 
DNA Repair (Amst) 6, 885-890. 
Pizzolato, J., Mukherjee, S., Schärer, O.D., and Jiricny, J. (2015). FANCD2-
associated Nuclease 1, but Not Exonuclease 1 or Flap Endonuclease 1, Is Able 
to Unhook DNA Interstrand Cross-links in Vitro. Journal of Biological Chemistry 
290, 22602-22611. 
Pontel, L.B., Rosado, I.V., Burgos-Barragan, G., Garaycoechea, J.I., Yu, R., 
Arends, M.J., Chandrasekaran, G., Broecker, V., Wei, W., Liu, L., et al. (2015). 
Endogenous Formaldehyde Is a Hematopoietic Stem Cell Genotoxin and 
Metabolic Carcinogen. Mol Cell 60, 177-188. 
Radha, S., Tameem, A., and Rao, B.S. (2014). Karyomegalic interstitial nephritis 
with focal segmental glomerulosclerosis: A rare association. Indian J Nephrol 24, 
117-119. 
Rafnar, T., Gudbjartsson, D.F., Sulem, P., Jonasdottir, A., Sigurdsson, A., 
Jonasdottir, A., Besenbacher, S., Lundin, P., Stacey, S.N., Gudmundsson, J., et 
 230 
al. (2011). Mutations in BRIP1 confer high risk of ovarian cancer. Nat Genet 43, 
1104-1107. 
Rahman, N., Seal, S., Thompson, D., Kelly, P., Renwick, A., Elliott, A., Reid, S., 
Spanova, K., Barfoot, R., Chagtai, T., et al. (2007). PALB2, which encodes a 
BRCA2-interacting protein, is a breast cancer susceptibility gene. Nat Genet 39, 
165-167. 
Raschle, M., Knipscheer, P., Enoiu, M., Angelov, T., Sun, J., Griffith, J.D., 
Ellenberger, T.E., Scharer, O.D., and Walter, J.C. (2008). Mechanism of 
replication-coupled DNA interstrand crosslink repair. Cell 134, 969-980. 
Reid, S., Schindler, D., Hanenberg, H., Barker, K., Hanks, S., Kalb, R., Neveling, 
K., Kelly, P., Seal, S., Freund, M., et al. (2007). Biallelic mutations in PALB2 
cause Fanconi anemia subtype FA-N and predispose to childhood cancer. Nat 
Genet 39, 162-164. 
Riballo, E., Kuhne, M., Rief, N., Doherty, A., Smith, G.C., Recio, M.J., Reis, C., 
Dahm, K., Fricke, A., Krempler, A., et al. (2004). A pathway of double-strand 
break rejoining dependent upon ATM, Artemis, and proteins locating to gamma-
H2AX foci. Mol Cell 16, 715-724. 
 231 
Ridpath, J.R., Nakamura, A., Tano, K., Luke, A.M., Sonoda, E., Arakawa, H., 
Buerstedde, J.M., Gillespie, D.A., Sale, J.E., Yamazoe, M., et al. (2007). Cells 
deficient in the FANC/BRCA pathway are hypersensitive to plasma levels of 
formaldehyde. Cancer Res 67, 11117-11122. 
Ristow, H., and Obe, G. (1978). Acetaldehyde induces cross-links in DNA and 
causes sister-chromatid exchanges in human cells. Mutat Res 58, 115-119. 
Rodrigo, R., Vergara, L., and Oberhauser, E. (1991). Effect of chronic ethanol 
consumption on postnatal development of renal (Na + K)-ATPase in the rat. Cell 
Biochem Funct 9, 215-222. 
Rosado, I.V., Langevin, F., Crossan, G.P., Takata, M., and Patel, K.J. (2011). 
Formaldehyde catabolism is essential in cells deficient for the Fanconi anemia 
DNA-repair pathway. Nat Struct Mol Biol 18, 1432-1434. 
Rosenberg, P.S., Greene, M.H., and Alter, B.P. (2003). Cancer incidence in 
persons with Fanconi anemia. Blood 101, 822-826. 
Rossi, D.J., Bryder, D., Seita, J., Nussenzweig, A., Hoeijmakers, J., and 
Weissman, I.L. (2007). Deficiencies in DNA damage repair limit the function of 
haematopoietic stem cells with age. Nature 447, 725-729. 
 232 
Rothman, A., Proverbio, T., Fernandez, E., and Proverbio, F. (1992). Effect of 
ethanol on the Na(+)- and the Na+,K(+)-ATPase activities of basolateral plasma 
membranes of kidney proximal tubular cells. Biochem Pharmacol 43, 2034-2036. 
Sanghani, P.C., Stone, C.L., Ray, B.D., Pindel, E.V., Hurley, T.D., and Bosron, 
W.F. (2000). Kinetic mechanism of human glutathione-dependent formaldehyde 
dehydrogenase. Biochemistry 39, 10720-10729. 
Schardijn, G.H., and Statius van Eps, L.W. (1987). Beta 2-microglobulin: its 
significance in the evaluation of renal function. Kidney Int 32, 635-641. 
Scharer, O.D. (2005). DNA interstrand crosslinks: natural and drug-induced DNA 
adducts that induce unique cellular responses. Chembiochem 6, 27-32. 
Schmid, W., and Fanconi, G. (1978). Fragility and spiralization anomalies of the 
chromosomes in three cases, including fraternal twins, with Fanconi's anemia, 
type Estren-Dameshek. Cytogenet Cell Genet 20, 141-149. 
Sclare, G. (1976). A case of unexplained karyomegaly. Beitr Pathol 157, 301-306. 
Seal, S., Thompson, D., Renwick, A., Elliott, A., Kelly, P., Barfoot, R., Chagtai, T., 
Jayatilake, H., Ahmed, M., Spanova, K., et al. (2006). Truncating mutations in the 
 233 
Fanconi anemia J gene BRIP1 are low-penetrance breast cancer susceptibility 
alleles. Nat Genet 38, 1239-1241. 
Segui, N., Mina, L.B., Lazaro, C., Sanz-Pamplona, R., Pons, T., Navarro, M., 
Bellido, F., Lopez-Doriga, A., Valdes-Mas, R., Pineda, M., et al. (2015). Germline 
Mutations in FAN1 Cause Hereditary Colorectal Cancer by Impairing DNA Repair. 
Gastroenterology 149, 563-566. 
Seitz, H.K., and Becker, P. (2007). Alcohol metabolism and cancer risk. Alcohol 
Res Health 30, 38-41, 44-37. 
Semlow, D.R., Zhang, J., Budzowska, M., Drohat, A.C., and Walter, J.C. (2016). 
Replication-Dependent Unhooking of DNA Interstrand Cross-Links by the NEIL3 
Glycosylase. Cell 167, 498-511 e414. 
Shah, S., Kim, Y., Ostrovnaya, I., Murali, R., Schrader, K.A., Lach, F.P., Sarrel, 
K., Rau-Murthy, R., Hansen, N., Zhang, L., et al. (2013). Assessment of SLX4 
Mutations in Hereditary Breast Cancers. PLoS One 8, e66961. 
Shimamura, A., and Alter, B.P. (2010). Pathophysiology and management of 
inherited bone marrow failure syndromes. Blood Rev 24, 101-122. 
 234 
Simsek, D., Furda, A., Gao, Y., Artus, J., Brunet, E., Hadjantonakis, A.K., Van 
Houten, B., Shuman, S., McKinnon, P.J., and Jasin, M. (2011). Crucial role for 
DNA ligase III in mitochondria but not in Xrcc1-dependent repair. Nature 471, 
245-248. 
Smith, A.L., Alirezaie, N., Connor, A., Chan-Seng-Yue, M., Grant, R., Selander, I., 
Bascunana, C., Borgida, A., Hall, A., Whelan, T., et al. (2015). Candidate DNA 
repair susceptibility genes identified by exome sequencing in high-risk pancreatic 
cancer. Cancer Lett. 
Smogorzewska, A., Desetty, R., Saito, T.T., Schlabach, M., Lach, F.P., Sowa, 
M.E., Clark, A.B., Kunkel, T.A., Harper, J.W., Colaiácovo, M.P., et al. (2010). A 
genetic screen identifies FAN1, a Fanconi anemia-associated nuclease 
necessary for DNA interstrand crosslink repair. Mol Cell 39, 36-47. 
Smogorzewska, A., Matsuoka, S., Vinciguerra, P., McDonald, E.R., 3rd, Hurov, 
K.E., Luo, J., Ballif, B.A., Gygi, S.P., Hofmann, K., D'Andrea, A.D., et al. (2007). 
Identification of the FANCI protein, a monoubiquitinated FANCD2 paralog 
required for DNA repair. Cell 129, 289-301. 
Solomon, M.J., and Varshavsky, A. (1985). Formaldehyde-mediated DNA-protein 
crosslinking: a probe for in vivo chromatin structures. Proc Natl Acad Sci U S A 
82, 6470-6474. 
 235 
Songur, A., Ozen, O.A., and Sarsilmaz, M. (2010). The toxic effects of 
formaldehyde on the nervous system. Rev Environ Contam Toxicol 203, 105-118. 
Sonoda, E., Hochegger, H., Saberi, A., Taniguchi, Y., and Takeda, S. (2006). 
Differential usage of non-homologous end-joining and homologous 
recombination in double strand break repair. DNA Repair (Amst) 5, 1021-1029. 
Spoendlin, M., Moch, H., Brunner, F., Brunner, W., Burger, H.R., Kiss, D., 
Wegmann, W., Dalquen, P., Oberholzer, M., Thiel, G., et al. (1995). 
Karyomegalic interstitial nephritis: further support for a distinct entity and 
evidence for a genetic defect. Am J Kidney Dis 25, 242-252. 
Staab, C.A., Alander, J., Morgenstern, R., Grafstrom, R.C., and Hoog, J.O. 
(2009). The Janus face of alcohol dehydrogenase 3. Chem Biol Interact 178, 29-
35. 
Stein, S., Lao, Y., Yang, I.Y., Hecht, S.S., and Moriya, M. (2006). Genotoxicity of 
acetaldehyde- and crotonaldehyde-induced 1,N2-propanodeoxyguanosine DNA 
adducts in human cells. Mutat Res 608, 1-7. 
Stone, M.P., Cho, Y.J., Huang, H., Kim, H.Y., Kozekov, I.D., Kozekova, A., Wang, 
H., Minko, I.G., Lloyd, R.S., Harris, T.M., et al. (2008). Interstrand DNA cross-
 236 
links induced by alpha,beta-unsaturated aldehydes derived from lipid 
peroxidation and environmental sources. Acc Chem Res 41, 793-804. 
Svendsen, J.M., Smogorzewska, A., Sowa, M.E., O'Connell, B.C., Gygi, S.P., 
Elledge, S.J., and Harper, J.W. (2009). Mammalian BTBD12/SLX4 assembles a 
Holliday junction resolvase and is required for DNA repair. Cell 138, 63-77. 
Thongthip, S., Bellani, M., Gregg, S.Q., Sridhar, S., Conti, B.A., Chen, Y., 
Seidman, M.M., and Smogorzewska, A. (2016). Fan1 deficiency results in DNA 
interstrand cross-link repair defects, enhanced tissue karyomegaly, and organ 
dysfunction. Genes Dev 30, 645-659. 
Tischkowitz, M., Xia, B., Sabbaghian, N., Reis-Filho, J.S., Hamel, N., Li, G., van 
Beers, E.H., Li, L., Khalil, T., Quenneville, L.A., et al. (2007). Analysis of 
PALB2/FANCN-associated breast cancer families. Proc Natl Acad Sci U S A 104, 
6788-6793. 
Tome, S., Manley, K., Simard, J.P., Clark, G.W., Slean, M.M., Swami, M., 
Shelbourne, P.F., Tillier, E.R., Monckton, D.G., Messer, A., et al. (2013). MSH3 
polymorphisms and protein levels affect CAG repeat instability in Huntington's 
disease mice. PLoS Genet 9, e1003280. 
 237 
Trocho, C., Pardo, R., Rafecas, I., Virgili, J., Remesar, X., Fernandez-Lopez, J.A., 
and Alemany, M. (1998). Formaldehyde derived from dietary aspartame binds to 
tissue components in vivo. Life Sci 63, 337-349. 
Tulpule, A., Lensch, M.W., Miller, J.D., Austin, K., D'Andrea, A., Schlaeger, T.M., 
Shimamura, A., and Daley, G.Q. (2010). Knockdown of Fanconi anemia genes in 
human embryonic stem cells reveals early developmental defects in the 
hematopoietic lineage. Blood 115, 3453-3462. 
Uz, E., Bayram, Y., Haltas, H., Bavbek, N., Kanbay, M., Guz, G., and Akçay, A. 
(2011). Karyomegalic tubulointerstitial nephritis: A rare cause of chronic kidney 
disease. Nephro Urol Mon 3, 201-203. 
Van Thiel, D.H., Gavaler, J.S., Little, J.M., and Lester, R. (1977). Alcohol: its 
effect on the kidney. Metabolism 26, 857-866. 
Vaz, F., Hanenberg, H., Schuster, B., Barker, K., Wiek, C., Erven, V., Neveling, 
K., Endt, D., Kesterton, I., Autore, F., et al. (2010). Mutation of the RAD51C gene 
in a Fanconi anemia-like disorder. Nat Genet 42, 406-409. 
Vinciguerra, P., Godinho, S.A., Parmar, K., Pellman, D., and D'Andrea, A.D. 
(2010). Cytokinesis failure occurs in Fanconi anemia pathway-deficient murine 
and human bone marrow hematopoietic cells. J Clin Invest 120, 3834-3842. 
 238 
Voigt, M.D. (2005). Alcohol in hepatocellular cancer. Clin Liver Dis 9, 151-169. 
Wagner, J.E., Tolar, J., Levran, O., Scholl, T., Deffenbaugh, A., Satagopan, J., 
Ben-Porat, L., Mah, K., Batish, S.D., Kutler, D.I., et al. (2004). Germline 
mutations in BRCA2: shared genetic susceptibility to breast cancer, early onset 
leukemia, and Fanconi anemia. Blood 103, 3226-3229. 
Walden, H., and Deans, A.J. (2014). The Fanconi anemia DNA repair pathway: 
structural and functional insights into a complex disorder. Annu Rev Biophys 43, 
257-278. 
Walport, L.J., Hopkinson, R.J., and Schofield, C.J. (2012). Mechanisms of human 
histone and nucleic acid demethylases. Curr Opin Chem Biol 16, 525-534. 
Walsh, T., Casadei, S., Lee, M.K., Pennil, C.C., Nord, A.S., Thornton, A.M., Roeb, 
W., Agnew, K.J., Stray, S.M., Wickramanayake, A., et al. (2011). Mutations in 12 
genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by 
massively parallel sequencing. Proc Natl Acad Sci U S A 108, 18032-18037. 
Wang, A.T., Kim, T., Wagner, J.E., Conti, B.A., Lach, F.P., Huang, A.L., Molina, 
H., Sanborn, E.M., Zierhut, H., Cornes, B.K., et al. (2015). A Dominant Mutation 
in Human RAD51 Reveals Its Function in DNA Interstrand Crosslink Repair 
Independent of Homologous Recombination. Mol Cell 59, 478-490. 
 239 
Wang, A.T., Sengerova, B., Cattell, E., Inagawa, T., Hartley, J.M., Kiakos, K., 
Burgess-Brown, N.A., Swift, L.P., Enzlin, J.H., Schofield, C.J., et al. (2011). 
Human SNM1A and XPF-ERCC1 collaborate to initiate DNA interstrand cross-
link repair. Genes Dev 25, 1859-1870. 
Wang, M., McIntee, E.J., Cheng, G., Shi, Y., Villalta, P.W., and Hecht, S.S. 
(2000). Identification of DNA adducts of acetaldehyde. Chem Res Toxicol 13, 
1149-1157. 
Wang, R., Persky, N.S., Yoo, B., Ouerfelli, O., Smogorzewska, A., Elledge, S.J., 
and Pavletich, N.P. (2014). DNA repair. Mechanism of DNA interstrand cross-link 
processing by repair nuclease FAN1. Science 346, 1127-1130. 
Wang, W. (2008). A major switch for the Fanconi anemia DNA damage-response 
pathway. Nat Struct Mol Biol 15, 1128-1130. 
Wang, X., Peterson, C.A., Zheng, H., Nairn, R.S., Legerski, R.J., and Li, L. 
(2001). Involvement of nucleotide excision repair in a recombination-independent 
and error-prone pathway of DNA interstrand cross-link repair. Mol Cell Biol 21, 
713-720. 
 240 
Wang, Y., Ghosh, G., and Hendrickson, E.A. (2009). Ku86 represses lethal 
telomere deletion events in human somatic cells. Proc Natl Acad Sci U S A 106, 
12430-12435. 
Ward, I.M., Reina-San-Martin, B., Olaru, A., Minn, K., Tamada, K., Lau, J.S., 
Cascalho, M., Chen, L., Nussenzweig, A., Livak, F., et al. (2004). 53BP1 is 
required for class switch recombination. J Cell Biol 165, 459-464. 
Wheeler, V.C., Lebel, L.A., Vrbanac, V., Teed, A., te Riele, H., and MacDonald, 
M.E. (2003). Mismatch repair gene Msh2 modifies the timing of early disease in 
Hdh(Q111) striatum. Hum Mol Genet 12, 273-281. 
Williams, H.L., Gottesman, M.E., and Gautier, J. (2012). Replication-independent 
repair of DNA interstrand crosslinks. Mol Cell 47, 140-147. 
Wyatt, H.D., Laister, R.C., Martin, S.R., Arrowsmith, C.H., and West, S.C. (2017). 
The SMX DNA Repair Tri-nuclease. Mol Cell 65, 848-860 e811. 
Wyatt, H.D.M., Sarbajna, S., Matos, J., and West, S.C. (2013). Coordinated 
actions of SLX1-SLX4 and MUS81-EME1 for Holliday junction resolution in 
human cells. Mol Cell 52, 234-247. 
 241 
Xia, B., Dorsman, J.C., Ameziane, N., de Vries, Y., Rooimans, M.A., Sheng, Q., 
Pals, G., Errami, A., Gluckman, E., Llera, J., et al. (2007). Fanconi anemia is 
associated with a defect in the BRCA2 partner PALB2. Nat Genet 39, 159-161. 
Yamamoto, K.N., Kobayashi, S., Tsuda, M., Kurumizaka, H., Takata, M., Kono, 
K., Jiricny, J., Takeda, S., and Hirota, K. (2011). Involvement of SLX4 in 
interstrand cross-link repair is regulated by the Fanconi anemia pathway. Proc 
Natl Acad Sci U S A 108, 6492-6496. 
Yan, Z., Guo, R., Paramasivam, M., Shen, W., Ling, C., Fox, D., 3rd, Wang, Y., 
Oostra, A.B., Kuehl, J., Lee, D.Y., et al. (2012). A ubiquitin-binding protein, 
FAAP20, links RNF8-mediated ubiquitination to the Fanconi anemia DNA repair 
network. Mol Cell 47, 61-75. 
Yannone, S.M., Khan, I.S., Zhou, R.Z., Zhou, T., Valerie, K., and Povirk, L.F. 
(2008). Coordinate 5' and 3' endonucleolytic trimming of terminally blocked blunt 
DNA double-strand break ends by Artemis nuclease and DNA-dependent protein 
kinase. Nucleic Acids Res 36, 3354-3365. 
Yoshida, A., Rzhetsky, A., Hsu, L.C., and Chang, C. (1998). Human aldehyde 
dehydrogenase gene family. Eur J Biochem 251, 549-557. 
 242 
Yoshikiyo, K., Kratz, K., Hirota, K., Nishihara, K., Takata, M., Kurumizaka, H., 
Horimoto, S., Takeda, S., and Jiricny, J. (2010). KIAA1018/FAN1 nuclease 
protects cells against genomic instability induced by interstrand cross-linking 
agents. Proc Natl Acad Sci USA 107, 21553-21557. 
Zakhari, S. (2006). Overview: how is alcohol metabolized by the body? Alcohol 
Res Health 29, 245-254. 
Zhang, H., Kozono, D.E., O'Connor, K.W., Vidal-Cardenas, S., Rousseau, A., 
Hamilton, A., Moreau, L., Gaudiano, E.F., Greenberger, J., Bagby, G., et al. 
(2016). TGF-beta Inhibition Rescues Hematopoietic Stem Cell Defects and Bone 
Marrow Failure in Fanconi Anemia. Cell Stem Cell 18, 668-681. 
Zhang, J., and Walter, J.C. (2014). Mechanism and regulation of incisions during 
DNA interstrand cross-link repair. DNA repair 19, 135-142. 
Zhao, Q., Xue, X., Longerich, S., Sung, P., and Xiong, Y. (2014). Structural 
insights into 5' flap DNA unwinding and incision by the human FAN1 dimer. Nat 
Comms 5, 5726. 
Zhou, W., Otto, E.A., Cluckey, A., Airik, R., Hurd, T.W., Chaki, M., Diaz, K., Lach, 
F.P., Bennett, G.R., Gee, H.Y., et al. (2012). FAN1 mutations cause 
 243 
karyomegalic interstitial nephritis, linking chronic kidney failure to defective DNA 
damage repair. Nat Genet 44, 910-915. 
 
